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Diffuse large B-cell lymphoma (DLBCL) is a very heterogenous disease that has 
historically been divided into two subtypes driven by distinct molecular mechanisms. The 
activated B-cell (ABC) subtype of DLBCL has the worst overall survival and is 
characterized by activation of the NF-κB signaling pathway. Although many genetic 
alterations have been identified in DLBCL, there remain cases with few or no known 
genetic drivers. This suggests that there are still novel drivers of DLBCL yet to be 
discovered. In this thesis I aimed to leverage whole genome sequencing data to identify 
novel regions of the genome that were recurrently mutated, with a specific focus on non-
coding regions. Through this analysis we identified numerous novel putative driver 
mutations within the non-coding genome. One of the most highly recurrently mutated 
regions was in the 3′ untranslated region (UTR) of the NFKBIZ gene. Amplifications of 
this gene have been previously discovered in ABC DLBCL and this gene is known to 
activate NF-κB signaling. Therefore, we hypothesized that these 3′ UTR mutations were 
acting as drivers in DLBCL. The remaining portion of this thesis is focused on the 
functional characterization of NFKBIZ 3′ UTR mutations and how they drive DLBCL and 
contribute to treatment resistance. To this end, I induced NFKBIZ 3′ UTR mutations into 
DLBCL cell lines and determined that they cause both elevated mRNA and protein 
expression. These mutations conferred a selective growth advantage to DLBCL cell lines 
both in vitro and in vivo and overexpression of NFKBIZ in primary germinal center B-
cells also provided cells a growth advantage. Lastly, I found that NFKBIZ-mutant cell 
lines were more resistant to a selection of targeted therapeutics (ibrutinib, idelalisib and 
masitinib). Taken together, this thesis highlights the importance of surveying the entire 
cancer genome, including non-coding regions, when searching for novel drivers. I 
demonstrated that mutations in the 3′ UTR of a gene can act as driver mutations 
conferring cell growth advantages and treatment resistance. This work also implicates 
NFKBIZ 3′ UTR mutations as potentially useful biomarkers for predicting treatment 
response and informing on the most effective treatment options for patients. 
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Chapter 1.  
 
Introduction 
Cancer is a disease of the genome; it occurs when a sufficient number and 
combination of heritable changes to the genome allow a cell to grow uncontrollably. One 
main objective of cancer research, particularly cancer genomics, is to identify these 
alterations and use that knowledge to effectively predict, prevent, diagnose, and treat 
cancer. Historically, cancer treatments have been limited to brute-force treatment 
options such as radical surgery, chemotherapy, and radiation. These have been 
effective in eradicating tumours but can also be damaging to other cells, toxic to the 
patients being treated and do not effectively treat every cancer. Given the fundamental 
relationship between mutations and oncogenesis (the development of cancer), a core 
goal in cancer genomics is to catalogue and understand the repertoire of genetic drivers 
of individual malignancies and to ultimately determine avenues to exploit these as 
vulnerabilities using targeted therapeutics. With the advent of next generation 
sequencing (NGS), the discovery of new drivers of cancer has increased dramatically. 
Instead of focusing on individual candidate genes, researchers can now survey the 
entire genome of a tumour and discover novel mutations in numerous cancer genes 
simultaneously. It has become increasingly apparent that cancers are very heterogenous 
and not all cancers, even those of the same type, share all the same genetic features. 
As such, there is a need for tumours to be treated differently depending on their 
individual genetics. To effectively treat and cure cancer it is crucial to fully understand 
the underlying genetics that drive each tumour.  
The following sections in this introduction provide an overview of the field of 
cancer genomics and the commonly used techniques for the discovery of genetic 
alterations that are fundamental to cancer research. Further, I discuss the clinical 
characteristics and genomics relating to lymphomas, specifically diffuse large B-cell 
lymphoma, and the current state of treatment options. I then discuss the background of 
the NF-κB signaling pathway and the current literature relating to the NFKBIZ gene. 
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1.1. Cancer Genomics 
1.1.1. Driver and Passenger Mutations 
Cancers arise through the acquisition of genetic mutations that confer selective 
growth advantages to cells. The mutations that confer these advantages usually affect 
what are described as “cancer genes” and therefore were named “driver” mutations, as 
they drive the cancer and are subjected to positive selection1. Conversely, mutations that 
do not provide cells with a selective advantage are termed “passenger” mutations, as 
they are not involved in driving the cancer1. This distinction between driver and 
passenger mutations is important because all somatic cells can acquire mutations over 
time, but only a subset of these mutations have the potential to drive oncogenesis and 
give rise to a tumour.  
 
1.1.2. Oncogenes and Tumour Suppressor Genes 
Cancer genes are broadly classified into two categories, oncogenes2 and tumour-
suppressor genes (TSGs)3. Oncogenes are genes that, when activated or expressed in 
certain contexts, can cause cells to grow and divide. In contrast, TSGs delay growth or 
regulate the cell cycle and are commonly altered by deletions or loss of function 
mutations. Cancer research has been focused on the discovery of which genes can act 
as oncogenes and TSGs and whether the mutations affecting these genes are acting as 
drivers or passengers. This understanding of the genetic drivers of cancer has important 
implications for drug development and treatment options for patients and therefore is 
widely being studies to this day.  
The discovery of the c-src gene was the first example of a human gene could be 
modified in a way that caused cancer4. This revolutionized the field of cancer research 
and was the beginning of the ongoing search for new cancer-causing genes and 
mutations. The Philadelphia chromosome (Ph) which resulted from a translocation 
between chromosomes 9 and 22 leading to a gene fusion called BCR-ABL was the first 
description of a chromosomal alteration in cancer5–8. The first cancer specific point 
mutation or single nucleotide variant (SNV) was discovered in the gene HRAS 
 3 
(p.G652V) in the T24 human bladder carcinoma cell line9 and since then over 2,300 
additional cancer genes and drivers have been discovered10. RB1 was the first TSG 
discovered and the observation of heritable RB1 mutations underlying certain cancers 
lead to the “two-hit” hypothesis by Knudson, in which he described the need for TSGs to 
acquire two mutations (one in each allele) to inactivate them11. The TSG p53 (encoded 
by the gene TP53) is the most commonly mutated, and inevitably the most famous 
tumour suppressor gene. It is mutated in >50% of cancer types and is known as the 
master regulator of cellular stress response3,12. 
 
1.1.3. Hallmarks of Cancer 
Hanahan and Weinberg described six essential alterations that cells acquire 
through genetic mutations to become cancerous, which they termed the hallmarks of 
cancer13. These included: evading apoptosis, self-sufficiency in growth signals, 
insensitivity to anti-growth signals, sustained angiogenesis, limitless replicative potential, 
and tissue invasion and metastasis13. More recently this model was amended with two 
emerging hallmarks: deregulating cellular energetics and avoiding immune destructions 
as well as two enabling characteristics: genome instability and tumour-promoting 
inflammation14. Understanding the hallmarks of cancer and how genetic alterations lead 
to these hallmarks is the pillar of cancer research, in order to develop novel treatments 
targeting these hallmarks it is necessary to discover what is causing them (Figure 1-1). 
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Figure 1-1  The hallmarks of cancer.  
Hanahan and Weinberg first described the six original hallmarks which are shown in red 
(sustained proliferative signaling, evading growth suppressors, inducing angiogenesis, activating 
invasion and metastasis, resisting cell death, and enabling replicative immortality)13. Later, two 
enabling factors were described and are shown in purple (deregulating cellular energetics and 
avoiding immune destruction) and two emerging hallmarks shown in green (tumour-promoting 
inflammation and genome instability and mutation)15. Adapted from “Hallmarks of Cancer: Circle”, 
by BioRender.com (2021). Retrieved from https://app.biorender.com/biorender-templates. 
1.1.4. Protein-Coding Mutations 
There are many varieties of somatic mutations that can act as drivers after being 
acquired by a cancer cell. These can range in size dramatically, including the 
substitution of one base pair for another, the insertion or deletion (indel) of a small 
number of base pairs, the gain or loss of large regions of the genome or entire 
chromosomes, and the rearrangement of chromosomes that can disrupt genes or alter 
their expression or function16–18.   
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Base substitutions and indels are collectively termed simple somatic mutations 
(SSMs). SSMs can lead to multiple types of mutations when they occur within a gene 
body including missense (change of amino acid), nonsense (premature stop codon), 
silent (no change in amino acid), frameshift (reading frame is shifted to change the code 
for amino acids downstream), and in-frame (indel does not affect reading frame 
downstream) (Figure 1-2).  
 
Figure 1-2 Simple somatic mutations. 
SSMs can include point mutations and insertions/deletions (indels). There are multiple ways in 
which these mutation types can affect the amino acid sequence of a protein. Silent mutations 
cause a DNA base-pair change but do not affect the amino acid. Nonsense mutations change an 
amino acid codon into a STOP codon, leading to a truncated protein. These are often inactivating 
mutations seen in TSGs. Missense mutations change the codon from one amino acid to another. 
Indels can affect just one amino acid codon but preserve the reading frame (in-frame indel) which 
is caused by insertions/deletions of a number of base-pairs that is a multiple of three. If the indel 
is not a multiple of three, the mutation causes a frame-shift mutations which affects all 
downstream codons. Adapted from “Point Mutations”, by BioRender.com (2021). Retrieved from 
https://app.biorender.com/biorender-templates. 
Larger structural variations (SVs) can also occur and can affect regions 
containing multiple genes including large deletions or insertions, translocations, 
inversions, and rearrangements both intrachromosomal (within a chromosome) and 
interchromosomal (between different chromosomes)16 (Figure 1-3). Copy number 
alterations (CNAs) are another type of somatic mutation which include amplifications and 
deletions that can affect large chromosomal regions or entire chromosomes. 
Amplifications can be only one extra copy of a gene or chromosome but also can include 
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Figure 1-3 Structural variants.  
A description of the multiple types of structural variants (SVs) that can occur in the genome and 
the resulting sequence effects. Adapted from “Genome Structural Variations”, by BioRender.com 
(2021). Retrieved from https://app.biorender.com/biorender-templates. 
1.1.5. Sequencing Methodologies 
Since the completion of the human genome project in 200319, sequencing 
technologies have greatly improved to become high throughput and much more 
affordable. NGS methodologies have given us the ability to search for novel candidate 
cancer genes and driver mutations on a much larger scale20–22. Below I will discuss the 
major types of NGS that are being used to study cancer genomics and the advantages 























Figure 1-4 Sequencing methodologies. 
The process of the DNA encoding a gene (containing 4 exons and 3 introns) is shown being 
transcribed into an mRNA with those same 4 exons spliced together and introns spliced out. The 
location of sequencing reads (coloured boxes) for each type of sequencing is shown. Genome 
sequencing (red) spans the entire DNA sequence including non-coding regions, exons, and 
introns. Exome sequencing (yellow) only covers the exons in the DNA. Targeted sequencing 
(green) only covers specific chosen regions, in this case only targeting exon 2 of this sequence. 
RNA sequencing (purple) covers the mRNA sequence that has already been spliced to contain 
only coding exons. Created with BioRender.com. 
Targeted Panel Sequencing 
Targeted sequencing (TS) is the most cost-effective application of NGS for 
cancer genomics. This entails a pre-determined panel of genes or genomic regions of 
interest that are enriched from a library to allow for sequencing. Such gene panels are 
designed based off previous knowledge of which areas of the genome are most likely to 
have mutations and provide the most information with the smallest panel size and cost. 
These can be extremely useful for specific cancer types where many of the driver 
mutations and cancer genes are known, and the goal is to determine which of these 
Exon 2 Exon 4 Exon 3 Exon 1 








Intron 1 Intron 2 Intron 3 
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known mutations are found in each tumour of that type. Panel sequencing is also very 
useful for performing ultra-deep sequencing to detect mutations with high sensitivity. 
This is important for applications such as circulating tumour DNA (ctDNA) or formalin 
fixed paraffin embedded (FFPE) DNA where tumour content is low, or DNA quality is 
poor23,24. In this respect it can also be useful for detecting sub-clonal mutations that have 
a low frequency of mutant alleles25. In a recent publication that I was co-first author on 
(Rushton et al.)26, we described the use of liquid biopsies (ctDNA) from relapsed or 
refractory DLBCL patients to discover novel drivers of intrinsic and acquired treatment 
resistance. We employed targeted panel sequencing of known lymphoma genes/regions 
of interest on ctDNA extracted from rrDLBCL patient blood samples. This led to the 
discovery that patients with TP53 or KMT2D mutations had significantly worse 
outcomes. In addition, we identified MS4A1 mutations in patients treated with R-CHOP 
that suggested they were acquiring resistance to rituximab. Unfortunately, due to the 
restrictiveness of a small panel of genes/regions that must be chosen based off prior 
knowledge, this approach is limited in its ability to discover novel driver mutations or 
cancer genes of interest.  
Exome Sequencing 
Whole exome sequencing (WES) has become a popular choice for sequencing 
tumours and offers an appealing balance of cost and coverage of the coding regions of 
the genome for many cancer genomics applications27–30. By sequencing the coding 
regions of the genome (the exome) that represent only ~1% of the entire genome, 
sequencing reads are not wasted on the 99% of the genome that does not encode 
proteins. Instead, this assay is focused on regions containing genes that are generally 
expected to harbour many driver mutations. In contrast to smaller panels, WES allows 
unbiased interrogation of all coding genes and thus novel mutations and cancer genes of 
interest can be detected without a prior knowledge of the genes relevant in that cancer. 
Currently, the vast majority of cancer genomic studies rely on WES as their main 
sequencing method including most of the studies that were conducted as part of The 
Cancer Genome Atlas project31. WES is an attractive option because it is cheaper than 
sequencing the entire genome and specifically focuses on genes and mutations that are 
the most likely to be easily interpretable as drivers and eventually clinically actionable. 
This means that most current studies are searching for coding mutations (in exons) and 
although protein-coding mutations are very common in cancer, there is recent evidence 
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than many of these studies could be missing novel non-coding driver mutations that do 
not occupy the exome32–39. 
Whole Genome Sequencing 
Whole genome sequencing (WGS) offers the most comprehensive approach to 
genetically characterize a tumour tissue sample40–42. The field of cancer genomics is 
becoming saturated with WES studies that have identified the most common protein-
coding mutations in most cancer types. Despite this deep understanding of the protein-
coding drivers of cancer, some cancers that have been studied through such 
approaches do not have known drivers. Even within well-characterized cancer types, a 
subset of tumours can have no detectable drivers in the coding genome. This suggests 
there could be other areas of the genome involved in driving cancer progression. The 
non-coding areas of the genome are beginning to become appreciated as areas that can 
contain relevant drivers of cancer, but these are only able to be identified by studies 
using WGS to search for novel driver mutations. WGS has been shown on numerous 
accounts to be important for the discovery of novel non-coding mutations that would 
otherwise be missed with WES32,34,42–47. Although it is more complicated to predict the 
effects of non-coding variants, it is still important to search for these mutations and 
further characterize their roles in driving cancer and determine their implications in 
treatment resistance.  
RNA-Sequencing 
RNA sequencing (RNA-seq) is a sequencing-based application used to quantify 
gene expression and to study other features of the transcriptome48,49. A goal in RNA-seq 
analysis commonly involves determining differentially expressed genes between 
groups50. These comparisons can include tumour vs. normal, mutant vs. wild-type, or a 
multitude of other different groups within cancer types. By identifying which genes are 
expressed in the tumours and their expression levels, we can determine which pathways 
are being upregulated (or downregulated) and which could potentially be targeted with 
therapeutics. RNA-seq is also used to investigate the effects of certain mutations to see 
if they are affecting the expression of a driver gene. In general, gene expression analysis 
can be a useful technique for determining novel biomarkers. Expression of certain genes 
can act as a biomarker to diagnose a certain cancer type (diagnostic), inform on patient 
outcome regardless of treatment (prognostic) or aid in determining the likelihood of 
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response to a certain drug (predictive)51–53. RNA-seq data has also been used to detect 
somatic mutations in actively expressed genes54,55. 
 
1.1.6. The Non-Coding Genome 
As discussed above, the bulk of cancer genomic studies to date have focused on 
the detection and characterization of protein-coding mutations that drive cancers. This 
has been perpetuated by the reliance on WES as the main sequencing method for many 
of these studies. The more recent interest in WGS to identify novel cancer drivers has 
afforded studies the option to not only search for mutations in the coding genome, but 
also explore the largely understudied non-coding genome that represents a much larger 
portion of the overall genome. The non-coding genome consists of various classes of 
functional elements that can regulate the expression of protein-coding genes. These 
include introns, cis-regulatory elements (CREs), non-coding RNAs (ncRNAs), and 
repetitive elements56–59 (Figure 1-5).  
Broadly, CREs are non-coding areas of the genome that regulate the 
transcription of nearby genes, they can be categorized as promoters, enhancers, and 
insulators. Because of their involvement in regulating gene expression, they have 
recently been recognized for their role in controlling the expression of oncogenes and 




Figure 1-5 The non-coding genome. 
Features of the non-coding genome and their functional role. This is Figure 1 adapted with 
permission from Zhang et al., 2020.47 
1.1.7. Non-coding and Regulatory Mutations 
The most widely documented type of regulatory mutation in cancer involves 
genomic structural rearrangements. In contrast to those involving the protein-coding 
region of genes, which lead to the formation of new oncogenic fusion proteins such as 
BCR-ABL
8, many important rearrangements in cancer genomes do not affect protein-
coding regions of cancer genes. For example, Burkitt lymphomas (BLs) all share a 
translocation between the chromosomes harbouring MYC and one of the 
immunoglobulin heavy chain (IGH) or light chain enhancer regions60. This puts MYC 
under the control of the IGH enhancer and leads to MYC overexpression. The 
amplification of enhancer regions is also seen as another way to overexpress 
oncogenes in cancer. For example, in multiple types of cancer amplifications of different 
enhancer regions of MYC have been found61–63. The co-amplification of oncogenes and 
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their enhancer(s) has also been seen in cancer, including in glioblastoma where the 
gene EGFR as well as multiple of its enhancers have been found to be co-amplified64. 
It is clear that protein-coding alterations are fundamental to most cancers but 
recent studies have begun to reveal a growing assortment of recurrent non-coding 
mutations in cancer genomes38,65,66. There is increasing evidence that the same types of 
mutations that affect protein-coding regions (discussed in a previous section) also affect 
non-coding regions. SSMs such as SNVs and small indels, as well as larger SVs like 
translocations and amplifications have all been seen to occur in the non-coding genome. 
Although the effects of these mutations are not always apparent, this next section will 
discuss a selection of examples of how mutations affecting the non-coding genome can 
act as cancer drivers and highlight the importance of studies that aim to discover and 
characterize novel non-coding mutations.  
Just as SNVs and indels can affect the protein-coding region of cancer genes in 
a way that can enhance fitness of cancer cells, so-called “silent” mutations can affect the 
function of regulatory elements, such as promoters and enhancers, in the non-coding 
genome. Although few examples of such regulatory driver mutations have been 
documented, these can theoretically lead to either enhanced expression of oncogenes 
or repression of TSGs. For example, in multiple cancer types, there have been SNVs 
found in the promoter of the gene TERT which encodes the protein telomerase67–69. 
These SNVs act as gain-of-function mutations by creating a de novo binding motif within 
the TERT promoter that allows the transcription factor (TF) GABP to bind and activate 
TERT
70. Similarly, SSMs have also been reported to affect the enhancers of ESR1 in 
breast cancer and FOXA1 in prostate cancer. In ESR1-positive breast cancers, somatic 
mutations affecting ESR1 regulatory elements were found to regulate ESR1 expression 
by modulating TF binding71. Six active CREs were found to regulate FOXA1 expression 
in prostate cancer, and SNVs affecting these regions were found to confer 
transactivating potential by modifying TF binding72. 
Finally, this thesis focuses on the remaining class of non-coding mutations with 
regulatory potential, namely those affecting the UTRs of genes. Mutations in the 3′ UTR 
are of interest because of the role of this region in a variety of post-transcriptional 
regulatory processes. The 3′ UTR can contain many cis-acting regulatory elements 
(including secondary structures such as stem-loops and pseudoknots) that are 
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recognized and bound by trans-acting regulatory elements such as RNA binding proteins 
(RBPs) or miRNAs. When mutations occur in these cis-regulatory regions, the post-
transcriptional mechanisms are disrupted and can lead to cancer gene overexpression. 
SSMs can disrupt miRNA binding sites33 and larger deletions have also been seen to 
delete the entire regulatory region of the UTR73. In the case of both of these examples, 3′ 
UTR mutations (both SNVs and large deletions) in the CD274 gene led to 
overexpression of the PD-L1 protein in multiple cancer types33,73. Additionally, this has 
also been seen in the gene CCND1 in MCL, where mutations (both SNVs and larger 
deletions) in the 3′ UTR stabilize the mRNA leading to an increase of CCND1 expression 
and worse survival for patients74. Notably, despite the potential impact of such mutations 
on gene expression, at the outset of this project there was a very limited number of 
documented examples of recurrent UTR mutations affecting cancer genes. 
 
1.2. Personalized Medicine 
The understanding that tumours are driven by somatic mutations underlies the 
concept of personalized or precision medicine. In essence, different therapies should 
benefit each cancer patient in a predictable manner, which is dictated (in part) by the 
suite of driver mutations in that tumour 24,75–77. To successfully implement personalized 
medicine, it is important to fully understand the genetics of a disease: what are the 
potential driver mutations of this disease and what targeted agents can we use to treat 
it? A targeted treatment requires the knowledge of a specific “target” in a tumour cells, 
such as a highly expression protein or a novel fusion protein, that the treatment is 
specifically designed against. This involves a thorough exploration of a tumour’s 
genetics using a variety of sequencing technologies to discover novel drivers of each 
cancer type as well as a functional investigation of candidates to confirm their relevance 
and investigate therapeutic options to target them (Figure 1-6). This means that the 
discovery, prioritization, and validation of novel drivers of cancer are of great importance 
to the scientific community and the fight against cancer. Understanding the genetics of 
the disease will inform on the best targets to develop novel therapeutics against. The 
promise of adopting precision medicine to improve outcomes in lymphomas has been 
elusive thus far, with only a single targeted therapeutic that has been approved for use in 




Figure 1-6 Personalized medicine workflow. 
The personalized medicine workflow resulting in targeted treatment selection for a patient 
involves many experimental steps combined with data integration. The use of multiple sample 
and nucleic acid types combined with analyses methods will hopefully result in the description of 
molecular profiles that suggest which targeted treatments are expected to be the most effective 
for each profile. Sample types can include blood samples and tumour biopsies (bulk tumour, 
single cells or fresh frozen formalin fixed (FFPE) samples). Different nucleic acids can be 
extracted from these samples (ctDNA, DNA and RNA). A multitude of assays can be run on these 
nucleic acid samples including CAPP-Seq (cancer personalized profiling), whole exome 
sequencing (WES), whole genome sequencing (WGS), RNA Sequencing (ex. NanoString) and 
fluorescent in situ hybridization (FISH). The data from these assays can be analyzed in a variety 
of ways to discover different types of mutations (point mutations, indels, or structural variations) 
and changes in gene expression. This information can then be used to determine the molecular 
profile of each tumour and identify relevant targeted treatments. Created with BioRender.com. 
1.3. Lymphoma is a Diverse Collection of Diseases 
There are currently over 40 different lymphoma entities described in the latest 
revision of the WHO classification of tumours of haematopoietic and lymphoid 
tissues79,80. Historically, lymphomas have been categorized in part by 
immunophenotype, which is associated with the cell lineage and stage of terminal 
differentiation from which they arise (i.e., the cell of origin) (Figure 1-7). Within 
lymphomas, the broadest division is the historical separation of Hodgkin’s lymphoma 
(HL) from non-Hodgkin’s lymphoma (NHL). HL is characterized by the presence of 
Reed-Sternberg cells and accounts for only about 10% of lymphoma cases. By 
exclusion, NHL includes all other lymphomas and represents a diverse range of both 
indolent (slow growing) and highly aggressive lymphomas that can arise from cells 
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of lymphoid entities and the genetic heterogeneity that underlies the differences in 
morphology, phenotype and clinical features of this group of diseases. Overall, NHL is 
the sixth most common cancer in Canada, with over 10,000 estimated new cases in 
Canada81 and 150,000 new cases worldwide82 in 2020. Lymphoid cancers are a diverse 
group of cancers that affect countless people around the globe. Their heterogeneity 
suggests that molecular classification will be particularly informative and indispensable 
for the development of novel targeted therapies and the clinical implementation of such 
targeted treatments.  
 
Figure 1-7 Lymphoid cancers. 
Distinct types of lymphoid cancers arise from cells that have been blocked at different stages of 
maturation. Shown here is the general set of steps in the latter stages of B-cell differentiation, 
beginning with a lymphoid blast leaving the bone marrow and transitioning through the germinal 
center (GC) to undergo positive or negative selection and, if successful, ultimately becoming a 
plasma cell or memory B-cell83. Each of a few common mature B-cell cancer types is shown in a 
red box derived from the lymphoid cell they are most likely derived from. Chronic lymphocytic 
leukemia (CLL) is often derived from naïve B-cells before they enter the GC but in some cases 
can also result from post-GC B-cells84,85. Marginal zone lymphoma (MZL) and Mantle cell 
lymphoma (MCL) arises from cells that have just entered the marginal and mantle zones of the 
GC, respectively86,87. The germinal center B-cell (GCB) subtype of diffuse large B-cell lymphoma 
(DLBCL)88, follicular lymphoma (FL)89, primary mediastinal large B-cell lymphoma (PMBCL)90, 
nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)80, as well as Burkitt lymphoma 
(BL)91 are all derived from cells in the germinal center, though recent evidence may point to more 
diverse origins of DLBCLs. The activated B-cell (ABC) subtype of DLBCL88 and intravascular 
large B-cell lymphoma (IVLBCL)92 are derived from cells that have passed through the germinal 
center to become memory B-cells. Similarly, multiple myeloma (MM) is derived from plasma cells 
that have successfully exited the germinal center93. Created with BioRender.com. 























1.3.1. Diffuse Large B-Cell Lymphoma 
This thesis focuses on diffuse large B-cell lymphoma (DLBCL), which is the most 
common form of NHL, accounting for almost 30% of all new NHL diagnoses82. This 
disease can occur at any age, but the incidence peaks in the mid-60s and is slightly 
more common in men94. It generally presents as a solid tumour mass in the lymph nodes 
but can also occur in other organs such as bone, central nervous system (CNS), 
gastrointestinal tract, sinuses, testicles, thyroid, or skin95. Frontline therapy for DLBCL is 
most commonly R-CHOP (rituximab, cyclophosphamide, doxorubicin 
(hydroxydaunomycin), vincristine (oncovin) and prednisone) chemotherapy, which cures 
approximately 60% of patients. Unfortunately for patients who are refractory to treatment 
or whose disease relapses (rrDLBCL), their objective response rate is only 26% with a 
median survival of just sixth months96. These poor outcomes for rrDLBCL patients 
highlight the need for a better understanding of why certain patients are not cured by R-
CHOP and the discovery of targeted therapeutics that will have a higher efficacy for 
these patients. Using molecular features to identify more effective alternative therapeutic 
strategies to enhance patient outcomes in DLBCL has been ongoing for decades and is 
the focus of this project. An important step towards this is to first understand the causes 
of clinical and biological heterogeneity in DLBCL. 
 
1.3.2. Molecular and Genetic Classifications of DLBCL 
Early applications of gene expression profiling (GEP) led to consistent 
approaches that could separate DLBCL into two molecular subgroups, namely germinal 
center B-cell-like (GCB) and activated B-cell-like (ABC), leaving around 15% of cases 
unclassifiable53,97,98. These two subtypes have gene expression features of, and thus 
may arise from, cells at different stages of lymphoid development, or cells-of-origin 
(COO). The ABC subtype has inferior outcomes to that of GCB DLBCL (3-year 
progression-free survival, approximately 40 to 50%, vs. 75%)99,100. These classifications 
are of interest because they are associated with prognostic differences for DLBCL 
patients treated with R-CHOP. Moreover, these two subgroups have distinguishing 
molecular features such as differential expression of signaling pathways that have been 
suggested to reveal distinct vulnerabilities that may be exploited therapeutically101–106. 
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Identifying alternative therapeutics for ABC DLBCL has been of particular interest given 
the poor outcome of these patients. 
Although GEP is considered the gold standard for determining COO molecular 
subtype97, until recently, no GEP application could be routinely applied in a clinical 
setting. In lieu of these, several immunohistochemistry (IHC)-based methods have been 
devised to allow COO to be inferred using the expression of a combination of protein 
markers107–111. The most common of these methods is the Hans algorithm which uses 
the expression of three proteins (CD10, BCL6 and MUM1) to classify samples as GCB 
or non-GCB (generally considered to represent ABC cases)107. More recently the 
Lymph2Cx NanoString assay has been described that is able to classify COO from the 
expression of 20 genes measured from RNA extracted from FFPE tissue, which allows 
its application to archival clinical specimens112. 
 
Germinal Center B-Cell-Like DLBCL 
GCB DLBCLs, by definition, exhibit a similar gene expression pattern to cells 
found within the germinal center, which includes high expression of CD10, LMO2 and 
BCL6
97,98. Ectopic expression of the antiapoptotic protein BCL2 driven by translocation 
with the IGH locus t(14;18)(q32;q21) has long been considered one of the common 
features of GCB DLBCL but, unlike in follicular lymphoma, this event is present only in a 
minority of cases. Through exome and genome sequencing, numerous additional 
recurrently mutated genes in GCB DLBCL have been identified. These include an 
assortment of genes involved in histone modification such as EZH2 (Tyr461 hotspot), 
KMT2D, CREBBP, and EP300 and also include GNA13, SGK1, and TNFRSF1455,113–119 
(Figure 1-8). Other cytogenetic abnormalities such as amplifications of c-Rel as well as 
loss of PTEN expression also commonly occur in this subtype106. Some GCB DLBCLs 
have both MYC and BCL2 or BCL6 translocations and are termed “double hit” (DHIT) 
lymphomas and some have translocation of all three genes and are termed “triple 
hit”43,120,121. These represent around 4-8% of DLBCLs and have a poor prognosis, even 
though they are generally considered GCB-like82. 
Another group of GCB DLBCLs are derived from the transformation of indolent 
follicular lymphoma (FL/tFL)122. FL is the second most common form of NHL with a 
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median survival of over 10 years123,124 and although slow growing, it is generally 
considered incurable125. The majority of FLs harbour the t(14;18)(q32;q21) translocation 
that is also commonly seen in GCB DLBCLs126,127. A small subset of FLs will 
histologically transform into more aggressive lymphomas, which are most commonly 
consistent with DLBCL morphology and the GCB subtype122,128. Often (t)FL and GCB 
lymphomas are studied together as they share similar genetic features and appear to 
both derive from germinal center B cells55,97,129. There is a growing appreciation that so-
called de novo GCB DLBCLs may arise from an underlying indolent lymphoma that 
evades diagnosis. As will be discussed in more detail below, FL may represent only one 
of several indolent lymphomas that may lead to the eventual manifestation of DLBCL.   
 
Figure 1-8 The germinal center B-cell subgroup of DLBCL. 
The most common mutation found in GCB DLBCLs is the t(14;18)(q32;q21) translocation which 
drives overexpression of BCL2. This leads to inhibition of apoptosis and prevents cell death. 
Mutations in histone modifying genes are also common in GCB DLBCL including those in EZH2, 
KMT2D, CREBBP, and EP300. Genes commonly seen mutated in GCB DLBCL are shown with 
red outlines. Created with BioRender.com. 
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Activated B-Cell-Like DLBCL 
The ABC subtype is comprised of cells derived from plasmablasts which have 
already passed through the germinal center to become activated and express a similar 
set of genes to mature memory B-cells or plasma cells102. ABC DLBCL is often 
characterized by activation of the NF-κB signaling pathway which promotes cell growth 
and survival97,98. Genes that are commonly found to be mutated in the ABC subtype 
include MYD88 (L265P hotspot), CD79A/B, CARD11, TNFAIP3, TBL1XR1, and 
BCL10
101,115,118,119,130,131
 (Figure 1-9). Genomic alterations affecting BCL2 are also 
common in the ABC subtype, however instead of translocations which are common in 
GCB, BCL2 is more commonly amplified in ABC DLBCL132. MALT1 amplifications are 
also seen in the ABC subtype133. 
 
Figure 1-9 The activated B-cell subgroup of DLBCL. 
Activation of the NF-κB signaling pathway is a feature of ABC DLBCL which can be explained, in 
part, by mutations that affect regulators of this pathway. Genes commonly mutated in ABC 









































1.3.3. Redefining DLBCL Classification with Genomic Features 
For a variety of reasons that will be discussed in a subsequent section, the COO 
subgroupings of DLBCL have been unable to provide sufficient granularity to allow their 
implementation in clinical practice. Recently, three separate studies describe their 
attempts to resolve this issue by suggesting a more refined set of subtypes of DLBCL 
that are defined by genetic features134–138. Briefly, Schmitz et al.135 first described four 
distinct genetic sub-groups based on co-occurrence of genetic alterations (MCD, EZB, 
BN2, and N1) which was then expanded upon by Wright et al.136 by the addition of two 
new subtypes (ST2 and A53) and the release of a publicly available classifier that 
assigns cases to one or more of these six clusters (termed LymphGen). Chapuy et al.134 
described a supervised clustering method that uses recurrent mutations, CNAs, and SVs 
to assign patients to one of five genetically similar clusters (C1-C5). This system, 
referred to henceforth as the Harvard system, does not yet have a publicly available 
approach that allows its application to additional data sets. Lastly, Lacy et al.137 
performed targeted sequencing on a large group of DLBCL patients and used Bernoulli 
mixture-model clustering to discover five molecular subtypes (MYD88, BCL2, 
SOCS1/SGK1, TET2/SGK1, and NOTCH2), which I will refer to as the HMRN system. 
Although these three groups used different data and analysis methods, the subgroups 
they reported share many of the same genetic features and can be grouped 
accordingly138 (Figure 1-10). Although there is much remaining to be determined, the 
defining features and biological characteristics of these individual groupings and their 




Figure 1-10 New genetic classifications of DLBCL. 
The progression of a lymphoid blast through the germinal center (GC) is shown, with the cancer 
types that originate from each step of differentiation. The novel genetic subclassifications 
described by the LymphGen135,136, Harvard134 and HMRN137 groups are shown with the other 
lymphoid malignancies they most closely resemble. Chronic lymphocytic leukemia (CLL), 
marginal zone lymphoma (MZL), double-hit lymphoma (DHL), Burkitt lymphoma (BL), follicular 
lymphoma (FL), nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), primary 
mediastinal B-cell lymphoma (PMBCL), primary central nervous system lymphoma (PCNSL), 
primary testicular lymphoma (PTL) and Waldenström macroglobulinemia (WM). Although these 
three groups separately described distinct molecular subgroups, they can all be mapped to seven 
related sets of genetic subgroups (boxes). Characteristics shared between each of these sets are 
shown in the boxes along with the common pathways/features of each set. FDC (follicular 
dendritic cell). Created with BioRender.com. 
The MYD88-CD79B subgroup (MCD) 
The MCD subgroup is characterized by MYD88 and CD79B mutations and is 
most similar to the Harvard C5 and HMRN MYD88 subgroups. It is also highly enriched 
for ABC cases. This subgroup commonly has mutations that activate the B-cell receptor 
(BCR) and NF-κB signaling pathway, including genes such as CDKN2A, ETV6, and 











































































including primary CNS lymphoma (PCNSL), and primary testicular lymphoma (PTL), 
which all derive from cells with a memory B-cell origin139. 
 
The BCL6-NOTCH2 subgroup (BN2) 
The BN2 subgroup is characterized by BCL6 and NOTCH2 mutations and is 
most similar to the Harvard C1 and HMRN NOTCH2 groups. This subgroup is also 
enriched for ABC cases and characterized by NF-κB signaling but commonly has 
mutations in genes such as SPEN, TNFAIP3, and BCL10. Mutations affecting immune 
evasion are also common including PD-L1 and PD-L2. The characteristics of BN2 cases 
make them genetically similar to marginal zone lymphoma (MZL), which originate from 
cells within the marginal zone of the germinal center140. 
 
The EZH2-BCL2 subgroup (EZB) 
The EZB subgroup is characterised by EZH2 hot spot mutations and 
immunoglobulin-BCL2 translocations and is the most similar to the Harvard C3 and 
HMRN EZH2 groups. When the Schmitz group released their LymphGen classifier136 as 
an update to their original paper, they further split the EZB subgroup into MYC+ and 
MYC- groups. EZB cases commonly have mutations in histone modifying genes such as 
KMT2D, CREBBP, EP300, ARID1A, and MEF2B. Both EZB-MYC+ and EZB-MYC- are 
most commonly GCB DLBCL cases, however EZB-MYC+ cases are DHIT+ and share 
genetic similarities with BL91 whereas EZB-MYC- cases are DHIT- and more similar to 
FL, which is derived from centrocytes in the germinal center light zone89. 
 
The NOTCH1 subgroup (N1) 
The N1 subgroup is defined solely by the presence of a subset of NOTCH1 
mutations that are known to induce Notch signaling. N1 cases make up a small minority 
of DLBCLs and were not defined by the Harvard or HMRN systems. This subgroup often 
has mutations in other genes such as ID3, ICOR, and IKBKB but these are also rare in 
DLBCL and not entirely restricted to N1. The main pathway signatures of this group are 
NOTCH signaling and quiescence. Although NOTCH1 mutations are considered rare in 
DLBCL, they are much more common in chronic lymphocytic leukemia (CLL) and 
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suggests that N1 cells are most closely similar to CLL cancers that derive from cells with 
a naïve B cell origin84,85. 
 
The SGK1-TET2 subgroup (ST2) 
This is one of two subgroups that was added more recently to the LymphGen 
classifier based on findings from other studies136. Based on shared features, it is most 
closely related to the Harvard C4 group and maps to the SGK1 subtype described by the 
HMRN group which was then subdivided into two distinct subtypes by this group. ST2 is 
characterized by mutations in SGK1 and is further split into SOCS1/SGK1 and 
TET2/SGK1 in the HMRN system. The SOCS1/SGK1 subgroup commonly has 
mutations in genes such as CTD83ET2, ITPKB, NFKBIE, and CIITA which often affect 
JAK/STAT signaling. In contrast, the TET2/SGK1 subgroup often has mutations affecting 
KLH6, ZFP36L1, BRAF, and KRAS and RAS/ERK signaling is often activated. The 
SGK1 mutations in ST2 cases are known to affect PI3K signaling and have a similar 
genetic signature to nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and 
primary mediastinal B-cell lymphoma (PMBCL)90. 
 
The TP53-copy number subgroup (A53)   
Although not originally described in the paper by Schmitz et al.135, later when the 
same group release the LymphGen classifier136, they acknowledged ST2 and A53 as 
additional subtypes. This group was most similar to the Harvard C2 group but had no 
corresponding group from the HMRN system, likely due to limited copy number data 
from their sequencing panel. This subtype was mainly characterized by TP53 mutations 
and deletions and was highly enriched for copy number alterations. Other genes seen 
commonly affected by copy number alterations in this subgroup were TNFAIP3, PRDM1, 




Although these novel subgroupings offering a more granular division of DLBCLs 
are meant to provide more distinct information on which pathways are affected in each 
tumour and relevant therapeutic vulnerabilities of each subtype, there still remain many 
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cases that are unclassified by these algorithms. The LymphGen classifier leaves over a 
third of DLBCLs unclassified (Other)136. The groups discussed above do not have perfect 
equivalencies between systems, which leads to ambiguity regarding the aetiology of 
cases that are classified differently by each system (Figure 1-11). This highlights the 
need to uncover novel mechanisms of lymphomagenesis and what drives the tumours 
that are currently being unclassified and include them in future iterations of these 
classification algorithms.  
 
Figure 1-11 Comparison between the LymphGen and Harvard classification 
system subtypes. 
Oncoplot (above) showing mutations in three separate cohorts and the most common mutations 
seen in the novel genetic subtypes described by LymphGen. This includes LymphGen with the 
A53 group and without (Original LymphGen). The alluvial plot (below) shows the agreement and 
discordance between the subtypes defined by the two groups. Although the subgroups from 
different systems overlap, there is still substantial differences between which subgroup patients 
are classified into. 
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1.3.4. Progress and Barriers in the Application of Precision Medicine 
Since the addition of rituximab, a monoclonal antibody targeting CD20, to CHOP 
chemotherapy in the early 2000s141,142, there have been virtually no advancements to 
frontline treatment for DLBCL patients that have changed patient care. The search for 
new targeted therapies for DLBCL is intriguing, but unfortunately thus far most clinical 
trials have shown minimal, mixed, or no benefit for patients and often result in high 
toxicity rates143–152. This section provides a brief overview of the goals and results from a 
selection of trials that explored individual candidate targeted therapies that each were 
intent on impacting DLBCL cases differentially based on the current understanding of 
cell of origin. 
The phase 3 trial REMoDL-B compared the effects of adding bortezomib to 
standard R-CHOP treatment for previously untreated DLBCL patients149. Bortezomib is a 
small molecule that inhibits the activity of the proteasome. The rationale for its use in 
DLBCL was based on the proteasomal degradation of IκBα as a key regulatory step in 
NF-κB signaling153. Unfortunately, even through the use of gene expression profiling to 
determine COO, there was no improvement in progression-free survival (PFS) for any 
group of patients, regardless of COO classification. Another study also tested the 
addition of bortezomib to R-CHOP but they too found that outcomes were not 
significantly improved in non-GCB previously untreated DLBCL patients154. 
The small molecule inhibitor ibrutinib blocks BCR signaling by binding to the 
active site of Bruton’s tyrosine kinase (BTK) and inhibiting its activity. It was therefore 
anticipated to produce favourable response rates in treating ABC DLBCL due to its 
reliance on BCR activated NF-κB signaling. A small phase I/II trial of ibrutinib in rrDLBCL 
revealed that patients treated with ibrutinib were more likely to have a complete 
response (CR) or partial response (PR) if they had ABC DLBCL (37%) compared to only 
5% if they had GCB DLBCL147. In the PHOENIX trial, addition of ibrutinib to R-CHOP 
improved PFS and overall survival (OS) in non-GCB DLBCL under the age of 60. 
Unfortunately in patients over 60, ibrutinib plus R-CHOP was also associated with 
substantially increased toxicity that led to worse outcomes overall150.  
Lenalidomide is an immunomodulatory drug that has been shown, among many 
other targets, to downregulate IRF4 expression in ABC DLBCL155. There have been 
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multiple trials investigating the use of lenalidomide to treat previously untreated DLBCL, 
but the results have been mixed with no clear consensus on its utility. The ROBUST trial 
considered the addition of lenalidomide to R-CHOP in ABC DLBCL patients only, but did 
not show any significant survival benefits between treatment arms148. In contract, the 
ECOG-ACRIN trial did see an improvement of outcome in newly diagnosed DLBCL 
including ABC DLBCL when lenalidomide was added to R-CHOP (R2-CHOP)145. This 
contradictory pair of trials leave the potential of this therapeutic in ABC DLBCL an open 
question. Given the ongoing changes to DLBCL classification, retrospective analyses of 
these data sets may help resolve this and could shed light on which genetic subgroups 
may benefit from this therapy.  
Other notable trials that failed to show a benefit compared to conventional R-
CHOP treatment include the GOYA trial (obinutuzumab)156, CAVALLI trial (R/G-CHOP 
with venetoclax)152 and the SENIOR study (R2-miniCHOP)146. 
This collection of trials is representative of a larger pattern of results that 
collectively suggest that targeted therapies may benefit small subsets of patients, but 
with a deficit in the understanding of what molecular or genetic features (if any) affects 
which patients benefit. To overcome this, we need to discover the genetic basis for why 
patients respond or do not respond to each targeted drug. Such knowledge could 
theoretically facilitate the stratification of patients based on the genetics of their disease 
such that they could be assigned a therapy with a higher chance of success in clinical 
trials. This requires further research into the genetics that drive DLBCL to ensure we 
have a comprehensive understanding of the genetics of this heterogenous disease and 
the interplay between genetics and response to targeted therapeutics. 
 
1.4. NF-κB Signaling Pathway 
NF-κB is a family of inducible transcription factors comprised of NF-KB1 (p50 and 
precursor p105), NF-KB2 (p52 and precursor p100), RelA (p65), RelB and c-Rel157–160. 
These proteins are normally kept in an inactive state by association with the inhibitory 
proteins IκBα, IκBβ and IκBε161. Bcl-3 is known to act as a co-activator, complexing with 
NF-κB subunits rather than inhibiting them162,163. Upon stimulation, these inhibitory 
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proteins are released and degraded by the proteasome, leaving he NF-κB proteins 
available to translocate into the nucleus. Individual NF-κB monomers complex to form 
either heterodimers or homodimers that can either activate or repress transcription, 
respectively164. NF-κB dimers translocate into the nucleus and activate transcription of 
specific target genes by binding to κB sites in their respective promoters or enhancers. 
Recently, it has been shown that dimers share overlapping target regions but also have 
distinct regions depending on the components of the dimer165. This adds another level of 
complexity to the NF-κB signaling pathway that has yet to be fully explored.  
The main activation targets of the NF-κB pathway include chemokines, immune 
receptors, adhesion molecules, stress response genes, apoptosis regulators, 
transcription factors, growth factors, and cell cycle regulators166. The collective result of 
activation of this pathway generally is the maintenance of cell growth, proliferation, and 
survival signals, thus this pathway promotes multiple hallmarks of cancer (Figure 1-12).  
 
1.4.1. Canonical NF-κB Signaling 
The canonical (classical) NF-κB signaling pathway is activated by ligands binding 
to TNFR1/2, T-cell receptors (TCRs), BCRs, or toll-like receptors (TLRs)164 (Figure 1-12 
left). The activation of these receptors leads to the phosphorylation of the IκB proteins by 
the IκB kinase (IKK) complex. This phosphorylation leads to the eventual degradation of 
the IκB proteins by the proteasome, releasing the NF-κB proteins to translocate into the 
nucleus. This allows the formation of the NF-κB dimers p50/p65 and p50/c-Rel which 
bind to the DNA to activate target gene transcription167. The target genes of the 
canonical pathway include chemokines, cytokines, and adhesion molecules, which 
together promote inflammatory responses and cell survival. 
 
1.4.2. Non-canonical NF-κB Signaling 
The non-canonical (alternative) NF-κB signaling pathway is triggered by the 
activation of tumour necrosis factor (TNF) receptors such as LTβR, CD40, and CD30164 
(Figure 1-12 right). The activation of these receptors leads to IKKα phosphorylating the 
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p100 precursor of p52 which allows the formation of the p52/RelB dimer. The target 
genes activated by the p52/RelB dimers are involved in regulation of the adaptive 
immune system and lymphoid organ development. 
 
Figure 1-12 The NF-κB signaling pathway. 
The NF-κB signaling pathway is responsible for activating genes that lead to cell growth and 
survival. It can be split into two pathways, the canonical (shown in purple) and the non-canonical 
(shown in green) pathways. The canonical pathway relies on activation of target genes by the 
p65/p50 heterodimer that are responsible for inflammatory response and cell survival. The non-
canonical pathway relies on the RelB/p52 heterodimer to activate target genes involved in 
adaptive immunity and lymphoid development. Created with BioRender.com. 
1.4.3. NFKBIZ Gene 
NFKBIZ is the gene that encodes the IκB-ζ protein. As its name indicates, it was 
originally described as an inhibitory IκB protein, however more recently it has been 
shown to both activate and repress transcription of different sets of target genes168,169. 
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Expression of IκB-ζ is normally kept at a low level in resting cells, but its expression is 
rapidly induced by stimulation of the innate immune system170. The binding of many TLR 
ligands leads to induction of IκB-ζ including lipopolysaccharide, peptidoglycan, CpG 
DNA, bacterial lipoproteins, flagellin, and R-848 (an imidazoquinoline derivative)169,171.  
Unlike most other IκB proteins that act in the cytosol to inhibit NF-κB proteins, 
IκB-ζ acts as a trans-activating molecule, similar to Bcl-3163,169, where it functions in the 
nucleus and complexes with other NF-κB proteins in order to exert its effect. In a study 
that explored the effects of removing the nuclear localization signal (NLS), it was shown 
that IκB-ζ mutants with a defective NLS localized in the cytosol instead of the nucleus 
and acted more like conventional IκB proteins to inhibit NF-κB168. IκB-ζ was previously 
found to strongly associate with p50/p50 homodimers and p50/p65 heterodimers168 but 
has more recently been found to also interact with p52/p52 homodimers as well172. 
Through formation of a stable ternary complex with these NF-κB subunits, IκB-ζ is 
directly involved in regulation of NF-κB transcriptional activity. Normally homodimers are 
thought to repress transcription due to their lack of transactivating domains158,160,173, 
however IκB-ζ is able to confer transactivating potential to them and cause induction of 
numerous target gene expression. It appears that IκB-ζ may have a dual function role 
where it confers transactivating potential to p50/p50 or p52/52172,174 homodimers while 
simultaneously inhibiting the transcriptional activity of p50/p65 heterodimers175. As it has 
been seen to interact with both p50 and p52 NF-κB subunits, IκB-ζ appears to play a role 
in both canonical and non-canonical NF-κB signaling. 
 
1.4.4. NFKBIZ in DLBCL 
NFKBIZ was found to be highly expresses in ABC DLBCL and its downregulation 
was selectively toxic only to this subtype172. Amplifications of this gene were discovered 
in about 10% of DLBCLs176 as well as PTL and PCNSL139. Nogai et al. showed that 
knockdown of NFKBIZ was toxic to ABC DLBCL cell lines (but not GCB or other 
lymphoma cell lines) and that known NF-κB targets were downregulated after NFKBIZ 
knockdown using shRNA172. These putative novel targets of IκB-ζ identified by RNA-
sequencing of NFKBIZ knockdown experiments included SOCS3, BATF, BCL3, 
CDC25A, IL5RA, and EBI3 as well as IL-6 and IL10 via ELISA and BCL-XL, JUNB, IκBα, 
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and pSTAT3 via western blot. In that study, however, it was noted that no mutations in 
the coding sequence of NFKBIZ were found172. 
 
1.5. Problem Statement 
Although the majority of DLBCL patients are cured with conventional R-CHOP 
chemotherapy, there remain cases that are refractory to frontline treatment and/or 
eventually relapse. Many novel targeted therapeutic agents are at various stages of 
evaluation for their potential utility in treating these rrDLBCLs but efforts thus far have 
been disappointing. This can be attributed, at least in part, to the vast genetic 
heterogeneity of DLBCLs, which is becoming more appreciated with the advent of the 
new molecular profiling subtypes that were recently described134–137. It is becoming clear 
that to select patients to receive the targeted therapy that will cure their disease, we 
need a full understanding of the genetic drivers of their disease. This includes both the 
extensively studied coding areas of the genome as well as the under-studied non-coding 
genome. The discovery of novel drivers of DLBCL, including mutations that affect the 
regulation of gene expression, requires an integrative analysis involving a combination of 
genome, exome, or targeted sequencing along with gene expression data from matched 
samples. In addition, to discovering novel driver mutations, it is important to follow their 
discovery with functional characterizations to fully understand how the cancer is being 
driven and determine the best ways to exploit those pathways with existing or novel 
targeted therapies.  
 
1.6. Hypotheses 
1. Novel somatic non-coding mutations are present and act as drivers in 
diffuse large B-cell lymphoma. 
2. NFKBIZ 3′ UTR mutations act as driver mutations by causing protein 
overexpression which promotes activation of the NF-κB signaling 
pathway and affect response to targeted therapeutics in ABC DLBCL. 
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1.7. Research Aims and Thesis Outline 
In this work, I aimed to discover novel somatic non-coding driver mutations 
through WGS of DLBCL samples. Chapter 2 was published in Nature Communications 
and presents our findings from the analysis of WGS data from 153 DLBCL matched 
tumour/normal pairs, where we developed a novel strategy to identify coding and non-
coding mutations. Candidate driver mutations were discovered in the 3′ UTR of the 
NFKBIZ gene and Chapter 3 of this thesis describes the functional characterization of 
these mutations in the context of driving lymphoma and their utility in predicting the 
response to targeted therapeutics in DLBCL. 
This thesis consists of an introductory chapter, two data chapters describing 
original research and a general discussion chapter, which includes concluding remarks 
and an outline of future research directions. 
 
The structure of this thesis follows three specific aims: 
 
1. Identify cis regulatory non-coding driver mutations in DLBCL. 
2. Investigate the functional role of NFKBIZ 3′ UTR mutations in DLBCL. 




Chapter 2.  
 
Genome-wide Discovery of Somatic Regulatory 
Variants in Diffuse Large B-Cell Lymphoma 
Data presented in this chapter were previously published32. Sarah E. Arthur*, Aixiang 
Jiang*, Bruno M. Grande*, Miguel Alcaide, Razvan Cojocaru, Christopher K. Rushton, 
Anja Mottok, Laura K. Hilton, Prince Kumar Lat, Eric Y. Zhao, Luka Culibrk, Daisuke 
Ennishi, Selin Jessa, Lauren Chong, Nicole Thomas, Prasath Pararajalingam, Barbara 
Meissner, Merrill Boyle, Jordan Davidson, Kevin R. Bushell, Daniel Lai, Pedro Farinha, 
Graham W. Slack, Gregg B. Morin, Sohrab Shah, Dipankar Sen, Steven J. M. Jones, 
Andrew J. Mungall, Randy D. Gascoyne, Timothy E. Audas, Peter Unrau, Marco A. 
Marra, Joseph M. Connors, Christian Steidl, David W. Scott, and Ryan D. Morin. 2018. 
“Genome-Wide Discovery of Somatic Regulatory Variants in Diffuse Large B-Cell 
Lymphoma.” Nature Communications 9(1):4001. *Contributed equally. 
Contributions: AJ, BMG, CKR, EYZ, LC, SJ, LC, NT, PP, DL, SS, SJMJ, and RDM 
performed statistical and/or bioinformatics analysis of the data. BM, MB, DWS, DE, CS, 
JMC, RDG collected, processed, and annotated patient tissue samples and associated 
clinical data. I along with MA, RC, PU, AJM, GBM, MAM, TEA, DS performed 
experiments and/or collected/interpreted the data. PF and GWS scored the tissue 
microarrays. Specifically, I designed and conducted all functional validation experiments 
of NFKBIZ 3′ UTR mutations and data analyses presented in Figure 2-9. I, along with the 
other co-fist authors (AJ and BMG), DWS and RDM interpreted data and wrote the 
manuscript. All authors contributed to editing of the manuscript. 
 
2.1. Abstract 
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer originating from 
mature B-cells. Prognosis is strongly associated with molecular subgroup, although the 
driver mutations that distinguish the two main subgroups remain poorly defined. Through 
an integrative analysis of whole genomes, exomes, and transcriptomes, we have 
uncovered genes and non-coding loci that are commonly mutated in DLBCL. Our 
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analysis has identified novel cis-regulatory sites and implicates recurrent mutations in 
the 3′ UTR of NFKBIZ as a novel mechanism of oncogene deregulation and NF-κB 
pathway activation in the activated B-cell (ABC) subgroup. Small amplifications 
associated with over-expression of FCGR2B (the Fcγ receptor protein IIB), primarily in 
the germinal centre B-cell (GCB) subgroup, correlate with poor patient outcomes 
suggestive of a novel oncogene. These results expand the list of subgroup driver 
mutations that may facilitate implementation of improved diagnostic assays and could 
offer new avenues for the development of targeted therapeutics. 
 
2.2. Introduction 
It has been established that DLBCL, although genetically heterogeneous, can be 
robustly divided at the gene expression level into two “cell of origin” (COO) subgroups 
based on markers of B-cell differentiation and NF-κB activity pathways, where high NF-
κB activity is a hallmark of the ABC subgroup53. EZH2115, SGK1, GNA13, and MEF2B115 
exemplify genes that are mutated exclusively in GCB cases, whereas mutations in 
MYD88
131, CD79B101 and CARD11130 are reportedly more common in ABC. Some 
DLBCL cases have few mutations that are characteristic of either subgroup, suggesting 
that additional genetic changes may shape the malignancy. Similarly, the over-
expression of proteins with potential therapeutic and clinical relevance cannot always be 
explained by known genetic alterations177. Gaining a more complete understanding of 
the genetic features of DLBCL in general, and each subgroup in particular, should lead 
to improved methods for sub-classification, and further inform on the molecular and 
genetic underpinnings of the lymphoma found in individual patients. Such enhancements 
have the potential to facilitate the development of therapies such as small molecule 
inhibitors178 or monoclonal antibodies and immunotherapies that target somatic 
mutations or cell surface proteins179.  
Although there have now been thousands of DLBCL tumours analysed using 
targeted strategies such as array-based copy number analysis180 or whole exome 
sequencing (WES)181, a limited number of complete DLBCL genomes have been 
described to date118,182,183. Nonetheless, further analysis of DLBCL using whole genome 
sequencing (WGS) has significant potential to uncover new somatic structural variations 
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(SVs), copy number alterations (CNAs) and other cis-acting regulatory mutations that 
may be cryptic to more targeted approaches. In several lymphoid cancers, including 
DLBCL, the enzyme AID (encoded by AICDA), in cooperation with POLη, induces 
mutations in actively transcribed genes through the process of aberrant somatic 
hypermutation (aSHM)36, which affects a substantial number of loci in these cancers 
relative to other B-cell lymphomas184. As the repertoire of known aSHM targets in 
lymphoma continues to grow, it has become apparent that this process can also impact 
non-genic loci associated with super-enhancers. Given the disproportionate 
representation of mutations in non-coding regions, a thorough evaluation of the potential 
for regulatory driver mutations in aSHM targets and elsewhere is warranted185,186.  
Here, we present a novel strategy to identify coding and non-coding regions with 
an enrichment of somatic mutations genome-wide in large cohorts of patients, allowing 
us to identify sites affected by aSHM or with clustered mutations resulting from positive 
selection and infer their potential cis-regulatory effects on coding genes118,182. We 
analysed WGS data from 153 DLBCL tumour/normal pairs (discovery cohort), perform 
validation on an additional 338 cases (internal validation cohort) and compare these 
results to existing WES data from over 1000 additional cases (external validation 
cohort)181 to identify coding and non-coding loci recurrently affected by somatic single 
nucleotide variants (SNVs) or indels, collectively referred to as simple somatic mutations 
(SSMs) in DLBCL. Through the analysis of matched RNA-seq data, we uncovered the 
effect of recurrent structural variations (SVs) and recurrently mutated non-coding regions 
in mediating the transcriptional or post-transcriptional regulation of numerous genes with 
relevance to DLBCL. 
 
2.3. Results 
2.3.1. Local Mutation Density of SSMs 
Local mutation density of SSMs. In each of the 153 paired DLBCL genomes 
(cohort details in Supplementary Data 1, Appendix B), we detected between 1,689 
and 121,694 SSMs (median: 14,026; Supplementary Data 2, Appendix B). We 
separately inferred somatic copy number variations (CNVs) and 12,609 structural 
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variation (SV) breakpoints (range: 0–390; median 66; Supplementary Data 3, 
Appendix B) and annotated these based on proximity to genes. We implemented two 
new algorithms, Rainstorm and Doppler, that infer regions of arbitrary span with SSM 
density elevated above the local background. Rainstorm considers the positions of 
mutations pooled from a cohort of cancer genomes (optionally excluding any variants 
within the coding region of genes) and calculates local mutation density relative to each 
mutation, similar in principle to rainfall plots187. Doppler then infers the presence and 
boundaries of peaks of elevated local mutation rate. An initial analysis that excluded all 
mutations in coding regions detected 4,386 such peaks among the discovery cohort 
ranging from a single nucleotide to many kilobases (kb) in length (median length: 664 
nucleotides; Figure 2-1A; Supplementary Data 4, Appendix B). The regions within 
these peaks exhibited a median mutation density of 10.3 per kb, whereas a randomly 
selected region showed, on average, 1.00 mutation per kb. Our analysis also revealed 
examples of non-coding loci with mutation peaks, for example the two adjacent long 
non-coding RNA (lncRNA) genes NEAT1 and MALAT1 and the microRNA miR-142. 
Mutations at each of these loci have been previously noted in DLBCL and FL with a 
pattern consistent with aSHM188,189.  
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Figure 2-1 Rainstorm and mutation signature analysis of DLBCL genomes. 
(A) An overview of mutation peaks and the rainstorm representation of cohort-wide inter-mutation 
distance for chromosome 16. Peaks identified by the Doppler algorithm that could be attributed to 
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a nearby gene are labelled below. Known aSHM targets such as CIITA and IRF8 are among the 
most visible peaks in the Rainstorm view. (B) Our de novo inference of mutation signatures from 
the entire cohort revealed 11 robust signatures. Each signature was assigned to a reference 
signature from the curated set of 30 signatures in the Catalogue of Somatic Mutations in Cancer 
(COSMIC) database based on cosine similarity. The individual pie charts represent the strength 
of this similarity. The rows are arranged such that those with weaker similarity to a known 
signature are near the bottom. (C) A heat map showing the exposure of all 11 signatures in the 
genomes. Cases (columns) and signatures (rows) are ordered based on hierarchical clustering 
on the relative exposures. (D) Comparison of the exposure for the signatures in GCB and ABC 
cases including the four signatures with significantly higher exposure in GCB cases (indicated 
with an asterisk). The lower, middle, and upper boxplot hinges correspond to the 25th, 50th and 
75th percentiles, respectively. The boxplot whiskers extend outwards past the hinges up to the 
inter-quartile range×1.5 or the farthest value, whichever is closest. 
To determine the suitability of our approach to identify loci with mutations 
relevant to DLBCL biology, we applied Rainstorm/Doppler to all mutations including 
those within coding regions. We found a similar number of peaks (4,405), which 
comprised the bulk of original regions along with peaks in genes with known mutation 
hot spots such as EZH2, FOXO1, and MYD88 (Supplementary Data 5, Appendix B). 
Aside from intergenic regions (2,214), the top three peak annotations were Intron 
(1,620), 5′ Flank (258) and 3′ Flank (208). These are also the regions typically affected 
by aSHM and, as expected, virtually all of the known targets of aSHM182,184 were 
represented among the Doppler peaks. Some genes recurrently affected by non-silent 
mutations in DLBCL also displayed an excess of mutations affecting their non-coding 
regions, including SGK1, PRDM1, TMSB4X, and TBL1XR1. 
The relative representation of SNVs affecting distinct trinucleotide contexts, 
known as mutation signatures, can inform on the major mutational processes in a 
tumour. Using standard methods190, we inferred a robust set of 11 de novo signatures 
from the entire cohort and assigned each to a COSMIC reference signature on the basis 
of cosine similarity (Figure 2-1B; Figure 2-2). Hierarchical clustering of the cases based 
on the relative abundance of each signature (“exposure”) did not recapitulate the 
molecular subgroups (Figure 2-1C), though a direct comparison between ABC and GCB 
cases revealed four signatures with significantly higher exposure among GCB cases 
(Wilcoxon rank- sum test, P < 0.05) (Figure 2-1D). These include V6, a signature closely 
resembling one attributed to AID-mediated SHM (COSMIC Signature 9), which was 
identified in lymphoid cancers190, and V2, one of the more unique signatures identified 
herein (Figure 2-2). Given that AID is a cytidine deaminase, we compared the proportion 
of mutations affecting the C (or G) within AID recognition motifs that fall within and 
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outside peaks and confirmed a significant enrichment of mutations in this context within 
the Doppler peaks (P < 2.2 × 10−16, Fisher’s exact test). Although this points to AID 
activity as a major process driving mutagenesis in DLBCL, there is clearly a variable 
collection of other mutagenic processes at play. ABC cases showed lower exposure to 
the AID-related signature, though there were ABC cases with mutations in some of the 
peaks attributed to known aSHM targets. Paradoxically, the expression of AID was 
significantly higher among the ABC cases in our internal validation cohort (P= 9.1 × 10−6, 
Wilcoxon rank-sum test). There was also substantial variability in the exposure to 
this signature within GCB genomes. Taken together, these data suggest that other 
biological variables beyond COO affect the extent of AID-mediated mutation and the 
specific loci targeted by this process in DLBCL. 
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Figure 2-2 Mutation signatures inferred from somatic SNVs in 153 DLBCL 
genomes.  
(A) Somatic single nucleotide variants (SNVs) were quantified and categorized by base change, 
collapsing complementary pairs by selecting the pyrimidine reference base. The number of 
structural variants per sample is also shown. (B) SNVs were further subdivided into 96 classes by 
incorporating the trinucleotide context of each mutation. De novo signature inference yielded an 
optimal solution of 11 signatures. Each signature has been assigned to the most similar signature 
in COSMIC, which is indicated in parentheses. 
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2.3.2. Identifying Candidate cis-Regulatory Mutations 
The predominant mutation type known to directly affect gene expression in cis in 
DLBCL are translocations and other SVs. As expected, genes most frequently proximal 
to SVs were oncogenes with known relevance in DLBCL including BCL2, BCL6, FOXP1, 
and MYC (Figure 2-3). Some SVs affecting known or suspected oncogenes appeared 
within the gene body, such as those in FOXP1191, TBL1XR1, or NFKBIZ, which can lead 
to novel isoforms or fusion transcripts192. We searched for putative cis-regulatory 
variation by comparing the proximity of SVs to CNV foci previously identified through 
analysis of our validation cohort (Table 2-1; Ennishi et al., unpublished). Tumour 
suppressor genes (TSGs) more commonly contained SV breakpoints (typically 
deletions) within the gene body, including TP53, CDKN2A, and CD58. Some loci 
affected by a combination of SVs and CNVs also had nearby Doppler peaks (e.g., 
MEF2B and NFKBIZ; Table 2-1). In contrast, TOX and WWOX harboured a substantial 
number of distinct breakpoints including several examples of focal deletions but rarely 
contained SSMs (Figure 2-4A). However, few patients harboured SVs in TOX and 
WWOX, indicating these genes may rarely act as tumour suppressor genes in DLBCL. 
Many of the known aSHM targets were also enriched for SVs including MEF2B, a gene 
with multiple known mutation hot spots, particularly in GCB DLBCL. The function of 
MEF2B mutation in DLBCL has not been definitively established193,194, and these 
putative inactivating mutations provides further evidence of its role as a tumour 
suppressor but does not eliminate the possibility of shortened isoforms with an 
enhanced or distinct activity. Further complicating matters, MEF2B SVs were 
predominantly found in ABC, whereas hot spot mutations are a known feature of GCB, 







Table 2-1 Overview of SVs and CNVs proximal to genes detected by WGS 
  Structural Variation Recurrent CNV Summary 
Del Tra Dup Inv Num (type) Median Minimum Total Doppler Peak? 
TCF4 5 2 2 1 41 (A) 12986372 73803 44 no 
CDKN2A 22 20 0 1 22 (D) 16505508 400124 42 none 
NFKBIZ 6 3 0 3 31 (A) 17720083 944075 36 3′ UTRa 
FOXP1 9 6 2 0 27 (A) 19034690 3207496 35 introna 
FCGR2B 2 0 0 2 33 (A) 11049954 96085 34 noa 
IKBKE 1 0 1 0 28 (A) 15176955 1095013 29 no 
CD58 14 10 4 0 11 (D) 8488587 559852 25 intronsb 
TOX 12 8 2 1 10 (D) 35182055 192657 22 no 
CIITA 13 9 1 3 7 (D) 6536287 1151750 20 introna 
TP53 4 2 0 0 18 (D) 9410568 1145996 21 noneb 
MEF2B 10 9 0 1 8 (D) 7855612 1863130 18 noneb 
ETV6 10 8 2 1 3 (D) 19441596 3190056 13 intron 1 
IRF8 4 2 1 1 3 (D) 7701889 185094 7 intron 1b 
BCL2L11 5 5 1 0 2 (D) 7321203 339970 7 intron 1 
SVs are separately counted by the type of event as determined by read pairing information. The total number of CNVs 
in the direction associated with the recurrent alteration (A or D) and the median and minimum of these is shown to 
highlight the focal nature of some of these events 
Tra, translocation; Del, deletion; Dup, duplication; Inv, inversion; A, copy number amplification or gain; D, copy number 
deletion 
aRegion was subjected to targeted sequencing to determine prevalence of coding and non-coding mutations 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2-3 Recurrence of SVs affecting known or suspected DLBCL-related 
genes identified by WGS. 
Based on a targeted sequencing experiment on a subset of these cases, the SVs detected by this 
approach have a specificity of 95%. SVs that deregulate the expression or impact the function of 
BCL2, MYC, FOXP1, CIITA, TBL1XR1, CKDN2A, CD58 and MIR17HG have been previously 
described in DLBCL and other lymphomas. In contrast to BCL2 and MYC, which are commonly 
rearranged with a limited number of partner loci, the more common trend among the remaining 
genes was a promiscuous repertoire of rearrangements. The overall diversity and recurrence of 
SVs affecting CD58 were notably more common than has been previously reported. Many of the 
additional examples are known aSHM targets including the PAX5 locus, CD83, and DMD which 
are subject to double-strand DNA breaks due to AID activity. 
 
Figure 2-4 Structural and copy number alterations indicative of tumour 
suppressors or oncogenes. 
(A) Two examples of genes with SV breakpoint and CNV patterns indicating tumour suppressor 
function are shown. MEF2B has two main mutation hotspots. This locus and TOX are both 
affected by multiple focal deletions across the cohort of genomes, whereas amplifications and 
gains of these loci are rare. (B) Two genes with recurrence of SVs and CNVs showing elevated 
expression in cases with either mutation type. Only chromosomes involved in at least one SV are 
displayed for each gene. The red region represents the cumulative number of gains/amplifications 
encompassing each locus across the cohort of genomes. The expression level of the gene with 
(red) or without (grey) either a SV or CNV gain affecting the locus is shown (centre). Some of the 
SVs affecting each of NFKBIZ and FCGR2B occur in the gene body and may partially disrupt or 
alter their normal function. SVs involving NFKBIZ were all intrachromosomal and included a 
striking number of small deletions affecting the 3′ UTR. This region was also enriched for SSMs 
and was identified by Doppler analysis. Similarly, there were numerous examples of focal CNVs 
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We utilised RNA-seq-derived expression values from a subset of the discovery 
cohort cases to infer cis effects of these events on expression. Through this analysis, 
both NFKBIZ and FCGR2B were identified as candidate oncogenes based upon 
significantly elevated expression in cases with either a gain or proximal SV (Figure 2-
4B). NFKBIZ has been reported as a target of amplification in some DLBCLs but has 
not, to our knowledge, been shown to be deregulated through SVs172. We extended this 
analysis to identify Doppler peaks with potential relevance in modulating transcription by 
determining peaks whose mutation status was associated with the expression of nearby 
genes (Figure 2-5). Most protein-coding loci whereby expression correlated with 
mutation status were known targets of aSHM (including SERPINA9, CD44, and PIM1) or 
novel targets identified herein (including DNMT1 and AICDA). However, there are many 
additional genes with high expression levels that did not appear to be influenced by 
aSHM, demonstrating that expression alone is insufficient to explain aSHM. 
Nonetheless, this subset of genes that are affected by aSHM may act as a permanent 
record indicating sustained or past high gene expression and thereby a genetic marker 
of their cell of origin. Although the bulk of these may therefore not represent driver 
mutations, the unprecedented breadth of mutations affecting potential regulatory regions 
including enhancers proximal to these genes suggests the potential for some to affect 
gene expression and thus warrants further investigation. 
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Figure 2-5 Genes with differential expression associated with proximal non-
coding mutations. 
(A) This box-whisker plot shows the expression of all genes with significantly different mRNA 
abundance in cases with and without mutations in a proximal mutation peak identified by wavelet 
analysis. The bulk of these genes have higher expression in mutated cases (green) compared to 
cases lacking a mutation in the region (red) and they largely represent known or suspected 
targets of aSHM. ZCCHC7 is adjacent to the PAX5 locus, which contains an enhancer found 
previously to be recurrently mutated in CLL. These mutations were associated in that study with 
higher expression of PAX514. (B) Two examples of genes affected by aSHM with higher 
expression in mutated cases are shown. PRDM1 is a tumour suppressor gene that is commonly 
mutated and deleted in DLBCL, though here was found to have elevated expression in cases with 
mutations (mainly intronic). The recurrence of mutations in the first intron identified here, most 
likely due to aSHM, has not been reported. These mutations were strongly enriched in ABC 
cases. Given these mutations were associated with higher expression, the bulk of these is 
unlikely to be functional, though it is conceivable that a subset of aSHM-derived mutations lead to 
reduced expression. AICDA, which encodes the AID enzyme, also had a mutation peak enriched 
in ABC. The expression of this gene is strongly associated with this molecular subgroup, though 

















































































































































































































































































































































2.3.3. Recurrently Mutated Loci Associated with ABC or GCB DLBCL 
By comparing mutation abundance within peaks derived from the full set of 
mutations, we identified 89 sites significantly enriched for mutations in either ABC (37) or 
GCB (52) cases (Figure 2-6; Supplementary Data 6, Appendix B). The bulk of 
mutations in many of these loci affected introns, the 5′ UTR or upstream of the 
transcriptional start site (TSS), and unsurprisingly, many were known aSHM targets 
discussed above (Figure 2-7A; Figure 2-8). Some hypermutated loci contained multiple 
discrete peaks. For example, the BCL6 locus and its nearby super-enhancer 
contained 31 discrete peaks (Figure 2-6B). We also noted a second mutation peak in 





Figure 2-6 Coding and non-coding mutations with differential representation 
between COO subgroups.  
(A) The top 36 mutation peaks showing significant enrichment for mutations in either ABC or 
GCB genomes are shown. For each patient (columns), the colour indicates the variant 
classification for the mutation affecting that locus. The percentage of patients with mutations in 
each region (based on WGS) is shown on the side for GCB (left) and ABC (right) cases. (B) 
BCL2 is a known target of SHM that is typically attributed to translocation to the immunoglobulin 
heavy chain locus and proximity to the IGH super-enhancer. We detected two GCB-associated 
mutation peaks in BCL2 with one spanning the TSS and 5′ UTR and the second residing in the 
intron. Based on the histone acetylation state (H3K27) determined by ENCODE, both of these are 











































































































































Figure 2-7 Differences in mutational representation between DLBCL molecular 
subgroups. 
(A) An enhancer proximal to PAX5 was preferentially mutated in GCB cases. A nearby peak in 
GRHPR near PAX5 was more commonly mutated in ABC cases. Non-coding mutation of the 
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enhancer proximal to PAX5 has been reported in CLL but has not, to our knowledge, been 
described in other lymphoid cancers. The mutation pattern in DLBCL resembles that of other 
super- enhancers (Figure 2-6B). (B) S1PR2 is a known target of aSHM, and the mutations 
mainly affect the first intron. DNMT1 is adjacent to S1PR2 and has a similar mutation pattern. 
Both of these peaks were enriched for mutations in GCB, indicating the potential for co-regulation 
of these genes using a common set of regulatory regions. (C) Coding and non-coding mutations 
that may be associated with either ABC or GCB COO are shown based on our recurrence cohort 
and are ordered on the strength of the association. For genes with missense mutation hot spots 
or (for NFKBIZ) a 3′ UTR hot spot, only mutations affecting that region were considered (indicated 
in parentheses beside the gene). Either hot spot, coding, or all mutations were used for this 
calculation, depending on the gene, as indicated in the legend. (D) The mutations detected in 
these genes are shown for each patient in our validation cohort. For genes affected by aSHM, 
mutations are represented using grey scale to indicate the number of mutations detected in each 
patient 
We tested each of the COO-associated peaks for association with treatment 
outcome in the discovery cohort using univariate Kaplan-Meier models. We identified a 
significant association between each of CIITA and IGHG1 mutation status and shorter 
time to progression (TTP) and disease-specific survival (DSS), but these did not retain 
significance after correction for multiple hypothesis testing. Using our internal validation 
cohort (Supplementary Table 1, Appendix B), we performed targeted sequencing on 
both the coding regions for a large set of known DLBCL-related genes and genes 
identified from this analysis as enriched for non-silent mutations (Supplementary Table 
7, Appendix B) along with a selection of these non-coding peaks. Of those selected for 
validation, we confirmed 10 loci were enriched for mutations in ABC and 26 were 
enriched in GCB (Figure 2-7C,D). In contrast to prior studies, CARD11 mutations were 
found here to be significantly enriched in GCB cases. The four sites with the strongest 
specificity for ABC were CD79B (Y197), MYD88 (L273), MPEG1, and the 3′ UTR of 
NFKBIZ (Figure 2-6; Figure 2-7). The majority of mutations affecting CIITA, IGHG, and 
NFKBIZ were non-coding and, with the exception of NFKBIZ, were consistent with being 
aSHM targets (Figure 2-8A). NFKBIZ mutations were almost entirely within the 3′ UTR, 
and most did not affect AID motifs (Figure 2-9A). In our external validation cohort, we 
found a nearly identical pattern of SSMs in the NFKBIZ 3′ (Figure 2-9B), and within the 
ABC sub-type, mutations in NFKBIZ and MYD88 were significantly mutually exclusive 
(P= 0.0042, CoMEt exact test). We determined the prevalence of this mutation in other 
lymphoid cancers with available WGS data including CLL, FL, and BL. FL had the next 
highest prevalence of NFKBIZ 3′ UTR mutations with mutations appearing in <3% of 
cases, suggesting these mutations are specific to DLBCL. 
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Figure 2-8  Mutation peaks and changes in allele expression. 
(A) Genes with mutation peaks detected separated by pattern. Using the annotation of mutations 
within the peaks, we determined the most common annotation per patient/peak combination. In 
most known aSHM targets, this is typically either 5′ flank, 5′ UTR or intronic mutations. We 
identified the genes that had other annotations more common than these as genes less likely to 
be affected by aSHM. Some of these are RNA genes and thus do not have UTRs (e.g. MALAT1, 
NEAT1) and many histone genes, which are small and may have a different pattern due to their 
length but may nonetheless be affected by aSHM. Others are genes with mutation hot spots such 
as MEF2B, CD79B and EZH2. Among these genes, NFKBIZ appeared distinct 3′ UTR mutations 
was the only mutation type within its Doppler peak. (B) We identified somatic mutations which 
lead to significant changes in RNA abundance by comparing the frequency of somatic mutations 
identified through DNA sequencing with the corresponding frequency obtained from RNA 
sequencing. For each gene, the proportion of patients in allelic imbalance (AI) was determined by 
comparing the number of cases with at least one mutation in AI in that gene, to the total number 
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2.3.4. Functional Characterisation of NFKBIZ 3′ UTR Variants 
 The specificity of NFKBIZ 3′ UTR mutations (Tables A-1, A-2 and A-3, 
Appendix A) to DLBCL (particularly ABC cases) suggests a strong selective pressure 
and implicates them as having a regulatory role in cis (Figure 2-9). The mutated region 
is highly conserved and has been predicted to form multiple stable secondary structures 
which are thought to contain a destabilising element that promotes rapid mRNA 
turnover195,196. Through available DLBCL cell line WGS data118, we identified 3′ UTR 
mutations in two cell lines (DOHH-2 and SU-DHL-6) and amplification of this locus in two 
additional lines (OCI-Ly10 and HBL-1). NFKBIZ mRNA levels were consistently higher 
among cases with 3′ UTR mutations or amplifications, supporting a common role in 
promoting NFKBIZ expression. To determine whether this effect was in cis, we searched 
for evidence of allelic imbalance (AI) in matched RNA-seq data from the internal 
validation cohort. Of the cases with sufficient depth and at least one heterozygous SNP 
in NFKBIZ, 24 SNPs in 18 tumours exhibited significant AI favouring the mutant allele. 
Furthermore, when examining AI of somatic mutations, NFKBIZ showed one of the 
highest frequencies of imbalance (21/33 patients, 64%) compared to other lymphoma-
associated genes (Figure 2-8B). 
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Figure 2-9 Mutations affecting the NFKBIZ locus and functional effects on 
mRNA and protein levels.  
(A) NFKBIZ mutations were predominantly found within a highly conserved region of the 3′ UTR 
and were significantly enriched in ABC cases (blue) relative to GCB cases (orange). (B) A 
detailed view of the mutated region including the location predicted to have conserved structure 
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(in grey). The pattern of mutations is similar in both the internal validation cohort (322 cases) and 
the external validation cohort (984 cases). (C) Mutations in NFKBIZ and MYD88 within ABC and 
GCB cases in the larger external validation cohort. The same trend of mutual exclusivity was 
observed in both validation cohorts. (D) Comparison of mutant variant allele fractions (VAFs) from 
DNA sequencing and RNA-seq of patient samples with NFKBIZ mutations. VAFs higher in RNA 
relative to the corresponding DNA indicates allelic imbalance favouring the mutant allele. 
Significant differences are indicated (*P < 0.05, **P < 0.01, ***P < 0.001, Wilcoxon rank-sum 
test). (E) We applied a custom ddPCR assay to eight DLBCL cell lines to determine NFKBIZ 
mRNA expression levels. Mutant cell lines consistently showed increased NFKBIZ mRNA, and 
we could attribute this to the mutant allele in lines with 3′ UTR mutations (green). Cell line IκB-ζ 
expression was assessed by western blot. Only mutant cell lines (green and blue) showed 
increased protein. (F) Luciferase reporter assay results show reduced protein expression in the 
presence of wild-type UTR with restored expression in mutant constructs. Luciferase expression 
is normalized to a construct containing a latter portion of the UTR. Error bars represent s.d. from 
three replicates. 
Mutations affecting predicted structural elements in the 3′ UTR of NFKBIZ more 
commonly exhibited significant AI than those downstream or within the coding sequence 
(CDS) (Figure 2-8D). To confirm these observations, we implemented a ddPCR assay 
that separately quantifies mutant and wild-type NFKBIZ alleles and tested mRNA 
extracted from eight cell lines (Figure 2-8E top) and a subset of RNA-seq data from the 
internal validation cohort. Samples with NFKBIZ mutations or amplifications had 
significantly higher mRNA levels. We confirmed AI favouring the mutant allele in the two 
cell lines with NFKBIZ 3′ UTR deletions (DOHH-2 and SU- DHL-6) and higher IκB-ζ 
protein levels (encoded by the NFKBIZ gene) in these NFKBIZ mutant lines relative to 
those lacking such events (Figure 2-8E bottom). One cell line (Pfeiffer) which lacked any 
detectable NFKBIZ mutation had elevated NFKBIZ mRNA levels relative to un-mutated 
lines. We suspect this is due to alternative transcriptional regulation, such as STAT3, 
which is mutated in this cell line and suggested to play a role in NFKBIZ activation197,198.  
We then created a series of five UTR constructs, a wild-type fragment 
representing the well-conserved portion of the 3′ UTR, some of the commonly observed 
deletions, and two SNVs which affect it. We generated RNA from each of these and, 
using a combination of methods, found that each mutant altered the RNA structure 
relative to the wild-type 3′ UTR fragment (Figure 2-10, Supplemental Data 8 and 9, 
Appendix B). Further implicating these mutations in modulating the expression of 
NFKBIZ, when placed 3′ to the luciferase CDS, each of the variants caused elevated 
ectopic expression compared to the wild-type sequence (Figure 2-8F). 
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Figure 2-10 Structural changes in NFKBIZ 3′ UTR induced by common 
mutations. 
(A) We performed Selective 20 -hydroxyl acylation analyzed by primer extension (SHAPE) on a 
fragment of the UTR. We generated RNA from synthetic DNA templates representing the wildtype 
or five mutants including three distinct deletions (Del1-Del3) and two SNVs (SNV1 and SNV2), 
indicated with coloured arrows on the left of the gel. We prepared a sequencing ladder for each 
ddNTP using reverse-transcribed RNA from the wild-type template. Each of lanes U, A, G, C 
represent the complementary ddNTP and are numbered according to the position in the UTR 
fragment (counting from the 5′). The portion of the sequence resolved on the gel is shown to the 
left along with numbers corresponding to the position in the RNA fragment. Bands in the 
remaining lanes indicate the length of truncated RNA caused by modification of exposed 
nucleotides by NMIA treatment. All RNAs showed reproducible base pairing in some regions. 
Each of SNV2, Del1 and Del3 exhibited distinct changes in protection, indicating a local change in 
structure. In SNV1 and Del2, there was de-protection of nucleotides in the same region (orange 
boxes), which corresponds to the general location of the mutation hot spot (approximately 70-90 
in the fragment). (B) We also compared the two SNV mutants to wild-type using circular 
dichroism (CD). CD spectra for the WT and two mutants resemble the classical ‘A type’ helical 
duplex, a conformation typical of double-stranded RNA. Given the equal lengths of the three 
RNAs, CD allows a relative quantitative comparison of Watson-Crick pairs. In agreement with the 
SHAPE result, each SNV mutation caused a reduction in paired bases relative to wild type with 
SNV1 having the more extreme effect. 
2.3.5. Molecular Features Associated with Patient Outcome 
Another striking pattern of mutations identified in this analysis were the focal 
copy number gains and amplifications affecting the Fcγ receptor locus, a complex region 
of the genome comprising multiple paralogs that have arisen through a series of 
segmental duplications199(Figure 2-11A, B). In four genomes, the boundaries of somatic 
gains could be mapped unambiguously by a combination of read pairing and read depth 
(Figure 2-12A). The nature of these events and some evidence for fusion transcripts 
between the co-amplified genes could imply amplification as an extra-chromosomal 
double minute (Figure 2-12B). It is conceivable, however, that additional structural 
variants were missed due to a limited ability to uniquely mapping short reads. 
Establishing the overall incidence of relevant CNVs affecting this locus is also 
confounded by the presence of common copy number alterations in this region as many 
of the single copy gains could be explained by germline events in the absence of paired 
samples. Using a custom multiplex droplet digital PCR (ddPCR) assay, we confirmed the 
CNVs and identified seven additional examples of amplifications and several additional 
gains not detected by SNP arrays. Based on these results, the prevalence of 
amplifications affecting FCGR2B was at least 14 out of 451 (3.1%). This is a 
conservative value including only those events causing changes in copy number beyond 
those expected from germline CNVs. Further characterisation of these cases with long-
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read sequencing could allow additional somatic gains detected by this assay to be 
differentiated from germline CNVs. Among the genes in this region, only the expression 
of FCGR2B (P= 0.0357) and FCRLA (P= 0.0210) were significantly associated with 
amplification status (generalised linear model, Figure 2-11C). Notably, amplifications 
were mainly found in GCB cases and tumours with an amplification showed strong Fcγ 
receptor IIB protein (CD32B) staining on a tissue microarray, though additional cases 
with strong staining were also observed (Figure 2-13A). Several gene-expression, CNV, 
or mutation-based strategies have been devised to predict outcome in DLBCL180,181, with 
COO and co-occurrence of MYC and BCL2 translocation being the most widely 
accepted200. Translocations involving the Fcγ receptor locus and immunoglobulin regions 
have been described201, but the recurrence of focal amplifications that deregulate 
FCGR2B expression has not been appreciated. Although their prevalence was low, 
these amplifications were nonetheless significantly associated with inferior outcome in 
GCB cases. Taking into account the apparent effect of gains on FCGR2B over-
expression, we hypothesised that elevated FCGR2B mRNA and protein was a relevant 
feature of DLBCL. FCGR2B mRNA level was significantly associated with outcome 
when treated as a continuous variable in a univariate Cox model. We were also able to 
stratify GCB patients into two groups with significantly different DSS and TTP in 
univariate Kaplan–Meier analysis spanning a range of thresholds (Figure 2-11E, F and 
Figure 2-13B, C). Using the internal validation cohort, we combined CIITA and IGHG3 
mutation status into a multivariate Cox model along with COO and FCGR2B expression 
level and mutation status. Although the trend was preserved for CIITA, only FCGR2B 
expression remained a highly significant predictor of outcome in this model (Table 2-2). 
This model was highly significant within the external validation cohort and, potentially 




Table 2-2 Multivariate analysis of FCGR2B expression on disease-specific 
survival and time to progression 
OS/DSSa TTP 
Cohort, Model Variable HR p-value HR p-value 
  FCGR2B mRNA > median 2.41 0.156 2.18* 5.7 × 10−3 
BC (GCB only), FCGR2B AMP 2.15 0.140 1.44 0.460 
n = 210 Any CIITA mutation 1.42 0.308 1.68 0.0942 
without IPI Any IGHG1 mutation 1.149 0.747 1.31 0.494 
  IPI 3.10* 1.03 × 10−3 3.07* 2.54 × 10−4 
  FCGR2B mRNA > median 1.37 0.387 1.96* 0.0397 
BC (GCB only) FCGR2B AMP 2.13 0.183 1.48 0.472 
n = 210 Any CIITA mutation 1.29 0.476 1.61 0.143 
with IPI Any IGHG1 mutation 1.23 0.652 1.30 0.535 
  FCGR2B mRNA > 5 1.52* 1.29 × 10−3 — — 
Reddy (All) GCB 0.711 0.0536 — — 
n = 530 IPI 2.50* 7.55 × 10−8 — — 
aDSS and TTP was only available only for the BC cohort. Overall survival (OS) was used in place of DSS for analysis 




Figure 2-11 Somatic and germline events affecting the Fcγ receptor locus. 
(A) The genes in the locus are shown with the recent duplication delineated in yellow and blue. 
Binned read depth from tumours is summarized using vertical bars. Germline CNVs, such as the 
gain and deletion shown in orange, are common in this region but can be readily distinguished 
from somatic events in paired analyses. In pink are four examples of somatic FCGR2B 
amplifications. FCRLA is completely or partially co-amplified in these. Blue arrows indicate 
breakpoints identified through visual inspection of data. Horizontal bars delineate the coordinates 
inferred to be contained within the amplified region. A break in the blue bar corresponding to 
approximately diploid coverage is indicative of the amplification affecting an allele representing 
the common deletion CNV. (B) In our validation cohort, we used custom ddPCR and targeted 
hybridization capture to infer the presence of gains, deletions, and amplifications. Due to a lack of 
constitutional DNA for the validation cohort, we are unable to determine the proportion of single-
copy gains and losses that can be attributed to common germline CNVs. The expression of each 
Fcγ receptor and FCRLA genes in the locus is shown with the cases separated by copy number 





















































































































HR = 2.9 (1.2 − 6.9)










state. Clustering on the expression of the four genes affected by amplifications groups amplified 
cases alongside some tumours with gains or no alteration detected, indicating the potential for 
additional avenues leading to FCGR2B over-expression. (C) Although rare overall, cases with the 
amplification showed a significantly shorter DSS and TTP (P = 0.012 and 0.044, respectively; log- 
rank test). (D) FCGR2B expression alone was also significantly associated with DSS and TTP 
within GCB cases. Specifically, stratifying on median expression or at any cut point above shows 
that GCB cases with higher FCGR2B exhibit significantly shorter TTP (P = 4.8 × 10−3, log-rank 
test), although DSS differences require a more stringent cutoff (see also Figure 2-13). 
 
Figure 2-12 Details and proposed mechanism of FCGR2B co-amplification with 
FCRLA.  
(A) The distal breakpoints for focal FCGR2B amplifications identified in four DLBCL genomes are 
shown. Each lies within introns of either FCRLA or FCRLB or the intergenic space between these 


















































genes. In patient 07-25012, a second breakpoint representing a copy-neutral inversion was also 
detected in this region. (B) Because only a single breakpoint pair is detected in most cases, the 
gain of multiple copies of the locus is consistent with formation of a double minute chromosome 
containing FCGR2B and varying amounts of FCRLA. The circular extrachromosomal segment 
could arise from intrachromatid recombination or aberrant class-switch recombination. Most of the 
examples of this phenomenon show reduced coverage between FCGR2C and FCGR2B, which is 
consistent with this event affecting a germline allele harbouring a deletion and concomitant fusion 
of FCGR2C-FCGR2B. (C) The presence of read pairs in RNA from these cases also supports the 
presence of a circular double minute. In two patients, reads mapping to FCGR2C and FCGR2B 
each have mates that map to FCRLA. Green horizontal lines represent reads pairs oriented per 


























































HR = 0.31 (0.17 − 0.57)











Threshold vs significance of TTP association Threshold vs strength of TTP association
HR = 0.37 (0.18 − 0.73)
logrank P = 0.0028
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Figure 2-13 Determining the relationship between FCGR2B mRNA level on 
patient outcome.  
(A) Depending on the threshold used to stratify patients, a substantial proportion of FCGR2B-high 
cases have no detectable focal amplification or translocation affecting the locus. We stained a 
tissue microarray with anti-CD32B to visualize the protein level in patients having and lacking this 
genetic alteration. A representative example of a FCGR2B-normal DLBCL with moderate CD32B 
staining is shown (DLC0111) alongside five examples that each harbour a somatic amplification. 
(B) The expression of FCGR2B alone was significantly associated with outcome within the GCB 
cases analyzed by RNA-seq. We stratified patients into FCGR2B-high and -low strata and tested 
these two groups for significant differences across a range of thresholds. The P value (left) and 
hazard ratio (right) showed that any cutoff above the median allowed significant separation of 
patients on TTP. A similar trend was seen for DSS (not shown). (C) A more stringent threshold of 
normalized FCGR2B expression >10.5 demonstrated a striking separation of cases with very 
short TTP (left) and DSS (right) reminiscent of ABC DLBCLs. 
2.4. Discussion 
There has been considerable effort placed on developing assays to robustly infer 
the COO of DLBCL patients, most of which rely on RNA from frozen or formalin-fixed 
specimens202. DNA-based assays may have benefits when RNA is not available and 
could allow the use of circulating tumour DNA (ctDNA) for this application203. Our 
analysis has revealed numerous non-coding regions with mutations that are associated 
with COO, and for many, the association is stronger than non-silent COO-associated 
mutations (Figure 2-7). In our validation cohort, we found mutations in NFKBIZ in 13.9% 
of cases, and 18.0% of cases are mutated when CNVs are also considered. These 
mutations were significantly enriched in ABC DLBCLs (P= 4.72 × 10−10, Fisher’s exact 
test), affecting 33.9% of cases in our data. Multiple studies have already attributed a 
165-bp region in the UTR that harbours the bulk of the mutations we detected as 
destabilising elements195,204. The observation of AI strongly implicates them in perturbing 
mRNA turnover, but the functional mechanism is not clear. NFKBIZ is one of several 
genes subject to post-transcriptional regulation by the endoribonucleases Regnase-1 
(Reg-1, encoded by ZC3H12A) and Roquin204. This process involves mRNA turnover 
and/or sequestration mediated by interactions between these proteins and specific stem-
loops in the 3′ UTRs of their targets205. Interestingly, ZC3H12A was among the novel 
genes identified herein as recurrently mutated in DLBCL (Figure 2-8). MYD88, an 
adaptor protein that is commonly mutated in ABC, is also important for protecting 
NFKBIZ mRNA from this process206. Moreover, B-cell receptor signaling, which is active 
in most ABC DLBCLs, can also promote stabilisation of NFKBIZ mRNA via the UTR195. 
Amplifications of NFKBIZ in DLBCL cell lines has previously been shown to induce 
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expression of a set of NF-κB target genes in ABC DLBCL172. Elucidating the mechanism 
whereby 3′ UTR mutations impact the NF-κB pathway in DLBCL is highly relevant given 
the growing list of therapeutic strategies designed to inhibit this pathway directly or by 
perturbing upstream signaling events. To the best of our knowledge, recurrent 3′ UTR 
mutations are the first example of a common somatic UTR alteration that can directly 
increase the expression of an oncogene.  
Recent data have implicated common polymorphisms and gene expression 
differences in tumour tissue in variable response to rituximab, but whether this was due 
to their effect on cis or trans interactions remained unclear. In CLL, cis interactions of Fc-
γ receptor on malignant cells is associated with an elevated rate of internalisation of 
CD32B bound to IgG relative to its other family members207. In trans, CD32B is directly 
involved in antibody-dependent cell-mediated cytotoxicity (ADCC), which is triggered by 
monoclonal antibody-based (mAb) therapies including cetuximab, trastuzumab, and 
rituximab208. We hypothesise that elevated CD32B expression on malignant cells, due in 
part to the focal amplifications we have identified herein, attenuates the normal immune 
response to rituximab as seen with alternative isoforms and polymorphic variants of this 
gene. This was strongly supported by the significantly inferior outcome of FCGR2B-high 
GCB patients treated with R-CHOP (Figure 2-11) and is consistent with a smaller study 
that showed a correlation between CD32B protein staining and outcome in FL209. In light 
of this, alternative immunotherapy approaches may be warranted for this high-risk sub-
population. Potential avenues of exploration include Type II monoclonal antibodies 
directed at CD20 or other proteins, which are not internalised by the same process and 
thus may be beneficial in these patients, or direct targeting of CD32B alone or in 
combination with anti-CD20 immunotherapy210. Beyond somatic copy number alterations 
and possibly some influence from germline CNVs, we also identified an elevated level of 
SSMs in two introns of FCGR2B that could promote intron retention and lead to a 
truncated isoform. As none of the tumours sequenced herein had been exposed to 
rituximab at the time of biopsy, the effect of these genetic alterations is presumed to also 
provide a selective advantage in lymphomagenesis, suggesting an oncogenic function 
for FCGR2B. Further exploration of the processes leading to FCGR2B over-expression 




2.5.1. Whole Exome Sequencing Data and Analysis 
For some of the results, we include included WES data from seven separate 
published cohorts119,181,211–213. We used the largest cohort, consisting of WES data from 
over 1000 DLBCL cases181 as our external validation cohort. Analysis of the 
relapsed/treatment refractory DLBCLs and the TCGA cohort was recently described by 
our group214. 
 
2.5.2. Whole Genome Sequencing 
Patients were diagnosed according to the 2008 WHO classification, as 
determined by standardised review by expert hematopathologists. Patients were 
excluded if they had any of the following: primary mediastinal large B-cell lymphoma; 
primary or secondary central nervous system involvement at diagnosis; a previous 
diagnosis of an indolent lymphoproliferative disorder; positive HIV serology; a secondary 
malignancy or major medical co-morbidity that precluded treatment with curative intent. 
This study was reviewed and approved by the University of British Columbia–BC Cancer 
Agency Research Ethics Board, in accordance with the Declaration of Helsinki, and all 
participants were recruited with informed consent.  
The genomes included in our analysis represent a compendium of cases from 
three sources, referred to as the discovery cohort. Namely, we included 39 cases from 
our previous publication118, 41 cases obtained with permission from the ICGC215, and 
another 73 de novo DLBCLs recently sequenced in house. Libraries from the latter were 
all prepared using PCR-free protocols as previously described216. Peripheral blood was 
used as a source of normal DNA for all cases in the WGS cohort. We performed 
alignment and detection of SVs, CNVs, and SSMs using matched tumour/normal pairs 
using standard algorithms and default parameters unless otherwise specified. For SVs, 
we used Manta and retained variants that pass all default filters217. We identified CNVs 
using Sequenza218 and SSMs using Strelka219. The ICGC genomes and matched RNA-
seq data were downloaded in BAM format and re-analysed using the same methods. 
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2.5.3. Targeted Sequencing and Analysis 
 We developed a custom gene panel comprising known and candidate DLBCL-
related genes and sequenced these regions in tumour DNA from 338 de novo DLBCL 
patients using a custom hybridisation-capture strategy. This group of samples is 
described throughout as the internal validation cohort. Of note, a slightly smaller number 
of cases in this cohort were subjected to RNA-seq (below). First, we sheared genomic 
DNA to an average of 300 bp using a COVARIS E220 focused ultrasonicator (Covaris) 
and built libraries from individual DNA samples using the NEBNext UltraII library prep kit 
(New England BioLabs) according to the protocol provided by the manufacturer. 
We measured library yields using Qubit (ThermoFisher Scientific) before pooling in 
batches of 12–16 libraries and mixed with 5 μl of Cot-1 DNA (ThermoFisher Scientific) 
and 2 μl of xGen Universal Blockers for Illumina platforms (Integrated DNA 
Technologies). We completely dried each pool in a SpeedVac centrifuge and then 
resuspended, denatured, and hybridised for at least 4 h with 4 pmol of a panel of xGen 
Lockdown probes targeting the exons and hotspots of ADAMTS12, ADPRHL1, ARID1A, 
ATM, B2M, BCL10, BCL2, BIRC6, BTG2, CARD11, CBWD7, CCND1, CCND3, CD58, 
CD79B, CREBBP, DDX3X, DSG4, EBF1, EP300, ETS1, EZH2, FAS, FBXO11,FOXO1, 
GABRB3, GHDC, GNA13, GNAI2, HIST1H1C, HIST1H1E, HVCN1, ID3,IL4R, IRF4, 
IRF8, KHDRBS2, KLHL6, KMT2C, KMT2D, MEF2B, MPEG1, MS4A1, MYC, MYD88, 
NFKB1, NFKBIA, NFKBIE, NFKBIZ, NOTCH1, NR3C1, P2RY8, PCBP1, PDS5B, PHF6, 
PIM1, POU2F2, PTPN1, RB1, RBM38, RFX7, RHOA, S1PR2, SGK1, SIN3A, 
SMARCA4, SOCS1, SPEN, ST8SIA1, STAT6, TBL1XR1,TCF3, TFAP4, TMEM30A, 
TMSB4X, TNFAIP3, TNFRSF14, TP53, UBR4, USP7, ZC3H12A, and ZFP36L1. We 
supplemented this pool with our own biotinylated baits targeting the NFKBIZ 3′ UTR 
region. We performed targeted enrichment experiments according to the hybridisation 
capture of DNA libraries using xGen Lockdown probes and reagents protocol (Integrated 
DNA Technologies)213,220. We sequenced enriched libraries on pools on an Illumina 
MiSeq instrument using PE 150 bp reads and, after alignment with BWA MEM, analysed 
BAM files for simple somatic mutations (SSMs) using Strelka with an unmatched quasi-
normal. Common germline variants with a MAF exceeding 1% in any ExAC population 
were subtracted, and the remaining variants were annotated the Ensembl Variant Effect 
Predictor221 and converted into the MAF format using vcf2maf 
(https://github.com/mskcc/vcf2maf). We also inferred SVs with Manta and curated to 
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remove highly recurrent variants likely to represent common variants and  recurrent 
artefacts. 
 
2.5.4. Gene expression analysis and cell-of-origin determination 
All RNA-seq libraries were generated using a strand-specific protocol with poly[A] 
selection. We used featureCounts (version 1.6.0) to quantify gene-wise expression using 
all Ensembl gene IDs from the GRCh37.87 release and set the minimum mapping 
quality to 10. We normalised gene-wise summary counts for library size using the R 
package DESeq2, and the resulting normalised expression matrix was used for all 
subsequent analyses and visualisations. These data were available from 319 cases in 
the internal validation cohort and from 143 of the genome discovery cohort. We identified 
180 cases as GCB using the Bayesian classifier (below) and use this subset for 
FCGR2B differential expression analysis and outcome prediction. Given the requirement 
of genome-wide information for identifying the effect of genome-wide mutations on 
expression, we used the data from only the genome discovery cohort for those analyses.  
We assigned set of loci previously used to discern ABC and GCB cases to the 
following 169 distinct Ensembl genes with associated gene names: A4GALT, ADAT3, 
AEN, ANKRD13A, ANUBL1, ARHGAP17, ARHGAP24, ARID3A, ARID3B, ASB13, 
AUTS2, BATF, BAZ2B, BCL2, BCL2L10, BCL6, BIC, BLNK, BMF, BPGM, BSPRY, 
BTLA, C11orf41, C13orf18, CARD11, CCDC50, CCDC144B, CCND2, CCNG2, CD47, 
CFLAR, CLECL1, CLINT1, COPB2, CREB3L2, CSNK1E, CYB5R2, DCTD, DDEFL1, 
DENND3, DKFZP434I0714, DNAJC10, DOCK10, EEPD1, ENTPD1, ERP29, ETV6, 
FAM108C1, FAM46C, FAM53B, FLJ32065, FLJ42418, FOXP1, FUT8, GNA13, GNL3, 
HCK, HDAC1, HIP1R, HOPX, HSP90B1, ICOSLG, IER2, IL12A, IL16, IRF4, ITPKB, 
JDP2, KCNH8, KCNK12, KIAA0746, KLHL21, KLHL5, LANCL1, LHFPL2, LIMD1, 
LMAN1, LMO2, LOC100129034, LOC196415, LOC645431, LPP, LRMP, LRRC33, 
MAML3, MAPK10, MARCKSL1, MAST2, MME, MPEG1, MRPL3, MYBL1, NEIL1, NEK6, 
NFKBIZ, NIPA2, NR3C1, OSBPL3, P2RX5, PAG1, PDE9A, PDLIM1, PFKL, PFTK1, 
PHF16, PI4K2B, PIM1, PIM2, PLEKHF2, PMM2, PRKAB1, PTK2, PTPN1, RAB7L1, 
RAP1B, RAPGEF5, RASGRF1, RBM9, RECK, RILPL2, RUNDC2B, S1PR2, SACS, 
SEPX1, SERPINA9, SH3BP5, SLA, SLAMF1, SLC1A1, SLC33A1, SLC38A5, 
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SMARCA4, SPINK2, SSBP2, SSR3, ST6GALNAC4, STAG3, STAMBPL1, STK17A, 
STS, SUB1, SULT1A2, SYTL4, TARS, TBC1D27, TBL1XR1, TCEB3, TCF4, TCTN3, 
TEX9, TGIF1, TMEM123, TMPRSS6, TNFAIP8, TNFRSF13B, TNKS, TOX2, TRAM2, 
TTC9, USP46, VGLL4, WNT9A, ZBTB32, ZFAT, ZNF318, ZNF385C, ZNF511, and 
ZPBP2.We implemented the Bayesian classifier described previously and calibrated it 
with all cases having a COO prediction from the Lymph2Cx NanoString nCounter 
assay202. Any case designated as “U” by this assay or with no COO information available 
were then classified using a cutoff of P(ABC) <0.9 for ABC and P(GCB) > 0.9 for GCB. 
This was only used to assign molecular subgroup to the genome discovery cohort, 
including the ICGC cases. For the internal validation cohort, all numbers reported were 
based on Lymph2Cx results rather than this consensus subgroup assignment. 
 
2.5.5. Allelic Imbalance in NFKBIZ 
Heterozygous SNPs were first identified across all samples in our cohort and 
annotated using the Ensembl VEP using vcf2maf. For samples with both DNA and RNA 
sequencing data available, the number of reads supporting the reference and alternate 
allele of each SNP were quantified using samtools mpileup (version 1.3.1) and a custom 
script. Intronic SNPs and SNPs with less than 12-fold coverage were excluded from 
further analysis. Of the remaining positions, any SNP showing evidence of allelic 
imbalance (AI) was identified by comparing the count of reads supporting each allele 
between the RNA and DNA BAM files using the Fisher's exact test (Python Fisher 
package version 0.1.4). Samples with significant AI (p-value threshold: 0.05) were 
further cross- referenced with NFKBIZ mutation and SV calls from the targeted 
sequencing data and copy number information determined using Affymetrix SNP6.0 
arrays and OncoSNP. A subset of cases showing AI were selected for validation by 
ddPCR. AI of somatic mutations was determined through a similar method, using the 
somatic variant calls obtained from targeted sequencing of the internal validation cohort, 
as described above. Following false discovery rate correction (Benjamini and Hoch- berg 
method), any mutation with Q < 0.1 was considered significant. The ratio of patients with 
AI in each gene was calculated by comparing the total number of patients with at least 
one mutation in AI to the the total number of patients with at least one mutation overall, 
for each gene. 
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2.5.6. NFKBIZ Digital Droplet PCR Assay 
We designed a hydrolysis probe-based assay targeting the NFKBIZ 3′ UTR 
hotspot region. PCR amplicons were chosen to be as small as possible (60–80 bp) and 
hydrolysis probes with Tm at least 3°C higher than that of PCR primers. We targeted the 
3′ UTR with a FAM-conjugated probe and a designed a separate HEX-conjugated probe 
to target a conserved region of exon 1. This allowed quantification of total transcripts 
(exon 1 probe) and wild- type transcripts (UTR probe) in cell lines with NFKBIZ 
mutations55. We prepared ddPCR reactions in a final volume of 22 μL containing 11 μL 
of 2X ddPCR Supermix for Probes (no dUTP), a final concentration of 1.0X was used for 
hydrolysis probes labelled with FAM and HEX fluorophores and a variable amount of 
input DNA (depending on availability and DNA concentration) and generated droplets 
using an AutoDGTM System (Bio-Rad). The emulsion of droplets is initially incubated at 
95°C during 10 min in a C1000 TouchTM Thermal Cycler, then followed by 80 cycles of 
30 s at 94°C and 1 min at optimised annealing temperature (58°C). We determined 
optimal annealing temperature empirically through a temperature gradient using a DNA 
sample known to carry an NFKBIZ mutation. The emulsion of droplets is incubated at 
98°C during 10 min and kept at 4°C until analysis in a QX200TM Droplet Reader. We 
analysed the resulting data and assigned clusters using QuantaSoftTM software, 
Regulatory edition (Bio-Rad). 
 
2.5.7. Cell culture and western blot 
Cell lines were cultured in RPMI (Invitrogen) with 10% fetal calf serum (Sigma-
Aldrich), except for SU-DHL-4 and SU-DHL-6 which were cultured in RPMI with 20% 
fetal calf serum, and OCI-Ly10 which was cultured in Iscove‘s modified Dulbecco 
medium with 10% fetal calf serum. All cell lines were maintained at 37 °C. SU-DHL-4, 
SU-DHL-6, Karpas422, DOHH-2 and WSU-DLCL2 were purchased from DSZM, Pfeiffer 
was purchased from ATCC and OCI-Ly10 and HBL-1 were gifts from the Weng lab 
(BCCRC) to the LCR lab. All cell lines were authenticated by STR profiling. SU-DHL-6. 
HBL-1 and WSU- DLCL2 were not mycoplasma tested but all others tested negative.  
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Western Blotting was performed as described172 using the Rabbit Polyclonal IκBζ 
Antibody (TA336346) (Origene) (dilution 1:500) and the Histone H3 Antibody #9715 (Cell 
Signaling) (dilution 1:1000).  
 
2.5.8. In vitro NFKBIZ 3′ UTR Variant Effects on Protein Expression 
 A fragment of the NFKBIZ 3′ UTR was synthesised as a gBlock (Integrated DNA 
Technologies, Coralville, IA) for the wild-type UTR and four patient-derived mutations: 
SNV1, Del1, Del2 and Del3 (Supplementary Data 8). The gBlocks were PCR amplified 
with primers (Supplementary Data 8) to add XbaI sites for cloning. An unrelated region 
of the 3′UTR was amplified from normal human DNA to act as a control sequence. 
These PCR amplicons were subcloned into the pGL3-Promoter Vector (Promega) 
located 3′ to the firefly luciferase translational stop codon. The nucleotide orientation and 
sequence of constructed plasmids were confirmed by DNA sequencing. For luciferase 
reporter assays, HEK-293T cells (7 × 105) were seeded in 24-well plates 2 days prior to 
transfection. Cells were co-transfected with 500 ng of pGL3-pro-NFKBIZ-3UTR (wild-
type, mutant or control) firefly luciferase vector and 10 ng of the pRL-TK (Promega) 
Renilla luciferase vector, using Lipofectamine 2000 (Invitrogen). Assays were performed 
24 h after transfection using the Dual-Luciferase Reporter Assay System (Promega). 
The firefly luciferase signals were normalised to the Renilla luciferase transfection 
control. Transfections were done in technical and biological triplicates. 
 
2.5.9. Investigating Fc Receptor Copy Number Alterations 
We designed a multiplex ddPCR assay targeting two known genetic 
polymorphism in FCGR2A (rs1801274) and FCGR2B (rs1050501) and coding regions of 
both BTG2, also located in chromosome 1, and ALK (located in chromosome 2). Probe 
and primer sequences are shown in supplementary tables. Contrary to standard ddPCR 
assays, we employed single hydrolysis probes to genotype both SNPs222 and leveraged 
variable final concentrations and two distinct fluorescent dyes for each hydrolysis probe- 
based assay. ddPCR reactions were carried out in a Bio-Rad QX200 system, using 10–
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20 ng of tumour-derived DNA and analysed using QuantSoftTM software, Regulatory 
Edition (Bio-Rad). Copy number gains, losses and amplifications affecting FCGR genes 
were inferred by calculating and comparing the number of positive droplets for each one 
of the FCGR genes and those corresponding to each one of the two additional genes 
used as reference. Our assay targeting rs1050501 co-amplified fragments of both 
FCGR2B and FCGR2C. We conducted an independent assay, which replaced the 
rs1050501 probe with a FCGR2B-specific probe that targeted a fixed nucleotide different 
in exon 3, to differentiate between FCGR2B and FCGR2C-specific events in a subset of 
samples. We were then capable to associate common germline deletions and gains with 
FCGR2C and detect focal amplifications of FCGR2B with high confidence. Other 
somatic gains and amplifications in a reduced number of samples involved FCGR2B and 
other Fcγ receptor genes. 
Further evidence supporting germline and somatic copy number alterations 
affecting the Fcγ region were derived from an independent next generation sequencing 
experiment relying on targeted hybridisation capture. We built genomic libraries from 
fresh frozen tumour DNA extracts using the NEBNext UltraII library prep kit (New 
England Biolabs). These libraries were pooled and enriched using a custom pool of 
biotinylated xGen lockdown probes (Integrated DNA Technologies) spanning the last two 
introns of FCGR2B and other non- coding regions found to be recurrently mutated in 
DLBCL. Given the high sequence similarity between paralogs, FCGR2B-specific probes 
also retrieved DNA sequences at equivalent positions for both FCGR2A and FCGR2C. 
Enriched libraries were sequenced on a MiSeq instrument (Illumina Inc.) using PE 150 
bp reads. Raw FastQ files were imported and analysed using the desktop genomic 
workbench Geneious (ver. 9.1.5, Biomatters Ltd). Raw reads were aligned using a 
stringent algorithm that only retained reads displaying high quality mapping scores 
(â‰¥40) and did not display more than 2% mismatches or indels >3 bp with respect to 
the reference genome. We then calculated and compared normalised coverage for each 
gene using for that purpose only annotated regions in the reference genome that 
enabled an ambiguous assignment of reads. This analysis confirmed elevated FCGR2B 
coverage for those patients suggested to carry focal amplifications by ddPCR and 
helped corroborate common germline copy number alterations involving a large part or 
the totality of FCGR2C. 
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2.5.10. FCGR2B Immunohistochemistry 
Tissue microarrays (TMAs) were constructed by using duplicate 0.6-mm cores 
from diagnostic pre-treatment FFPE tissue223,224. Staining was performed on the Ventana 
platform (Roche, Basel, Switzerland) using routine staining protocols. IHC staining for 
expression of CD32B (Abcam EP888Y) was independently reviewed by two 
hematopathologists (G.W.S. and P.F.). 
 
2.5.11. RNA Structural Analysis 
For SHAPE analysis, WT and other mutant RNA (~1 pmoles) were denatured by 
boiling them at 95 °C for 3–4 min and then incubated with the folding buffer (Final 
concentration: 111 mM HEPES, pH 8.0, 6.67mM MgCl2, 111 mM NaCl) for 20 min at 
room temperature. The folded RNA was then treated with 10 mM NMIA (n-methylisatoic 
anhydride) for 45 min (5 half-lives) at 37 °C or with clean DMSO for control experiment, 
followed by ethanol precipitation. The ethanol precipitated RNA was re-dissolved in 10 μl 
TE (10 mM Tris, pH 7.4 and 0.1 mM EDTA) and mixed with 32P-5-labelled primers. 
Primers were annealed to RNA by incubating the mixture at 65 °C for 5 min and then at 
37 °C for 5 min and finally placed on ice for 1 min. SHAPE enzyme mixture (Final Con- 
centration: 75mM KCl, 50mM Tris HCl, pH 8.3, 0.5 mM each dNTP, 5.1 mM DTT, 3 mM 
MgCl2) was then added to the RNA-primer annealed mixture. The whole mixture was 
incubated at 50 °C for 1 min followed by the addition of Superscript III and further 
incubation at 50 °C for 50 min. After 50 min of incubation at 50 °C, the mixture was 
treated with 1 μl 4M NaOH and incubated at 95 ° C for 5 min to degrade the RNA. The 
reaction was stopped by providing equimolar HCl to neutralise the base. Denaturing dye 
(95% formamide, 1 mM EDTA, and loading dyes) was then added to the mixture and it 
was heated to 95° for 3 min before loading on 10% denaturing/sequencing gel.  
To generate four separate ladders, ~1 pmoles of wild-type RNA was denatured at 
95 °C for 3–4 min followed by the addition of radiolabelled primers. Primers were 
annealed to the RNA by incubating the mixture at 65 °C for 5 min and then at 37 °C for 5 
minutes and finally placed on ice for 1 min. SHAPE enzyme mixture (Final 
Concentration: 75 mM KCl, 50 mM Tris HCl, pH 8.3, 5.1 mM DTT, 3 mM MgCl2) was 
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then added to the RNA-primer annealed mixture. 10 μM dNTPs/each were added to the 
mixture and following amounts of ddNTPs were added to get the separate sequencing 
ladders for the 4 bases (ddA: 50 ÂµM, ddT: 50 μM, ddC: 100 μM, ddG: 50 μM). The 
whole mixture was incubated at 50 °C for 1 min followed by the addition of Superscript III 
and further incubation at 50 °C for 50 min. After 50 min of incubation at 50 °C, the 
mixture was treated with 1 μl4M NaOH and incubated at 95 °C for 5 min to degrade the 
RNA. The reaction was stopped by providing equimolar HCl to neutralise the base. 
Denaturing dye (95% formamide, 1 mM EDTA, and loading dyes) was then added to the 
mixture and it was heated to 95 °C for 3 min before loading on 10% denaturing gel.  
For the circular dichroism, each RNA was diluted to a working concentration of 
2.5 μM. CD spectra were recorded in a Jasco-810 Spectropolarimeter (Jasco, Easton, 
MD). The spectra were taken in a quartz cell of 0.5 mm optical path length. The 
scanning speed was set 500 nm/min with a response time of 1 s. The spectra represent 
an average of 5 sequential scans over a wavelength range of 200–340 nm, all measured 
at 22 °C with baseline correction. 
 
2.5.12. De novo Mutation Signature Discovery 
 Mutation signatures were discovered using the previously described framework 
by Alexandrov et al.225 We summarised somatic SNVs based on their mutational 
subtype, 5′ context and 3′ context. This resulted in a mutation catalog matrix of 96 SNV 
classes for each sample. We performed non-negative matrix factorisation on our 
mutation catalog to discover mutational signatures within the entire cohort. Signature 
stability was computed by bootstrap resampling over 1000 total iterations (10 iterations 
in each of 100 cores). The optimal "-signature solution "!"# which simultaneously 
maximised signature stability and minimised the Frobenius reconstruction error was 
automatically selected, 







where + and 3 are the vectors containing reconstruction errors and stability of each " -
signature solution, and +' and 3' are the reconstruction error and stability of the " -
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signature solution. To determine matches to known mutation signatures, cosine similarity 
metrics were computed against the 30 COSMIC mutation signatures. Where more than 
one signature matched to a single COSMIC signature, the highest similarity match was 
chosen and the remaining signatures were matched to the next most similar COSMIC 
signature. Differential exposures of mutation signatures between lymphoma subtypes 
was performed by the non-parametric Wilcoxon Rank-Sum test in R programming 
language and was adjusted for multiple comparisons by controlling false discovery rate. 
 
2.5.13. Rainstorm Analysis 
 As described in more detail elsewhere187, the standard rainfall calculation 
considers a monotonically increasing set of 6 positions 7	"( , . . . , :'; defining the location 
of mutations in a single tumour genome (simplified here to a single chromosome). The 
rainfall plot is a scatterplot of points 3 = (2( , <() where <( is given by <( = =>?@	"()* − 	"(A 
for each . ∈ {1,2, . . . , F − 1} . The points are often coloured with a scheme that indicates 
the nature of each mutation such that specific mutation signatures favouring a limited 
repertoire of substitutions can be visually observed. We note that this plotting method 
was developed to aid in the study of single cancer genomes226. This approach cannot be 
directly applied to a cohort of patients to highlight areas of the genome that may be 
affected by mutations more commonly than by chance. Our goal with the rainstorm 
approach was to overcome this limitation. We developed an extension of the genome 
wide inter-mutation distance calculation used to highlight local fluctuations in mutation 
rates within single cancer genomes226. Rather than using the distance to the adjacent 
mutation in the same genome, in our variant, the mean distance to the nearest  " 
mutations among unique genomes is used instead. This variation attempts to suppress 
signal from a limited number of genomes from contributing to the cohort-wide signature. 
The Rainstorm algorithm begins with a list of lists, H	 = @H*, H+, . . . H,A each 
comprising the monotonically increasing positions from one of the individual somatic 
mutations in ? patient genomes. H′ is the full (multi-) set of mutation positions 
H*⋃H+⋃. . . ⋃H, for all genomes being considered. We noted a consistent variation in local 
mutation rate across the genomes included in this analysis. The local trends generally 
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corresponded to the effect of genome replication timing, with regions that consistently 
replicate late in the cell cycle having a higher mutation rate227. We address this by 
creating a non-overlapping set of bins of equal length K (here,	K = 	100	MK) covering the 
length of the chromosome = with the positions contained by the .#- bin represented by N( 
and the final bin is constrained to only contain positions ≤ =. 
N( = (1, 2, . . . , K)
N+ = (K + 1, K + 2, . . . ,2	K)
⋮
 
The midpoint of each bin is equivalent to the mean of its values, N.R  . We then 
determine the mean number of mutations in each of these bins to obtain S, a list 






We perform local regression on the points (N[, S)  using the loess function in the R 
statistical computing language. This results in \(H), a function used here to approximate 
the mutation rate of each genomic position and adjust for this effect. 
For each patient genome we consider a query patient ], and we create a ^H0^ −
K<	 − 	? matrix _0. Vaguely, we initially populate the entries of _0 column-by-column by 
listing the differences in nearest pairs of terms in the H0 and the H1 being considered. In 
particular, for a given patient genome ` ∈ {1, 2, . . . , ?} − {]} , we pool their set of 
mutations with those of H0 as a multiset 
a1 = 7H0 	⋃	H1; 
and reorder the terms in increasing order to satisfy a1 = @Y*
1 , Y+
1 , Y2
1 , . . . , Y3




1 ≤	. . . ≤ 	 Y3
1 . Prior to reordering, we store a reference to each index of a1 
that derived from elements of H0 and H1. We fill column ` of _0 by comparing each 
original position from the query patient with the next highest position in the pooled 
multiset. Only the comparisons where Y( is originally from H0 are utilised and the ., `#- 
entry in _0 is sequentially populated for each of these values. For example, the ., `#- 
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entry of _0 we take the difference between the term at the .#- position originating from H1 
in a1 and its adjacent term in a1 etc. This is repeated for all values of ` with the exception 
of the case where ` = ], leaving one empty column in _0. 
We then apply a numeric sort to every row in _0, which correspond to the 
original mutation positions in H0. Owing to the convention we use to calculate the 
pairwise distance a1, this matrix has some useful properties. Mutations that are closer to 
another mutation in the same genome H0 relative to the comparison genome H4 are 
completely undefined and thus implicitly suppressed from any further consideration. 
After the sort, however, the individual rows of _0, no longer relate to the indexes in H4. 
This new ordering allows us to efficiently find the distance to the nearest mutation in the 
M#- genome with M starting at the genome having the nearest mutation to position ., M +
1,  being the genome with the second-nearest mutation to position ., etc. Using this 
property, we can approximate the density of mutations at every original position in H0 by 
calculating, for each row ., the mean of the values in the first M genomes (here, we use 
M = 4). We can increase the specificity of our algorithm to ignore local increases in 
mutation density in small numbers of patients by increasing M. Using the genome-wide 
mutation rate approximated by \(H), we then adjust each value for local mutation rate 
differences after converting to a logarithmic scale. We also correct for the total number 












This process is repeated for every genome ?0 such that we have points @H0 , +0A 
that can be plotted for each patient. The supersets of each, namely H′ (defined 
previously) and  +′ = +*⋃++⋃. . . ⋃+,, are also used for subsequent analyses. To 
generate a visualisation that we refer to as a “rainstorm plot" defined by an 
(2, <)	scatterplot @H0 , +0A  for all ] ∈ {1, 2, . . . , ?} using distinct colour for each ? with 
transparency to enhance visibility of overlapping points. 
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2.5.14. Doppler Algorithm 
 The Doppler algorithm delineates mutation peaks using the adjusted cohort-wide 
inter-mutation distance (as derived above) as input. The values are treated as a 
frequency variable with index (rather than genomic position) treated as the “time" 
variable. Wavelet transformations are used in signal processing to decompose a series 
of spatial or temporal correlated data points. This involves transforming 1-dimensional 
time series data into 2-dimensional wavelet space along a time scale. Instead of time, 
we use the index of the ordered set of positions in H′, or what we hereafter refer to as 
“relative position", or H′8. While the H′8 dimension is the same as in the original 
time/position series, a new scale is derived from the expanded dimension. We treat the 
relative position on the chromosome as equivalent to time such that the transformation 
generates a projection of mutation density along the length of the chromosome. 
There are two types of wavelet transform: discrete and continuous. For DWT 
(Discrete Wavelet Transform), the series data are decomposed into an approximation 
plus multiple levels of details. Approximation and detail decomposition are based on 
different wavelet base functions. For CWT (Continuous Wavelet Transform), only one 
basic wavelet function is used, however, the decomposition is based on continuously 
changing scales and time/locations. We use the CWT implemented in 
MassSpecWavelet R package228 with no prior and using a single variable, i.e. +′	~	H′. 
Applying the CWT also generates a set of discrete wavelet peaks, each associated with 
a signal-to-noise ratio (SNR). Manual inspection of the data showed that wavelet peaks 
are sensitive to small deviations in +′ values, leading to overly narrow peaks and 
fragmentation of some larger peaks. We post-process wavelets individually by 
chromosome by removing those with a SNR below the 95#- percentile, based on all 
wavelets on that chromosome where SNR ≥ 0. Based on the distribution of + values in 
the chromosome being considered, we define ∅ as the 95#- percentile and m as the 25#- 
percentile of +. Peaks for which + < ∅  are removed up-front. 
We define the set of positions contained by our .  individual peaks as N, where 
N = (o( , o( + 1, . . . , X(). The patient genomes represented within peak N(, 
?(
%9:; = @N(⋂H*, N(⋂H+, . . . , N(⋂H,A 
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are a useful metric of the potential biological relevance of mutations in that region to the 
tumour type represented by the samples. We allow the boundaries of peaks to be 
refined such that o( and X( are adjusted to either shrink or extend the peak size. We 
allow an extension of the upper and lower boundaries, o( and X( outward from the peak 
of the remaining wavelet positions by considering up to 12 indexes per side. We allow 
the inclusion of additional mutation positions in this range and stop this process when a 
mutation is encountered with + < m  . As well, using the new boundaries, we count the 
distinct number of patient genomes containing a mutation within the peak boundaries 
while maximising the outer bounds of N(. If necessary, boundaries are reduced iteratively 
until the criteria are met or it becomes impossible to meet the criteria for that peak. After 
this adjustment, we determine the actual mutation rate in each peak in mutations/kb: 
-(





Only the peaks satisfying the two additional criteria d?(
%9:;e ≥ 	4 and -(
8<#= ≥ 	6  are 
retained along with the start and end coordinates of the largest |N(| corresponding to the 




Chapter 3.  
 
Non-Coding NFKBIZ 3′ UTR Mutations Promote Cell 
Growth and Resistance to Targeted Therapeutics in 
Diffuse Large B-Cell Lymphoma 
A version of this Chapter has been uploaded to BioRxiv229 and has been submitted to 
Blood. Sarah E. Arthur, Jie Gao, Shannon Healy, Christopher K. Rushton, Nicole 
Thomas, Laura K. Hilton, Kostiantyn Dreval, Jeffrey Tang, Miguel Alcaide, Razvan 
Cojocaru, Anja Mottok, Adèle Telenius, Peter Unrau, Wyndham H. Wilson, Louis M. 
Staudt, David W. Scott, Daniel J Hodson, Christian Steidl, and Ryan D. Morin. “Non-
coding NFKBIZ 3′ UTR mutations promote cell growth and resistance to targeted 
therapeutics in diffuse large B-cell lymphoma.” (2021).  
Contributions: I conducted all of the experiments and data analyses with the exception 
of: I analyzed and interpreted results but RNA probing assays were performed by RC 
(Figure 3-4AB), all primary GC B-cell experiments were performed by JG (Figure 3-6E-
G), I prepared all cell lines and reagents but all mouse work was performed by SH with 
assistance from the animal care facility at BCCRC, I analyzed and interpreted the large 
cohort datasets to generate figures but re-analysis of external datasets was performed 
by CKR and JT, Figure 3-2 was generated by CKR, the LymphGen classifier was run on 
all cohorts involved in this analysis by CKR, RNA-seq analysis R code was originally 
written by NT which I modified and used for analyses and generation of all related 
figures, LKH, KD and RDM performed analyses of external WGS cohorts. I wrote the 
manuscript with RDM, and all co-authors contributed to edits. 
 
3.1. Abstract 
Amplifications and non-coding 3′ UTR mutations affecting NFKBIZ have been 
identified as recurrent genetic events in diffuse large B-cell lymphoma (DLBCL). We 
confirm the prevalence and pattern of NFKBIZ 3′ UTR mutations in independent cohorts 
and determine they are enriched in the ABC subtype as well as the recently described 
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novel BN2/C1/NOTCH2 classes of DLBCL. Presently, the effects of and mechanism by 
which non-coding mutations can act as cancer drivers has been relatively unexplored. 
Here, we provide a functional characterization of these non-coding NFKBIZ 3′ UTR 
mutations. We demonstrate that the resulting elevated expression of IκB-ζ confers 
growth advantage in DLBCL cell lines and primary germinal center B-cells as well as 
nominate novel IκB-ζ target genes with potential therapeutic implications. The limited 
responses to targeted treatments in DLBCL, particularly those targeting the NF-κB axis, 
led us to investigate and confirm that NFKBIZ 3′ UTR mutations affect response to 
therapeutics and suggest it may be a useful predictive biomarker.  
 
3.2. Statement of Significance 
Through functional characterization we reveal that non-coding NFKBIZ 3′ UTR 
mutations are a common driver in DLBCL, and mutation status may be a relevant 
biomarker to predict poor response to therapeutics targeting the NF-κB pathway. 
 
3.3. Introduction 
Diffuse large B-cell lymphoma (DLBCL) represents the most common form of 
non-Hodgkin lymphoma worldwide. Historically, DLBCL has been divided into two 
molecular subgroups through gene expression profiling (GEP), namely the activated B-
cell-like (ABC) and germinal centre B-cell-like (GCB) subgroups230. These distinct cell-of-
origin (COO) subgroups are generally appreciated as arising through unique 
mechanisms and rely on activation of specific oncogenic pathways. ABC DLBCLs are 
characterized by constitutive activation of the nuclear factor-κB (NF-κB) signaling 
pathway, which can often be explained by mutations in genes such as MYD88, 
CARD11, CD79A/B or TNFAIP3231–233. Patients with ABC DLBCL generally experience 
an inferior clinical response to standard-of-care treatment. Although many alterations 
leading to NF-κB pathway activation have been described, there are a substantial 
number of ABC cases with no clear genetic explanation for their NF-κB activation.  
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Recent work has shifted attention to the use of genetic features for classifying 
DLBCLs with shared biology that may inform on therapeutic vulnerabilities134,135,137. 
Despite the newly described subtypes representing a more granular division of this 
disease, there remain discrepancies between classification systems and many tumours 
still remain unclassifiable. This suggests that further refinement is needed to classify and 
predict treatment options for all DLBCL patients138. To enable the identification and 
validation of new treatment options and stratify DLBCL patients accordingly in relevant 
clinical trials, it is important to fully understand the molecular underpinnings of this 
heterogenous disease. Thus, the discovery and characterization of mutations which 
could act as relevant biomarkers for targeted treatments is ongoing. This includes the 
characterization of non-coding regulatory mutations that can represent bona fide driver 
mutations by dysregulating gene expression.  
Our group recently described a pattern of non-coding somatic mutations affecting 
the 3′ untranslated region (UTR) of the NFKBIZ gene234, which has since been confirmed 
by other studies38. NFKBIZ encodes for the IκB-ζ protein, an atypical member of the 
nuclear IκB protein family involved in the NF-κB signaling pathway168. Expression of IκB-
ζ is barely detectable in resting cells, but rapidly induced upon stimulation of Toll-like 
receptors168 and other stimuli feeding into the NF-κB pathway (e.g. LPS and 
interleukins169). IκB-ζ has been shown to regulate NF-κB signaling, however it has been 
implicated in both repression168 and, more recently, activation169 of this pathway. Recent 
studies suggest that it may inhibit and activate distinct subsets of NF-κB target genes172. 
Specifically, IκB-ζ may confer transactivating potential to p50 and p52 homodimers to 
promote transcription174, but may also block the formation of p65 heterodimers, thus 
inhibiting their function235. Nogai et al. found that IκB-ζ is highly expressed in most ABC 
DLBCL cell lines and it was previously discovered that the NFKBIZ locus is amplified in 
10% of ABC DLBCLs132.  
Given the high expression rates of NFKBIZ in ABC DLBCLs, we hypothesized 
that NFKBIZ 3′ UTR mutations act to promote IκB-ζ expression by stabilizing NFKBIZ 
mRNA. Consistent with this notion, DLBCL cell lines with naturally occurring NFKBIZ 3′ 
UTR mutations expressed elevated NFKBIZ mRNA and IκB-ζ protein levels relative to 
other DLBCL lines234.  Here, we provide a functional characterization of the mechanism 
and effect of non-coding NFKBIZ 3′ UTR mutations in DLBCL and suggest their potential 
utility as a predictive biomarker for response to targeted therapeutics. 
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3.4. Results 
3.4.1. NFKBIZ 3′ UTR mutations and amplifications are enriched in 
ABC DLBCL and the BN2 and A53 subtypes 
 
Figure 3-1 NFKBIZ mutation prevalence and mutual exclusivity in DLBCL.  
(A) Oncoplot showing the most commonly mutated genes within each of the LymphGen subtypes 
for patients in the Arthur32 and Chapuy134 and Schmitz135 cohorts. Cohort, cell of origin (COO) and 
LymphGen classifications are shown in tracks at the bottom. LymphGen classifications are 
simplified to show composite cases as their most likely subtype. (B) Oncostrip showing MYD88 
and NFKBIZ mutations split up by mutation type. MYD88 hotspot (L265P) mutations never co-
occur with NFKBIZ 3′ UTR mutations. (C) Somatic interactions plot for ABC DLBCL cases 
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(brown) (*P<0.05, •P<0.1, pair-wise Fisher’s Exact test). NFKBIZ and MYD88 mutations are 
significantly mutually exclusive. (D) Prevalence of all NFKBIZ mutations including 3′ UTR and 
amplifications in all DLBCLs and only considering ABC DLBCLs. (E) Prevalence of NFKBIZ 
mutations within each of the analyzed cohorts. (F) Prevalence of NFKBIZ mutations within each 
of the LymphGen classes compared to the breakdown of all cases within each subtype. 
Since the first description of non-coding mutations in the NFKBIZ 3′ UTR in 
DLBCL234, multiple studies have released sequencing data from additional cohorts but 
focused on protein coding region alterations134,135. We reanalyzed these datasets to 
search for non-coding NFKBIZ 3′ UTR mutations and compared their general prevalence 
among cohorts and within each of the molecular and genetic subgroups. A comparison 
of the mutations from our previously published dataset (Arthur et al.)234 with new 
mutation calls from Schmitz et al.135 and Chapuy et al.134 revealed a similar pattern of 
NFKBIZ mutations, with small deletions and single-nucleotide variants (SNVs) being the 
most common mutations affecting the 3′ UTR (Figure 3-1A, D and E). When 
amplifications and 3′ UTR mutations are considered, NFKBIZ was among the top seven 
recurrently altered genes in DLBCL (Figure 3-1A). Although coverage varied, most 
patient samples in the Schmitz cohort had sufficient sequencing depth for the most 
commonly mutated region of the 3′ UTR to be covered. The Chapuy dataset had 
consistently low coverage of the 3′ UTR, which limited our ability to detect mutations in 
those tumours (Figure 3-2). Interestingly, NFKBIZ 3′ UTR mutations (102/1006 patients) 
and MYD88L265P hotspot mutations (134/1006 patients) were never observed in the same 
tumour (Figure 3-1B). We found that all mutations in the MYD88 and NFKBIZ genes 
were significantly mutually exclusive (P < 1.25x10-3) within ABC DLBCLs, where these 
mutations are predominantly found (Figure 3-1C). Overall, NFKBIZ is mutated (UTR or 
amplification) in 17% of DLBCLs and 24% of the ABC subtype (Figure 3-1D, Table 3-1), 
however this is likely an underestimate due to the variability in coverage between 
datasets (Figure 3-1E, Table 3-1). We also searched for NFKBIZ 3′ UTR mutations in 
numerous other cohorts with whole genome sequencing (WGS) data and found 
mutations in DLBCL37,118,234, follicular lymphoma (FL)37,236, and from published and 
unpublished Burkitt lymphoma (BL) cohorts from the Burkitt Lymphoma Genome 
Sequencing Project (BLGSP)237 (Table 3-2 and 3-3). This confirmed our previous 
observation that these mutations are infrequently observed in other B-cell neoplasms. 
The mutations in DLBCL and the other malignancies show a similar pattern to that 
observed among exome-based data sets that comprised the core of our analysis. 
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Figure 3-2 Coverage of NFKBIZ 3′ UTR within each cohort.  
Median coverage at each base position across the NFKBIZ 3′ UTR position with the 25th and 
75th quartiles shown shaded in red for each of the three cohorts. The region specifically 
containing the stem-loops structures where most mutations occur is shown in between two 
vertical dashed lines. The Arthur cohort is targeted sequencing with probes for the UTR region. 
The Schmitz cohort is exome data with mostly sufficient coverage to call mutations, especially 
early in the UTR region. The Chapuy cohort coverage was very low and not “callable” in many 
cases, especially in the locations after SL2 (~chr3:101578280).  
Table 3-1  NFKBIZ mutation prevalence in the Arthur/Schmitz/Chapuy cohorts. 
   
Subtype (%) Cohort (%)   
All ABC Arthur Schmitz Chapuy  







 UTR 101 (10) 66 (13) 39 (12) 49 (11) 13 (6) 
Amplification 86 (8.5) 66 (12.9) 23 (7) 35 (8) 28 (13) 




Table 3-2 NFKBIZ 3′ UTR mutations in other WGS cohorts. 
Cohort # Patients NFKBIZ UTR mutations (%) Publication 
BL_Adult 81 1 (1.2) Grande_et_al,2019 
BL_Pediatric 124 1 (0.8) unpublished 
DLBCL_cell_lines 15 2 (13.3) Morin_et_al,2013 
DLBCL_BC 117 11 (9.4) Arthur_et_al,2018 
DLBCL_ICGC 87 11 (12.6) Hübschmann_et_al,2021 
FL_ICGC 100 4 (4) Hübschmann_et_al,2021 
FL_Kridel 48 1 (2.1) Kridel_et_al,2016 
 
 
Table 3-3 COO and LymphGen classifications of DLBCLs and FLs from other 
cohorts. 
 
  NFKBIZ UTR mutations (%) DLBCL (%) FL (%) 
CO
O 
ABC 13 (41.9) 13 (54.2) 0 (0) 
GCB 4 (12.9) 4 (16.7) 0 (0) 
UNCLASS 2 (6.5) 2 (8.3) 0 (0) 
NA 12 (38.7) 5 (20.8) 5 (100) 






BN2 13 (41.9) 9 (37.5) 3 (60) 
EZB 4 (12.9) 2 (8.3) 2 (40) 
ST2 1 (3.2) 1 (4.2) 0 (0) 
Other 9 (29) 8 (33.3) 0 (0) 
Composite 2 (6.5) 2 (8.3) 0 (0) 
NA 2 (6.5) 2 (8.3) 0 (0) 





Table 3-4 LymphGen classifications of all patients and those with NFKBIZ 
mutations in Arthur/Schmitz/Chapuy cohorts. 
 





Classification All UTR Amplifications 
 
A53 35 (19.7) 10 (9.9) 28 (32.2) 103 (10.2) 
BN2 33 (18.5) 31 (30.7) 4 (4.6) 118 (11.7) 
EZB 7 (3.9) 4 (4.0) 3 (3.4) 166 (16.5) 
MCD 25 (14) 10 (9.9) 14 (16.1) 106 (10.5) 
ST2 1 (0.6) 1 (1) 0 (0) 57 (5.7) 
N1 0 (0) 0 (0) 0 (0) 18 (1.8) 
Unclass 65 (36.5) 37 (36.6) 32 (36.8) 357 (35.5) 
Composite* 12 (6.7) 8 (7.9) 6 (6.9) 81 (8.1) 
A53/MCD 3 0 3 
 
A53/ST2 1 1 1 
 
A53/BN2 1 1 0 
 
A53/EZB 1 1 1 
 
BN2/MCD 3 3 0 
 
BN2/ST2 1 0 1 
 
EZB/ST2 2 2 0 
 
TOTAL 178 101 87 1006 
*Breakdown of different types of composite cases are shown in rows below composite row (for 
NFKBIZ mutant cases only) 
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We next explored the relationship between NFKBIZ mutations and the newly 
described genetic subgroups of DLBCL134,135,137. Notably, gains/amplifications of 3q 
(location of NFKBIZ) and/or focal amplifications of NFKBIZ were genetic features used in 
some of these classifiers and are typically associated with cases assigned to the MCD 
subgroup135 (also corresponding to the C5134 and MYD88137 groups) but more recently, 
with the addition of extra subgroups to LymphGen, they are also enriched in the newly 
described A53 subgroup, which is mostly defined by copy number features238. In 
contrast, NFKBIZ 3′ UTR mutations were not considered when defining these 
classification systems. Using LymphGen136 to assign samples from all three cohorts to 
genetic subgroups, we observed a similar pattern of classification (Table 3-4), with a 
high proportion of NFKBIZ amplification cases classified as A53. Interestingly, NFKBIZ 3′ 
UTR mutations were most commonly observed in BN2 cases (Table 3-3 and 3-4). BN2 
is characterized by mutations in other components of the BCR-dependent NF-κB 
pathway (PRKCB, BCL10, TNFAIP3, TNIP1). This observation is consistent with the 
notion that NFKBIZ 3′ UTR mutations could be functionally distinct from amplifications 
and provide a selective advantage specifically in BN2 tumours. The mutual exclusivity of 
mutations in MYD88 and NFKBIZ may also explain the paucity of MCD tumours with 
these mutations. This highlights that distinct genetic alterations, each contributing to 
deregulation of NF-κB signaling, are appropriately segregated by current classification 
methods but the presence of some NFKBIZ-mutant tumours in the “unclassified” group 
should be noted. 
 
3.4.2. NFKBIZ 3′ UTR Secondary Structure 
Post-transcriptional regulation of genes can involve interactions between 
conserved sequences or secondary structures and either miRNAs or RNA-binding 
proteins (RBPs), which can lead to either stabilization or destabilization of transcripts. 
We sought to clarify the structural features of the NFKBIZ 3′ UTR that are commonly 
mutated. Using a combination of RNA secondary structure prediction tools239–242 (Figure 
3-3) accompanied by RNA probing assays (Figure 3-4A-C), we constructed a refined 
model of the NFKBIZ 3′ UTR secondary structure (Figure 3-4D-E). To do this, predicted 
structures were compared with the results from an RNA-probing assay which determined 
guanine (G) bases that were paired (protected) or unpaired (exposed) under 
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physiological conditions. Through this comparison we selected the most comprehensive 
model that included structural features predicted by multiple tools and fitted with 
experimental data. The structure comprises two novel stem-loops (SL1 and SL2) and 
three previously described stem-loops (SL3, SL4, and SL5)196,204,243,244. 
 
 
Figure 3-3 In Silico RNA folding algorithm predictions. 
(A) CentroidFold (B) IPknot (C) KineFold (D) RNAalifold. Bases are represented in circles and/or 
coloured bases, base pairs are represented by lines connecting the bases. Long blue lines in B 




















































































































































































































































Figure 3-4 Novel stem-loop structure predicted in the NFKBIZ 3′ UTR. 
(A) T1 RNase probing assays (single-stranded guanine bases) were performed with four variants 
of the NFKBIZ 3′ UTR RNA (WT, SNV1, Del1, Del2 and Del3). Four conditions were tested: 
Hydrolysis (all bases cut), denaturing (all G’s cut), N24 (native conformation at 24C) and N37 
(native conformation at 37 oC). Gels were run for different amounts of time to resolve both (A) 3′ 
and (B) 5′ ends of the RNA sequence. Green boxes beside each gel denote the location of 
suspected stem-loop structures (SL1-SL5). The red box shows the region containing SL2 and 
highlights the differences in structure between WT and mutants at this position. (C) Summary 
table of which G bases were protected (not cut – part of a structure) or exposed (cut – not part of 
a structure). This was used as a basis to confirm predicted structure of the region in panel D. (D) 
Consensus predicted structure of the NFKBIZ 3′ UTR. The final prediction is a representation of 
the structure with the most overlap between RNA folding prediction algorithms and that is still 
consistent with experimental T1 assay results. Protected and exposed guanine (G) bases from 
the T1 assay are shown in green and orange. Location of mutations in RNA used for probing 
assays are shown in red (SNV1, Del1, Del2 and Del 3).  (B) 3′ UTR region of NFKBIZ showing 
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stem-loop structures in dark green (novel SLs denoted by *), dashed lines connect SLs to the 2D 
structure from panel A, nucleotides in this region (dark blue: T, light blue: A, red: G, orange: C), 
the gene body is shown in dark blue with the last exon, stop codon (red) and 3′ UTR 
(untranslated region), the location of previously predicted microRNAs (miRNAs) are shown in light 
green and the location of patient mutations from three cohorts in Figure 1A (purple: Arthur, blue: 
Schmitz and pink: Chapuy). 
This region of the NFKBIZ 3′ UTR contains four known miRNA binding sites 
(Figure 3-4E), all found in the three known distal stem-loops (SL3, SL4 and SL5)206,245. 
Each of SL3, SL4 and SL5 have also been described as specific targets of the RBPs 
Regnase-1 and Roquin196,204,243,244,246. These RBPs are important for the degradation and 
translational silencing of many inflammation-related mRNAs such as the pro-
inflammatory cytokines TNFa and IL-6. The stem-loop SL2, the region most densely 
affected by mutations, is similar in structure to other targets of Regnase-1 and Roquin247–
249 and therefore we postulate that it may also be targeted by these RBPs. The distinct 
lack of mutations affecting SL1 is also notable and may imply a distinct function for this 
region. The enrichment of mutations affecting SL2 suggests that perturbations to this 
structure may have the most drastic effect on NFKBIZ (and IκB-ζ) expression levels. 
Through RNA-probing assays, we noted that the in vitro cleavage patterns of RNA 
representing four separate patient-derived mutations (Del1, Del2, Del3 and SNV1) was 
each distinct from WT RNA. We confirmed that the three mutations affecting the region 
containing SL2 (Del1, Del2 and SNV1) disrupted the structure of SL2 (Figure 3-4A-B).  
The extent to which mutations disrupt RBPs targets and/or miRNA binding sites is likely 
variable and dependent on the exact location of each mutation. Consistent with this 
model wherein NFKBIZ deregulation is achieved by modulating interactions with RBPs, 
we note the presence of recurrent non-silent mutations affecting the gene encoding the 
RBP Regnase-1 (ZC3H12A) in DLBCL (Figure 3-1A). 
 
3.4.3. CRISPR-induced NFKBIZ 3′ UTR mutations lead to elevated 
mRNA and protein levels 
 Using the CRISPR-Cas9 system, we introduced mutations into the NFKBIZ 3′ 
UTR of two DLBCL cell lines, one ABC and one GCB (U2932 and WSU-DLCL2, 
respectively). As the majority of patient mutations affect SL2, we designed a guide 
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targeting this region. To aid in comparing their potential role as driver mutations, we also 
designed a guide to target one of the other stem-loops (SL3) that is mutated at a lower 
incidence. Eight clones with different SL2 mutations were obtained from the WSU-
DLCL2 line (Figure 3-5A-C) including one 1 bp insertion, six small deletions and one 
large deletion. Five clones with mutations targeting SL2 and SL3 were obtained in the 
U2932 cell line (Figure 3-5A-B,D). WSU-DLCL2 is hemizygous at this locus and 
therefore mutants had no WT allele, whereas some U2932 clones had mutations on both 




Figure 3-5 CRISPR-induced NFKBIZ 3′ UTR mutations in DLBCL cell lines. 
(A) Location of mutations seen in CRISPR clones from two cell lines (WSU-DLCL2 and U2932) 
relative to SL structures described in Figure 2. (B) Table showing exact mutation sizes in each 
allele where relevant. (C) Sequence of mutations seen in WSU-DLCL2 clones targeting stem-loop 
2 region. (D) Sequence of mutations seen in U2932 clones targeting stem-loop 2 and stem-loop 3 
regions. NFKBIZ mRNA (top) and IκB-ζ protein expression (bottom) of (E) WSU-DLCL2 and (F) 
U2932 CRISPR clones compared to WT from droplet digital PCR (ddPCR) and western blot, 
respectively. 
The clone with the most striking change in NFKBIZ expression was WSU-DLCL2 
A4, which harbors a deletion that removes four of five stem-loops (SL2-SL5). We 
suspect that deletion of this entire region disrupts multiple regulatory features, leading to 






































U2932 MutationsCRISPR Clone Allele a Allele b
A2 +1 bp -
A3 -17 bps -
A4 -152 bps -
B1 -12 bps -
C2 -4 bps -
C3 -2 bps -
D3 -2 bps -
D5 -8 bps -
SL2-10 WT +1 bp
SL2-11 +1 bp -1/+10 bps
SL3-1 -2 bps -10 bps
SL3-4 -1 bp -11 bps
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comprising large deletions of the NFKBIZ 3′ UTR, small indels (especially deletions) in 
SL2 are far more frequent in patients. This could be explained by mutational processes 
that favour the introduction of small indels or may imply that the higher increase of 
expression accomplished by large deletions is not necessary or has additional 
consequences causing a reduced selective advantage.  
 
3.4.4. IκB-ζ expression confers a selective growth advantage 
To investigate the effect of elevated IκB-ζ expression caused by NFKBIZ 3′ UTR 
mutations on cell growth, we performed competitive growth assays comparing the 
parental (WT) cell line to mutant clones both in vitro (Figure 3-6A) and in vivo (Figure 3-
6D). WT and mutant WSU-DLCL2 lines were pooled and grown for 8-9 passages in cell 
culture or injected into a mouse and left to grow into a tumour xenograft.  Based on the 
relative proportion of each mutation in the population, all deletion-bearing clones 
outgrew WT (Figure 3-6B), with the A4 clone showing the highest representation. This 
clone exhibited the highest IκB-ζ expression levels, consistent with IκB-ζ expression 
conferring a selective growth advantage in culture as a function of expression level. In a 
separate experiment we compared WT individually to a subset of mutants and confirmed 
that each mutant clone can individually out-compete WT in vitro (Figure 3-6C). This 
highlights that the increased expression levels of IκB-ζ from small deletions are sufficient 
to cause a growth advantage, and large deletions (similar to A4), are not necessary to 
observe this effect. A similar growth advantage was observed in vivo through xenograft 
experiments. In mice, the A4 clone represented the majority of cells constituting the 
tumour at the endpoint (Figure 3-6F). Interestingly, when separately injected into mouse 
models, WT and A4 tumours grew at a similar rate, however it appeared that the A4 
group may have seeded detectable tumours slightly earlier (Supplemental Figure 3-7).  
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Figure 3-6 NFKBIZ expression provides a selective growth advantage to cells. 
(A) Schematic of in vitro competitive growth experiments. (B) Proportion of WT and mutant 
clones in the competitive growth assay pool of all clones grown together over multiple passages. 
DNA was extracted from cell pellets at each time point and sequenced to determine proportion of 
the pool made up by each clone. Each line represents the growth of a clone within one pooled 
experiment with three replicates. (C) Proportion of mutant clones when grown separately against 
WT in culture over multiple passages. DNA was extracted at each time point and ddPCR was 
used to differentiate WT and mutant sequences to infer proportion of the pool. Each line 
represents an individual experiment of three replicates. (D) Schematic of in vivo competitive 
growth experiments. (E) Schematic of primary germinal center B-cell NFKBIZ expression vector 
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transduction experiments. (F) Proportion of WT or mutant cells in xenograft tumour after grown to 
endpoint. DNA was extracted from the tumour at endpoint and sequenced to determine the 
proportion of each clone represented in the tumour. (G) Primary human germinal center B cells 
were purified from discarded tonsil tissue, cultured on irradiated YK6-CD40Lg-IL21 feeders and 
immortalized with BCL6-t2A-BCL2. Cells were then transduced with either NFKBIZ-IRES-GFP or 
control empty vector-GFP. The frequency of GFP-positive cells was measured by flow cytometry 
4 days after transduction (week 0) and at weekly intervals thereafter. The frequency of GFP-
positive cells, normalized to week 0, is shown for NFKBIZ and control cultures over a 4-week time 
course. Points represent mean and standard error of nine replicate cultures from six separate 
donors. 
 
Figure 3-7  Growth of xenografted tumours. 
Growth rate of tumours from three groups: WT (wild-type WSU-DLCL2 cells, A4: WSU-DLCL2 A4 
CRISPR-mutant cells, and pool: pool of WT, A4, C2 and D3 mutant cells). All appeared to grow at 
a similar rate. End point of experiment is shown by red dashed line (800mm3 tumour size). 
As cancer cell lines individually harbor advantageous mutations, we next sought 
to evaluate the effects of IκB-ζ expression in a genetically normal background. We 
directly determined the effect of increased IκB-ζ expression in primary germinal centre 
B-cells through ectopic expression. Primary human germinal centre B-cells immortalized 
with BCL6-t2A-BCL2 were transduced with a NFKBIZ overexpression vector or a control 
empty vector (Figure 3-6E). The growth of transduced cells was determined by 
measuring GFP-positive cells over time (Figure 3-6G and Supplemental Figure 3-8). 
Compared to cells transduced with a control vector, NFKBIZ overexpressing cells 
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Figure 3-8 Forced expression of NFKBIZ provides a competitive advantage to 
human primary germinal center B cells cultured ex vivo.  
Example flow cytometry plots showing progressive expansion of the GFP-positive population in 
NFKBIZ-transduced but not control cells by comparing percent of GFP cells at week 0 and 
week 4.  
3.4.5. Candidate IκB-ζ targets genes and pathways affected by 
NFKBIZ expression 
We hypothesized that the selective growth advantage of cells with elevated IκB-ζ 
expression observed in vitro and in vivo is afforded by the activation of target genes and 
pathways regulated by IκB-ζ. To elucidate the genes and pathways with expression 
changes associated with IκB-ζ overexpression, we performed RNA-seq on a subset of 
NFKBIZ CRISPR-mutant clones and WT replicates. The WSU-DLCL2 parental line is 
GCB based on the COO classification and is classified as EZB by LymphGen. By 
comparing genes differentially expressed between WSU-DLCL2 WT and mutant clones, 
we identified 34 genes suspected to be induced or suppressed by IκB-ζ (Figure 3-9A). 
These include potential novel IκB-ζ targets HCK, CD274 (PD-L1) as well as genes 
known to be affected by MYD88 knockdown (ARG2, LGALS3, CCR7, HTR3A)250. Next, 
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using gene set enrichment analysis (GSEA), we identified multiple hallmark pathways 
with significant changes in expression (Figure 3-9B). As expected, this included 
pathways relating to NF-κB signaling. Analysis of the gene expression changes in 
NFKBIZ 3′ UTR mutant lines revealed that a GCB line (WSU-DLCL2), following 
introduction of NFKBIZ 3′ UTR mutations, exhibited higher expression of pathways 
generally associated with ABC DLBCL such as TNF signaling via NF-κB and lower 
expression of GCB associated pathways such as MYC and MTOR (Figure 3-9B-D). 
This is consistent with NFKBIZ overexpression contributing, in part, to the ABC gene 




Figure 3-9 RNA-sequencing of CRISPR clones revealed novel targets and 
pathways activated by IκB-ζ. 
(A) Top genes differentially expressed between WSU-DLCL2 WT and NFKBIZ CRISPR-mutant 
clones. (B) Top pathways enriched in WSU-DLCL2 CRISPR mutant clones. Gene set signatures 
of top pathways upregulated (C) TNFa signaling via NF-κB and downregulated (D) MYC hallmark 
targets V2. (E) Expression of differentially expressed genes discovered in WSU-DLCL2 CRISPR 
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expressed genes were found between U2932 WT and CRISPR-mutant clones. HCK mRNA (top) 
and protein expression (bottom) of (F) WSU-DLCL2 and (G) U2932 CRISPR clones compared to 
WT from droplet digital PCR (ddPCR) and western blot, respectively. 
In contrast to WSU-DLCL2, U2932 has been classified as ABC (unclassified by 
LymphGen) and has high basal expression of many NF-κB targets and genes 
considered to be ABC-like but lacks mutations typical among ABC/MCD DLBCL such as 
MYD88, CD79B or NFKBIZ (Supplemental Figure 3-10). Despite the upregulation of 
IκB-ζ in U2932, we did not identify any significantly differentially expressed genes 
between WT and the mutant clones. We also directly assessed the effect of NFKBIZ 3′ 
UTR mutations in U2932 cells line by comparing the expression of candidate IκB-ζ 
targets determined through analyses of the WSU-DLCL2 RNA-seq data between the 
U2932 WT and mutant clones (Figure 3-9E). NFKBIZ itself and, as expected, many of 
these candidate target genes were highly expressed in all U2932 lines including the 
parental line. In aggregate, we interpret these results as the lack of further increase in 






















































































































































































































































Figure 3-10 Expression of genes associated with COO in WSU-DLCL2 and U2932 
WT and CRISPR Clones. 
Expression of genes used to assess COO status from gene expression profiling is shown for 
clones derived from the GCB-cell line WSU-DLCL2 and the ABC cell line U2932. ABC associated 
genes are highly expressed in the U2932 clones and some are highly expressed in the WSU-
DLCL2 NFKBIZ-mutant CRISPR clones. 
We next sought to validate the induction of HCK as a novel IκB-ζ target gene. We 
confirmed that the increase of HCK seen in RNA-sequencing was consistent with 
increased HCK mRNA through ddPCR and protein expression through western blot in 
CRISPR-mutant cell lines (both WSU-DLCL2 and U2932 clones) (Figure 3-9F and 3-
9G). Increased HCK expression was generally proportional to the level of IκB-ζ 
expression, with mutant clones showing a similar increase of both IκB-ζ and HCK protein 
levels. Given the role of HCK in other lymphoid cancers, it is appealing to consider 
whether the IκB-ζ induction of HCK may be contributing to the phenotype of NFKBIZ-
mutant cells. 
 
3.4.6. NFKBIZ 3′ UTR mutations impart differential vulnerability to 
targeted therapeutics 
Various targeted agents that have been or are currently being evaluated for their 
efficacy in treating ABC DLBCL have had limited success in clinical trials, with most 
providing therapeutic benefit in only a minority of patients143–151. Considering the genetic 
heterogeneity of DLBCL, it is important to understand the genetics underlying each 
tumour such that we may identify appropriate therapeutics that specifically target 
oncogenic pathways operative in that cancer. To this end, we used our engineered cell 
lines to investigate the effect of NFKBIZ overexpression on the efficacy of four targeted 
therapeutics that are under evaluation for application to DLBCLs, particularly those that 
either directly or indirectly perturb NF-κB signaling. 
Specifically, we explored the in vitro toxicity (IC50) of ibrutinib (a BTK 
inhibitor)147,150, idelalisib (a PI3Kd inhibitor)251,252, masitinib (a pan-SRC kinase 
inhibitor)253 and bortezomib (a proteasome inhibitor)149,153. Because the IκB-ζ protein acts 
downstream of many of these drug targets in the NF-κB pathway, we hypothesized that 
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these mutations may confer resistance to some of these agents. Consistent with this 
hypothesis we found that the WSU-DLCL2 CRISPR-mutant cell lines had a significantly 
higher IC50 than the WT line for each of ibrutinib, idelalisib and masitinib. Interestingly, 
there was no significant difference in IC50 between WT and mutant lines treated with 
bortezomib (Figure 3-11A-D). The three drugs with differential effects on mutant lines all 
target proteins upstream of IκB-ζ in the NF-κB pathway (Figure 3-12B), which could 
explain why an activating mutation in the NFKBIZ gene would afford cells resistance to 
these drugs. Bortezomib acts to inhibit degradation of the IκB proteins that inhibit NF-κB 
proteins from translocating into the nucleus where they form complexes with IκB-ζ. By 
blocking the release of NF-κB proteins, IκB-ζ is not able to confer trans-activating 
potential and bortezomib may be effective even in NFKBIZ mutant cases. The U2932 
parental cell line is already known to be resistant to many of these drugs254,255 and 
therefore was not evaluated.  
 
Figure 3-11 CRISPR-mutant cell lines response to DLBCL targeted therapeutics. 
Comparison of IC50 for WSU-DLCL2 wild-type and NFKBIZ CRISPR-mutant (A4, C2 and D3) cell 
lines for (A) Ibrutinib, (B) Idelalisib, (C) Maisitinib, and (D) Bortezomib. All points represent the 
IC50 calculated from independent drug dose-curve assays. All data represent the mean of three 
or four independent experiments ± SD. Significance was calculated by Student’s t-test or one-way 






















































Here, we have demonstrated that NFKBIZ 3′ UTR mutations provide a selective 
advantage to DLBCL and primary B cells in vitro and in vivo, firmly establishing these 
non-coding mutations as driver mutations. Through re-analysis of multiple large data 
sets, we have clarified the prevalence and pattern of NFKBIZ 3′ UTR mutations. 
Although these mutations have not been described in other B-cell malignancies, we 
observed rare examples in a small minority of FL and BL samples based on whole 
genome sequencing data, and we note a recent report of a similar pattern of NFKBIZ 3′ 
UTR mutations in T cell lymphoma34. This further highlights the importance of elucidating 
the functional role of IκB-ζ and mutations that affect its expression in hematologic 
cancers. 
Our previous study demonstrated that DLBCL cell lines harbouring NFKBIZ 3′ 
UTR mutations or amplifications generally exhibited higher levels of NFKBIZ mRNA and 
protein32. The additional data presented here validates that NFKBIZ 3′ UTR mutations 
cause elevated NFKBIZ mRNA and protein expression and provides insights into the 
mechanism. Isogenic mutant DLBCL cell lines exhibit a consistent selective growth 
advantage both in vitro and in vivo and introduction of these mutations into primary GC 
B-cells provides these cells a growth advantage. This is consistent with the notion that 
higher IκB-ζ levels resulting from these non-coding mutations promotes cell growth and 
survival. The most striking effect of these mutations was seen in the WSU-DLCL2 line, 
which normally exhibits low basal IκB-ζ expression. Despite a more subtle effect in 
U2932, we confirmed the induction of IκB-ζ expression caused by 3′ UTR mutations. The 
higher basal expression of IκB-ζ in U2932 WT cells may account for the less dramatic 
change in expression between mutants and WT compared to WSU-DLCL2 clones. 
Alternatively, this may be influenced by the nature of the mutations affecting SL3 in 
U2932, they may exert a different effect than the more common SL2 mutations. Although 
the RNA change was less obvious in these lines, there was an increase in protein 
expression, which may indicate that SL3 mutations affect translational efficiency rather 
than mRNA stability  
The growth advantage afforded to human primary germinal center B-cells by 
forced overexpression of NFKBIZ in ex vivo culture confirmed that this gene can confer a 
growth advantage to non-malignant cells without reliance on other common DLBCL 
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mutations. This result is not always achieved when expressing oncogenes in primary GC 
B-cells, with many requiring additional perturbations to allow cells to tolerate oncogene 
expression. Taken together, our data confirms that these non-coding mutations can act 
as bona fide drivers and further suggests that NFKBIZ could potentially arise as an early 
driver of lymphomagenesis. 
Currently, LymphGen is the only publicly available approach to classify DLBCLs 
using genetic features. By comparing the LymphGen assignments of NFKBIZ-mutant 
tumours, we determined that NFKBIZ 3′ UTR mutations tend to associate with the BN2 
subgroup which corresponds to the other recently described C1134 and NOTCH2137 
DLBCL classes. This separates them from MYD88L265P mutations which are features of 
the MCD (or C5/MYD88) class, which is consistent with our data showing these 
mutations are mutually exclusive. These data strongly support the necessity to include 
NFKBIZ mutations as features in future refinements of DLBCL genetic classification 
systems. We speculate that this would allow appropriate classification of the unclassified 
cases bearing these mutations, specifically into the BN2/C1/NOTCH2 subgroup. As 
these classifiers can leave up to 35% of cases unclassified, the inclusion of non-coding 
mutations could aid in increasing classification rates138. As the BN2/C1/NOTCH2 
subgroups are known to be enriched for NOTCH2 and BCR-dependent NF-κB signaling, 
it can be argued that NFKBIZ mutations that deregulate NF-κB targets are a reasonable 
addition to this group. The BN2/C1/NOTCH2 groups are also known to exhibit genetic 
alterations affecting immune escape and evasion. The discovery that PD-L1 expression 
is affected by NFKBIZ 3′ UTR mutations suggests NFKBIZ could not only be contributing 
to the NF-κB part of this signature, but also the immune escape. Further exploration of 
the interplay between these mutations and DLBCL biology will become more feasible 
only once the mutation status of this region becomes routinely determined through 
targeted sequencing panels including this region, exome designs with UTR baits, or 
through whole genome sequencing. 
Our analysis identified both PD-L1 and HCK as candidate targets of IκB-ζ, each 
with potential clinical relevance. Immunotherapies have gained traction in recent years to 
treat DLBCLs, however their efficacy has been largely dependent on which patients 
express the proteins relevant for this type of therapy143,144. PD-L1 upregulation in 
response to NFKBIZ 3′ UTR mutations could suggest a group of patients who could 
benefit from this type of treatment, specifically anti-PD1 or PD-L1 antibody therapy256.  
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HCK is a SRC family protein kinase that is expressed in hematopoietic cells257. 
The mutated form of MYD88 has been shown to trigger transcription and activation of 
HCK in Waldenström  macroglobulinemia258, a disease that shares genetic and 
biological features with ABC DLBCL. HCK has been discussed as a possible therapeutic 
target for small molecule inhibitors in multiple cancers259 and high expression of HCK 
has been associated with poor prognosis in mantle cell lymphoma260. Overexpression of 
HCK in other cancers can contribute to epithelial mesenchymal transition (EMT), hypoxia 
and TGFβ signaling261. All of these pathways were overexpressed in NFKBIZ CRISPR-
mutants based on GSEA analysis, consistent with HCK and downstream pathways as 
relevant targets of IκB-ζ. Knockdown of HCK has been shown to inhibit cell viability, 
migration and tumour growth261. Given the in vitro survival benefits afforded by NFKBIZ 
3′ UTR mutations in cell lines, it is conceivable that HCK expression is partially 
responsible for these changes and further exploration of its role in DLBCL is warranted.  
Induction of IκB-ζ expression through NFKBIZ 3′ UTR mutations has a differential 
effect on the sensitivity of DLBCL cell lines to targeted therapies. The enhanced 
resistance of these model cell lines to three of the four therapeutics suggests that 
NFKBIZ mutations could be informative as a predictive biomarker for investigational 
therapies. We were able to identify NFKBIZ mutations in patients from a small cohort of 
nine DLBCL patients treated with ibrutinib monotherapy. Strikingly, all patients 
harbouring NFKBIZ 3′ UTR mutations showed no response to ibrutinib monotherapy262. 
This highlights the pressing need for additional studies to explore the NFKBIZ mutation 
as a component of correlative analyses in clinical trials. This underscores the 
requirement to not only determine which pathways are mutated in a cancer, but also the 
location and role of the mutated protein in the affected pathway relative to the protein 
targeted by individual therapeutics.  
 
3.6. Methods 
3.6.1. Sequencing data re-analysis  
Targeted, exome and whole genome sequencing data for the Arthur cohort were 
combined from previously published papers120,234,263. Whole exome sequencing data 
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from Chapuy et al.134 and Schmitz et al.135 was obtained from the dbGAP (phs000450) 
and National Cancer Institute Genomic Data Commons (NCICCR-DLBCL), respectively, 
and reanalyzed using a standardized variant calling workflow. For Chapuy samples with 
matched constitutional exomes available, candidate small insertions and deletions were 
identified using Manta264, and these candidate events were provided to Strelka2265 to 
identify both single nucleotide variants and small indels. Passed variant calls were 
annotated using vcf2maf (https://github.com/mskcc/vcf2maf), and further filtered to 
remove low quality events using the following filtering criteria: 1) Min read depth >10, 2) 
Base quality bias p-value >0.01, as determined by comparing bases supporting the 
reference and alternate alleles using a t-test, 3) Strand bias p-value >0.01, determined 
by comparing reads supporting the reference and alternate alleles using a fisher’s exact 
test, 4) Mean mapping quality >50 for reads supporting the alternate allele. 16 samples 
with excessively high DNA damage were excluded from downstream analysis. 
For samples lacking a matched normal, an unpaired constitutional genome was 
used instead, and candidate small insertions and deletions were identified using 
Manta264 and provided to Strelka2265 to identify candidate somatic variants. Unfiltered 
variant calls (not selecting “PASS” variants) were converted to BED format and provided 
to MuTect2266 to obtain high-quality somatic variant calls, leveraging a panel of normals 
generated from 58 unrelated constitutional samples. Variant calls were annotated using 
vcf2maf, and post-filtered as described above. We also filtered any variant with a 
population allele frequency > 0.005 in any population, as reported in GenomAD267, and 
removed variants with a variant allele frequency < 0.01. Schmitz somatic variant calls 
were converted to hg19 alignments using CrossMap268. 
Poly(A) RNA-Seq BAMs from Schmitz et al.135 was obtained from the National 
Cancer Institute Genomic Data Commons (NCICCR-DLBCL). These samples were 
converted back into FASTQs and realigned against the human reference genome 
GRCh37 using STAR (star ref). Duplicate reads were identified using Picard 
MarkDuplicates (“Picard Toolkit.” 2019. Broad Institute, GitHub Repository. 
http://broadinstitute.github.io/picard/; Broad Institute), and gene-level expression data 
was calculated for each sample using FeatureCounts269, using transcript information 
from Ensembl V87. Allelic imbalance was calculated between DNA and RNA as 
described previously32. 
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3.6.2. Cell Culture and Reagents 
The cell lines WSU-DLCL2 was purchased from DSMZ and U-2932 was provided 
by M. Dyer (University of Leicester, UK) and authenticated using short tandem repeat 
(STR) typing (TCAG, SickKids, Toronto). All DLBCL cell lines were cultured in RPMI 
1640 medium (Invitrogen) supplemented with 10% FBS. Protein was extracted from 
5x106 cells with Pierce RIPA buffer (Thermo, 89901) containing proteasome inhibitor 
(Sigma, P8340) and quantified using the Pierce BCA Protein Assay Kit (ThermoFisher). 
25ug of protein lysate was resolved on a 4-12 % NuPAGE Novex Bis-Tris, 1.0mm Mini 
Protein Gel (Invitrogen, NP0326BOX) and transferred to a nitrocellulose membrane by 
wet transfer using the Trans-Blot turbo transfer pack (Bio-Rad). Antibodies for IκB-ζ (Cell 
Signaling, 9244S), HCK (E1I7F) (Cell Signaling, 14643S), and GAPDH (14C10) (Cell 
Signaling, 2118S) were diluted according to manufacturer’s recommendations (1:1000). 
Anti-rabbit IgG HRP conjugate (Promega, W401B) was used to visualize bands with 
Amersham ECL Western Blotting Detection Reagents (Cytiva, RPN2209) on a 
Chemidoc digital imager (Bio-Rad). 
 
3.6.3. CRISPR Gene Editing 
Cell lines were transfected using the Amaxa nucleofector with the IDT Alt-R 
CRISPR/Cas9 system following manufacturer’s recommendations. Briefly, crRNAs were 
designed using the IDT custom design tool to target the NFKBIZ 3′ UTR (SL2: 
AGCAACACTCACTGTCAGTT and SL3: ATAGACCATTTGCCTTATAT). 2x106 cells per 
line were electroporated with the generated RNP complex in nucleofector solution V 
(program X-001). Cells were grown to confluence, then single cell expanded in 96-well 
plates in 100uL MethoCult H4435 (StemCell). Mutations in clones were verified by 
Sanger Sequencing (GeneWiz) with primer: CCACATTGGCCATAAGAAAT. Wild-type 
cells were single cell expanded in the conditions as CRISPR cells to obtain single-cell 
expanded WT clones.  
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3.6.4. Droplet Digital PCR (ddPCR) 
RNA was extracted from 5x106 cells per sample using the AllPrep 
DNA/RNA/miRNA Universal Kit (QIAGEN) according to manufacturer’s 
recommendations with additional DNase I treatment for RNA extraction. RNA 
concentration was determined by NanoDrop and 800ug of RNA was used as input for 
cDNA synthesis using the AB High-Capacity cDNA Synthesis Kit (Applied Biosystems). 
cDNA was diluted 1:10 for used in ddPCR assays. Custom designed ddPCR assays 
were used to assess gene expression of NFKBIZ and TBP (control gene) as described 
before234. All plots represent ddPCR assays run on three biological replicates of 
extracted RNA. Data was analyzed using GraphPad Prism 9 (GraphPad Software). 
 
3.6.5. T1 RNase Probing Assays 
In vitro transcriptions. In vitro transcriptions were carried out in a mixture of 1 μM 
dsDNA template, 8 mM GTP, 2 mM UTP, 5 mM CTP and ATP in T7 buffer (2.5 mM 
Spermidine, 26 mM MgCl2, 10 mM DTT, 0.01% Triton X-100, 40 mM Tris-HCl pH 8.0 at 
25 °C) and 1.5 U/μL of T7 RNA polymerase (Applied Biological Materials). Reaction 
mixtures were incubated at 37°C for 2 h. Transcribed products were made up to 45% 
formamide, 10 mM EDTA, heated (95°C for 5 min) and subsequently purified by 
denaturing PAGE, eluted in 0.3 M NaCl and precipitated in 70% ethanol prior to use. 
CIP 5′ Dephosphorylation of RNA. 5′ dephosphorylation of RNA was carried out in a 
mixture of 1 pmol of RNA 5′ ends in 50 mM Potassium Acetate, 10 mM Magnesium 
Acetate, 100 µg/ml BSA, 20 mM Tris-acetate (pH 7.9 at 25°C) and 1 U/µl Alkaline 
Phosphatase, Calf Intestinal (CIP) (New England BioLabs). Reaction mixtures were 
incubated at 37°C for 30 min. Reactions were stopped by adding equivolume 90% 
formamide, 20 mM EDTA, heated (95°C for 5 min) and subsequently purified by 
denaturing PAGE, eluted in 0.3 M NaCl and precipitated in 70% ethanol prior to further 
use.  
T4 PNK 5′ Radiolabeling of RNA. Dephosphorylated RNA was 5′ radioactively labeled 
with T4 Polynucleotide kinase (PNK) in a mixture of 50 pmol of RNA 5′ termini, 20 pmol 
of [γ-32P] ATP in 10 mM Magnesium Chloride, 5 mM Dithiothreitol (DTT), 70 mM Tris-
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Hydrochloride (Tris-HCl, pH 7.6 at 25°C) and 1 U/µl T4 PNK (New England BioLabs). 
Reaction mixtures were incubated at 37°C for 30 min, stopped by heat inactivation, 
purified by denaturing PAGE and ethanol precipitated as described above, before further 
use. 
Alkaline Hydrolysis ladder. 5 pmol of 5′ radiolabeled RNA were incubated in 50 mM 
Sodium bicarbonate (NaHCO3) at 90°C for 15 min. Reactions were stopped with 100 mM 
Tris-HCl and equivolume 90% formamide, 20 mM EDTA, heated (95°C for 5 min) and 
resolved on 6-10% sequencing denaturing PAGE. Gels were analyzed using a GE 
Healthcare Amersham Typhoon scanner. 
Denaturing T1 Digestion. 5 pmol of 5′ radiolabeled RNA were incubated in a mixture of 
6 M Urea, 20 mM Sodium Citrate (pH 5 at 25°C) and 0.2 U/µl RNase T1 (ThermoFisher). 
Reaction mixtures were incubated at 50°C for 10 min prior to being stopped by flash 
freezing in liquid nitrogen for 5 min and adding equivolume 90% formamide, 20 mM 
EDTA and heated (95°C for 5 min). Samples were resolved on 6-10% sequencing 
denaturing PAGE and gels were analyzed using a GE Healthcare Amersham Typhoon 
scanner. 
Native T1 Digestion. 5 pmol of 5′ radiolabeled RNA were incubated in a mixture of 140 
mM Potassium Chloride, 1 mM Magnesium Chloride, 0.05% Tween-20, 10 mM Sodium 
phosphate (pH 7.2 at 25°C) and 0.2 U/µl RNase T1 (ThermoFisher). Reaction mixtures 
were incubated at 24°C for 10 min or at 37°C for 4 min. Reactions were stopped by flash 
freezing in liquid nitrogen for 5 min prior to adding equivolume 90% formamide, 20 mM 
EDTA, heating (95°C for 5 min) and being resolved on 6-10% sequencing denaturing 
PAGE. Gels were analyzed using a GE Healthcare Amersham Typhoon scanner. 
 
3.6.6. Competitive Growth Assays 
Cell lines were pooled together in equal amounts and grown in culture over 8-10 
passages, cells were passaged every 2-3 days when confluence was reached. At each 
passage a cell pellet was saved and used for DNA extraction with the AllPrep 
DNA/RNA/miRNA Universal Kit (QIAGEN). 150ng of DNA was used to make libraries 
with the QIAseq FX DNA Library Kit (QIAGEN). DNA libraries were pooled together for 
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hybridization capture of the NFKBIZ gene region using the protocol previously 
described234 based on the XGen hybridization capture workflow from IDT. Probes 
covering the NFKBIZ gene and UTR were used from Arthur et al234. Sequencing was 
performed on the Illumina MiSeq, data was analyzed using samtools and bwa-mem. 
Reads corresponding to each of the WT or mutant clones was counted and used to 
determine the proportion of each WT/mutant clone at each time point.  
 
3.6.7. Mouse Xenografts 
All cell lines were verified to be mycoplasma negative using the Venor GenM 
Mycoplasma Detection kit (Sigma Aldrich). 4x106 cells (WSU-DLCL2 WT, A4 or an 
equally mixed pool of WT/A4/C2/D3 lines) were diluted 1:1 in Matrigel HC and 
subcutaneously injected into the back of female NSG mice in a volume of 100uL. NSG 
mice were purchased from an in-house source (Animal Resource Centre, BC Cancer, 
Vancouver, BC). This study (A14-0259) was approved by the Institutional Animal Care 
Committee (IACC) at the University of British Columbia/BC Cancer, conducted in 
accordance with the Canadian Council on Animal Care Guidelines. This study was 
approved by the Research Ethics Board of the University of British Columbia and the 
BCCRC, conducted in accordance with the Declaration of Helsinki. Four mice per group 
were used. Tumour were measured twice weekly. Mice were observed daily and 
euthanized when they appeared in poor health or when tumours grew to a maximum of 
800 mm3. Tumour volumes were calculated according to the equation: length × width × 
height / 2. Xenograft tumours were immediately stored in RNAlater (Sigma-Aldrich) after 
excision. DNA was extracted following the “Simultaneous purification of Genomic DNA 
and total RNA, including miRNA, from tissues” protocol for the AllPrep DNA/RNA/miRNA 
Universal Kit (QIAGEN). The entire tumour was homogenized using the TissueRuptor 
system from QIAGEN and 600uL of homogenized tissue was used for DNA extraction. 
DNA library preparation and capture were performed as descried above for competitive 
growth assays and analyzed similarly.  
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3.6.8. RNA-Sequencing and Analysis 
RNA was extracted from cell lines as described above for ddPCR assays. 
Poly(A) RNA libraries were prepared and sequenced by the Genome Sciences Centre in 
Vancouver. Qualities of total RNA samples were determined using an Agilent 
Bioanalyzer RNA Nanochip or Caliper RNA assay and arrayed into a 96-well plate 
(Thermo Fisher Scientific). Polyadenylated (PolyA+) RNA was purified using the 
NEBNext Poly(A) mRNA Magnetic Isolation Module (E7490L, New England Biolabs) 
from 500 ng total RNA according to manufacturer’s instructions. First-strand cDNA was 
synthesized from heat-denatured purified mRNA using a Maxima H Minus First Strand 
cDNA Synthesis kit (Thermo-Fisher, USA) and random hexamer primers at a 
concentration of 200 ng/µL along with a final concentration of 40 ng/µL Actinomycin D, 
followed by PCR Clean DX (Aline Biosciences) bead purification on a Microlab NIMBUS 
robot (Hamilton Robotics, USA). cDNA was fragmented to by Covaris LE220 sonication 
to achieve 250-300 bp average fragment lengths. The paired-end sequencing library 
was prepared following Canada's Michael Smith Genome Sciences Centre at BC 
Cancer's strand-specific, plate-based library construction protocol on a Microlab 
NIMBUS robot (Hamilton Robotics, USA). DNA quality was assessed with Caliper 
LabChip GX for DNA samples using the High Sensitivity Assay (PerkinElmer, Inc. USA) 
and quantified using a Quant-iT dsDNA High Sensitivity Assay Kit on a Qubit fluorometer 
(Invitrogen) prior to library pooling and size-corrected final molar concentration 
calculation for Illumina HiSeq sequencing with paired-end 75 base reads. RNA-seq 
reads were pseudo-aligned using Salmon270 (version 0.8.6) to GRCh37. The tximport49 
Bioconductor R package was then used to summarize transcript level read counts at the 
gene level. The DESeq2271 Bioconductor R package was used to correct the read counts 
for library size and to obtain differentially expressed genes between conditions of 
interest employing a threshold of abs(log2FoldChange) > 0.585 and p < 0.05. DESeq2 
results were then fed into the FGSEA272 Bioconductor R package for pathway 
enrichment analyses, with a threshold of p < 0.05 set for enriched pathways. 
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3.6.9. Drug Treatments 
50uL of WSU-DLCL2 WT or CRISPR-mutant cells were seeded in 96-well plates 
at a concentration of 5x105 cells/ml to be diluted to a final concentration of 2.5x105 
cells/mL. Cells were then treated with Ibrutinib (PCI-32765 – Selleckchem), Idelalisib 
(HY-13026/CS-0256 – MedChemExpress), Masitinib (M1838 - AbMole BioScience), or 
Bortezomib (EMD Millipore Corp) using a ten-point dose titration scheme from 0.01uM to 
100 µM, 0.001 µM to 10 µM, 0.01 µM to 100 µM, or 0.001 µM to 10 µM respectively. 
After 48hr, cell viability was assessed using colorimetric WST-1 reagent (Roche, 
11644807001) as per manufacturer’s recommendations. All experimental points were a 
result of three technical replicates, and all experiments were repeated at least three 
times. The data was analyzed using GraphPad Prism 9 (GraphPad Software). 
Datapoints were normalized to an untreated control and the curves were fitted using a 
non-linear regression model with a sigmoidal dose response. Each plot shows the IC50 
calculated for 3 or 4 biological replicates with mean and standard deviations shown. 
One-way ANOVA with Dunnet’s multiple comparison’s test was used to compare WT to 
mutant IC50s for Ibrutinib and Idelalisib. Unpaired 2-tailed student’s t-test was used to 
compare the IC50s for Masitinib and Bortezomib. 
 
3.6.10. Plasmid for NFKBIZ Overexpression 
The coding sequence of NFKBIZ was amplified by PCR of cDNA from human 
germinal center B cells and cloned into pMSCV-IRES-GFP II (pMIG II) (addgene 
#52107) using BamHI and XhoI.  
 
3.6.11. Primary B-Cell Culture and transduction 
Primary GC B cells were purified from fresh tonsil tissue, sourced from 
Cambridge University Hospitals Trust. Written informed consent of the 
patient/parent/guardian. Ethical approval for the use of human tissue was granted by the 
Health Research Authority Cambridgeshire Research Ethics Committee (REC no. 
18/EE/0199). The YK6-CD40Lg-IL21 feeder line and protocol for expansion and 
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transduction of human germinal center B cells have been described previously273,274. 
Briefly, germinal center B cells were purified using the human B cell isolation kit 
(Miltenyi), modified to include negative selection antibodies to IgD and CD34. Cells were 
then cultured on irradiated YK6-CD40Lg-IL21 feeders and transduced 2-4 days later 
using GaLV-pseudotyped retrovirus. Retrovirus was produced by transfection of Lenti-X 
293T cells with packaging constructs and viral expression vector using TransIT-293 
(Mirus). Viral supernatant was harvested 48hr later transfection and filtered through a 
0.45 μM filter. Cells were transduced by centrifugation (1500 × g, 90 min at 32 °C) with 
the addition of 10 μg/ml Polybrene and 25 μM HEPES. The viral supernatant was then 




Chapter 4.  
 
General Discussion  
4.1. Summary of Research Findings 
The main objective of the research presented in this thesis was to investigate the 
non-coding genome in DLBCL and identify putative novel drivers of this disease. Next, 
focusing on one gene commonly affected by such mutations (NFKBIZ), I aimed to 
conduct a functional characterization of these mutations and their implications in 
lymphomagenesis and contribution to treatment resistance.  
The second chapter of this thesis encompasses the implementation of novel 
algorithms (Rainstorm and Doppler) that were used to identify regions of the genome 
enriched for mutations from WGS data32. We aimed to discover novel drivers of DLBCL 
in a non-biased way that specifically included the identification of non-coding regions 
recurrently affected by mutations. Using this approach, we identified previously known 
and novel targets of aberrant AID activity (somatic hypermutation) and collectively 
identified numerous novel non-coding loci affected by recurrent mutations in DLBCL. 
Besides aSHM sites, we found recurrent focal copy number gains and amplifications of 
the gene FCGR2B that lead to high expression of the CD32B protein. We found that 
amplified cases as well as cases with high expression of FCGR2B were significantly 
associated with worse outcome for GCB DLBCL patients treated with R-CHOP. As this 
indicates that these patients may be more resistant to rituximab, we suggest this group 
of patients could benefit from treatment with a different antibody targeting CD20. Our lab 
recently published findings that confirmed this association in additional cohorts and 
demonstrated that the association between FCGR2B expression and poor outcome is 
not preserved in patients treated with another anti-CD20 antibody (obinutuzumab)275 
(Figure 4-1). Although this discovery was not the focus of this thesis, it provides a 
second illustrative example of the potential for the use of genomics to identify novel 
biomarkers with therapeutic relevance.  
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Figure 4-1 Overview of FCGR2B expression effect on DLBCL patients outcome. 
FCGR2B-mediated internalization of antibodies is expected to occur for rituximab but not 
obinutuzumab (GA-101). Based on previous data it was hypothesized that patients with high 
FCGR2B expression (from RNA-seq/IHC) treated with R-CHOP would have worse outcomes. 
Results from the GOYA trial showed that high FCGR2B expression was associated with a worse 
outcome only in patients treated with R-CHOP but not G-CHOP. This figure is adapted from the 
graphical abstract from Nowicka and Hilton et al.275  
Through this same unbiased analysis of our cohort of patients, we discovered a 
striking pattern of recurrent mutations in the 3′ UTR of the NFKBIZ gene. I performed 
preliminary functional experiments to confirm that NFKBIZ mRNA and protein expression 
was higher in DLBCL cell lines harbouring naturally occurring NFKBIZ mutations 
(amplifications or 3′ UTR deletions). Additionally, I designed luciferase expression vector 
assays to demonstration the effect of 3′ UTR mutations on protein levels in HEK-293T 
cells.  
The third chapter of this thesis describes the comprehensive functional 
characterization of NFKBIZ 3′ UTR mutations and how they affect DLBCL cell lines and 
their response to a selection of lymphoma-related therapeutics. Following our initial 






























description of these mutations, I next confirmed the prevalence of NFKBIZ mutations in 
multiple independent cohorts that had since been released. I found that the same 
prevalence and distinct pattern of mutations is observed in all cohorts (17% of DLBCL 
and 24% of ABC DLBCLs). Mutations in NFKBIZ and MYD88 were significantly mutually 
exclusive in ABC DLBCL, specifically no patients harboured both NFKBIZ 3′ UTR and 
the MYD88 (L265P) hotspot mutations. This indicated that NFKBIZ and MYD88 may 
have similar roles in activating the NF-κB signaling pathway considering they are also 
enriched in the ABC subtype of DLBCL. I next found that NFKBIZ 3′ UTR mutations, 
which were not considered in the LymphGen molecular classifier, were highly enriched 
in the BN2 subtype. As a high proportion of cases are not currently classified by 
LymphGen (~35%)136, I postulated that NFKBIZ mutations could be a valuable addition 
to future classifiers in order to expand the number of patients classified in the group 
defined by BCL6 and NOTCH2 mutations (i.e., the LymphGen BN2 subgroup). 
As discussed in Chapter 1, driver mutations either influence the function of 
cancer genes or alter their expression. I hypothesized that NFKBIZ 3′ UTR mutations 
disrupt secondary structures in the mRNA that influence gene expression in cis. As 
NFKBIZ encodes an oncogene, I predicted that these mutations would lead to increased 
IκB-ζ levels. (Figure 4-2A) I used a combination of in silico modeling and experimental 
data to construct a revised model of the NFKBIZ 3′ UTR structure that is comprised of 
two novel stem-loops (SL1 and SL2) and three previously described stem-loops (SL3, 
SL4, and SL5). Based on these structural features, I used the CRISPR genome editing 
to induce NFKBIZ 3′ UTR mutations into specific regions of the UTR in DLBCL cell lines 
to evaluate their effects in an isogenic background. I found that 3′ UTR mutations, 
especially in the hotspot region of SL2 did lead to elevated NFKBIZ mRNA and IκB-ζ 
protein expression. One large deletion in particular, which removed four out of five SLs 
(SL2-SL5), exhibited very high mRNA and protein levels. 
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Figure 4-2 NFKBIZ overview models. 
(A) Proposed mechanism of non-coding 3′ UTR mutations in NFKBIZ and their effect on mRNA and protein expression and activation of the NF-κB 




A bona fide driver mutation provides a selective advantage to cells and such 
advantages can often be observed through in vitro experiments in biologically relevant 
cell lines. By using competitive growth assays, I demonstrated that elevated NFKBIZ 
expression, afforded by 3′ UTR mutations, confers a selective growth advantage to 
DLBCL cells. This was observed consistently both in culture (in vitro) and in a mouse 
xenograft model (in vivo). Ectopic expression of NFKBIZ in primary germinal center B-
cells also demonstrated that NFKBIZ expression could confer a selective growth 
advantage to primary cells. An important feature of these experiments was the absence 
of other driver mutations in the primary cells.  
The IκB-ζ overexpression caused by NFKBIZ 3′ UTR mutations led me to 
hypothesize that the transcriptional program under the regulation of this protein leads to 
the selective advantage, thereby contributing to lymphomagenesis. By applying gene 
expression analysis to the CRISPR-mutated cell lines, I identified several novel putative 
IκB-ζ targets that may underlie this phenotype. Unsurprisingly, there was a significant 
enrichment of genes in the NF-κB signaling pathway, confirming that the elevated levels 
of NKFBIZ expression caused by 3′ UTR mutations leads to activation of NF-κB 
signaling. Putative novel regulatory targets identified here include both the kinase HCK 
and the immunotherapy target PD-L1 (CD274 gene), each leading to the appealing 
speculation that these may present novel avenues for future exploration of therapeutics 
for NFKBIZ-driven DLBCL. Finally, I demonstrated that NKFBIZ 3′ UTR mutant cell lines 
were more resistant to three targeted therapeutics ibrutinib, idelalisib, and masitinib, but 
not bortezomib. This nuanced result suggests that is it not only important to know which 
pathways contain genetic alterations but also which level of the pathway the mutation 
affects (Figure 4-2B). I therefore assert that NKFBIZ 3′ UTR mutations could eventually 
be validated as biomarkers to predict the response of patients receiving targeted 
therapies. This would require further in vitro, in vivo, and ultimately data from 
retrospective or prospective analysis of clinical trial data, as has now been done to 
confirm the FCGR2B biomarker. 
The emerging genetic classification schemes134–137 that have been posited to 
inform on treatment options are an improvement on previous COO classification 
methods; however, these classification algorithms are currently either not publicly 
available or fall short of the ultimate goal of classifying all DLBCL patients into 
meaningful subgroups. This alone is consistent with the notion that there remains room 
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to improve these methods. The results presented in this thesis provide evidence that 
non-coding mutations could be a useful addition to these classifiers. Specifically, I 
highlight the potential utility of NFKBIZ 3′ UTR mutations in improving these classifiers 
and guiding the course of treatment for patients with these genetic alterations. 
 
4.2. Potential Clinical Applications  
4.2.1. Molecular Classifiers of DLBCL 
As discussed previously, the current version of the LymphGen classifier leaves, 
on average, more than one third of cases unclassified. Although a more granular 
classification approach for DLBCL that could potentially inform on treatment options is 
intriguing, I believe the current definition is incomplete135,136. Although the BN2 subgroup 
was enriched for NFKBIZ 3′ UTR mutant patients, a higher number of patients 
harbouring NFKBIZ 3′ UTR mutations were classified as “Other” (Table 3-4). This leads 
to me to speculate that the classification rate of the LymphGen algorithm could be 
improved if NFKBIZ 3′ UTR mutations were incorporated as another feature, theoretically 
for the BN2 subgroup. Here, I describe just one driver mutation that could improve the 
current classifiers, but it is plausible that others exist. If the eventual goal is to utilize 
these classifications in the clinic to determine the best course of treatment for a patient, 
it will be vital to have a classifier that classifies the highest number of patients. This 
means the inclusion of all drivers that could inform on treatment options is necessary. 
Although the pursuit of this is beyond the scope of the current thesis, my results provide 
strong evidence that further enhancement of these systems is an eventuality.  
Another important point regarding the BN2 classification of NFKBIZ 3′ UTR 
mutations is related to therapeutic responses. In the most recent study detailing the 
features of BN2, it was suggested the BN2 and MCD subgroups are the most likely to 
respond to the BTK inhibitor ibrutinib because they are both characterized by mutations 
affecting BCR-dependent NF-κB signaling pathway136. In the same study it was 
suggested that PI3K inhibitors would also be useful for treating MCD and BN2 tumours. 
Although these statements may hold true for many of the genetic alterations affecting 
this pathway, it is problematic to make such broad assertions without experimental 
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validation and comparison of the nuances of individual driver mutations. For example, in 
Chapter 3 I demonstrate that NFKBIZ mutations may confer increased resistance to 
ibrutinib treatment. This result suggests that not all BN2 tumours would respond to 
ibrutinib. Further, my data shows that NFKBIZ mutations may also contribute to 
resistance to the PI3K inhibitor idelalisib. Although these are preliminary results, they 
highlight that the effect of drivers on therapeutic response is much more nuanced and 
complex than is generally described. My data is also consistent with the notion that 
NFKBIZ mutations may eventually become an important biomarker for predicting which 
patients in this group would not benefit from certain therapies. 
 
4.2.2. Exploring Potential Novel Therapeutic Targets for DLBCL 
Through this work, I identified the kinase HCK as a potentially novel 
therapeutically relevant target of IκB-ζ. As discussed in Chapter 3, HCK was discovered 
by RNA-sequencing of NFKBIZ 3′ UTR mutant and WT clones. Through several 
experiments, I confirmed that HCK mRNA and protein expression is elevated in NKFBIZ-
mutant cell lines (Figure 3-9). HCK encodes a member of the SRC family of tyrosine 
kinases that is primarily expressed in hematopoietic cells including B lymphocytes. It 
plays a role in chemokine signaling, proliferation, apoptosis, and immune cell 
activation257,276–278. HCK expression is also known to be activated by mutated MYD88 in 
both ABC DLBCL and WM258,279. Interestingly, although its relevance is relatively 
unexplored, HCK is a prototypical ABC gene whose overexpression is used as a 
component of most COO classifiers. Due to the mutual exclusivity that exists between 
MYD88 hotspot and NFKBIZ 3′ UTR mutations, it is conceivable that driver mutations in 
either of these genes affect an overlapping set of target genes that includes HCK, 
thereby each helping shape the gene expression program that has been described as 
activated B cell-like (ABC).  
High expression of HCK has also been seen in numerous other types of cancer. 
In chronic myeloid leukemia (CML), HCK has been found to be highly expressed and 
associated with cellular transformation and treatment resistance to the drug 
imatinib280,281. Multiple myeloma (MM) expresses high levels of HCK that contribute to 
elevated IL6 signaling and cell proliferation and survival257,282 and a similar phenotype 
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has been described in acute lymphoblastic leukemia (ALL) cases exhibiting high HCK 
expression283,284. In MCL, high levels of HCK expression were associated with inferior 
outcomes. Owing to this, HCK  has been suggested as a candidate for the development 
of new therapeutics260. Amplifications of HCK have also been found in multiple cancers, 
including gastric cancer and colorectal cancer cell lines285,286. Given the high expression 
of HCK in other cancers and its association with NFKBIZ expression presented in this 
thesis, HCK is an attractive candidate to target with therapeutics for the treatment of 
DLBCL. 
Given the repeated successes of the therapeutic inhibition of kinases across 
numerous cancer types, it is conceivable that therapeutic inhibition of HCK is achievable.  
A small selection of existing HCK inhibitors have already been tested on different cancer 
cell lines including:  AML (RK-20449)287, CML (A-419259)288, and MYD88 mutant B-cell 
lymphomas (KIN-8193)289 which was published as a conference abstract in 2018 but no 
further studies have been published. These compounds would be a convenient starting 
point to investigate the effectiveness of HCK inhibitors for treating DLBCL. If any of 
these compounds can induce the preferential killing of NFKBIZ-mutant cell lines, it could 
suggest the utility of HCK inhibitors in treating NFKBIZ-mutant patients. The cell lines I 
produced for this work would be an ideal model for these experiments. Interestingly, 
although ibrutinib is generally considered a BTK inhibitor, it can also inhibit HCK 
activity290. This is counter-intuitive in the context of my observation of increased 
resistance to ibrutinib in NKFBIZ-mutant cell lines. This could indicate that these cells 
were not reliant on HCK activity or that more specific inhibitors of HCK are needed. It 
may also imply that the genetic background, or the full complement of driver mutations, 
is important for identifying which targeted agents will be effective.  
If the utility of HCK inhibition is excluded through additional experiments, this 
work nonetheless has led to other potential therapeutic targets. Importantly, IκB-ζ itself 
could be investigated as a novel option for the development of targeted therapeutics. 
NFKBIZ is highly expressed in many DLBCLs, especially those classified as ABC 
DLBCL, in many cases without evidence for any mutations or copy number alterations. 
Inhibition of NFKBIZ expression has been shown to be toxic to ABC DLBCL cell lines172. 
The current therapeutic approaches all affect upstream activators of NFKBIZ, for 
example B-cell receptor signaling, which I have shown to be ineffective in NFKBIZ-
mutant cases. I speculate that targeting IκB-ζ could theoretically lead to toxicity in NF-
 121 
κB-driven lymphomas in any mutational context, or even in the absence of mutations. 
There are currently no IκB-ζ inhibitors available, however the future exploration of drug 
screens targeting IκB-ζ are undoubtedly justified by the available data. 
Another candidate target of IκB-ζ identified in this thesis is CD274 (PD-L1). 
CD274 exhibited significantly elevated expression in the comparison of CRISPR 
NFKBIZ-mutant cell lines to WT. CD274 expression correlated with the level of NFKBIZ 
expression in the RNA-seq data (Figure 3-9). Expression of PD-L1, the protein encoded 
by CD274, on cancer cells is relevant because of its role in response to immune 
checkpoint blockade therapy144,256. Immunotherapies such as nivolumab and 
pembrolizumab have been successful in treating multiple types of solid cancer, 
melanoma, relapsed/refractory cHL and CLL143,291–295. These encouraging results 
indicate that immunotherapies should be explored thoroughly in other hematological 
malignancies, such as NHLs. However, it is important to know the relative expression of 
PD-L1/PD-L2 across lymphomas, to determine which would be suitable candidates to 
receive these treatments. A recent study determined the expression pattern of PD-L1 
and PD-L2 in a variety of lymphoma types using IHC; they found that only about 10% of 
DLBCLs have high expression of PD-L1296. This could indicate that although checkpoint 
blockade may not be an effective treatment option for all DLBCL patients, it could be 
useful in the subset of patients who express PD-L1. There are currently multiple studies 
underway to assess the effectiveness of anti PD-1 immunotherapies in DLBCL. One 
study recently published the results of their trial evaluating pembrolizumab in 
combination with R-CHOP for previously untreated DLBCL patients297. They found very 
high overall (OR) and complete response (CR) rates of 90% and 77% respectively, 
among the 30 patients in the trial. Interestingly, they found that patients who exhibited 
any level of PD-L1 expression via IHC had more favourable responses, especially those 
with a non-GCB subtype. This may suggest that high expression of PD-L1 is not 
completely necessary to see a response, but instead the presence of PD-L1 expression 
could be a useful biomarker. To select patients to receive therapy it would be useful to 
know which group of patients is most likely to express PD-L1, especially if IHC methods 
are not available. The data presented in this thesis suggests that NFKBIZ 3′ UTR 
mutated tumours may have high PD-L1 expression, but this requires experimental 
confirmation.  
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As discussed at length, NFKBIZ 3′ UTR mutations are significantly over-
represented among DLBCLs of the BN2 genetic subtype. One of the characteristics of 
BN2 that was described in the LymphGen study was genetic features associated with 
immune evasion136 . Consistent with this notion, the C1 subgroup from the Harvard 
system, which is most closely similar to BN2, is known to harbour SVs affecting PD-L1 
and PD-L2 as well as other immune escape genes134. The hypothesis that NFKBIZ 3′ 
UTR mutations are one of a variety of mutations that can contribute to high levels of PD-
L1 expression would be consistent with this general phenotype. Based on this, I 
speculate that BN2 tumours in general may be enriched for immune-related phenotypes 
and could benefit from immune checkpoint blockade therapies. A further investigation 
into the interplay of NFKBIZ mutations and PD-L1 expression as well as the 
effectiveness of checkpoint blockade therapies in these tumours is warranted. 
 
4.3. Ongoing Work and Future Directions 
4.3.1. Regnase-1 as a Regulator of NFKBIZ 
Early on in this work, we postulated that the regulatory protein Regnase-1 
(encoded by the gene ZC3H12A) is one of the main relevant regulators of NFKBIZ 
mRNA through post-transcriptional regulation. Consistent with this, we identified 
mutations affecting the ZC3H12A gene in 6% of DLBCLs and these are found among 
the various studies (Figure 3-1). Regnase-1 is a known negative regulator of TLR 
signaling by degradation of mRNA transcripts, therefore mutations inhibiting its function 
could lead to elevated NF-κB signaling. Regnase-1 can interact with two of the 
previously described stem-loops in the NFKBIZ 3′ UTR (SL4 and SL5). Based on this, I 
hypothesized that Regnase-1 may also target the novel SL2 that was identified through 
my analysis. Due to the majority of NFKBIZ 3′ UTR mutations affecting SL2, I was most 
interested in discovering which regulatory mechanisms targeted SL2 and how mutations 
in this stem-loop could affect that regulation. Although not a part of this thesis, there is 
additional experimental work underway to address this question.  
It is conceivable that multiple post-transcriptional regulatory processes act on the 
NFKBIZ 3′ UTR to regulate its expression, such as other RBPs or miRNAs. However, 
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due to the predominance of mutations affecting SL2, no predicted miRNA binding sites 
in SL2, Regnase-1 having other known binding sites within the NFKBIZ 3′ UTR, 
recurrent ZC3H12A mutations in DLBCL, and the known role of Regnase-1 in regulating 
NF-κB signaling, Regnase-1 is likely the main post-transcriptional regulatory mechanism 
impacted by SL2 mutations. I proposed that NFKBIZ 3′ UTR mutations affecting SL2 
cause structural changes in the stem-loop formation in such a way that Regnase-1 is 
unable to bind and/or cleave the RNA. The RNA is therefore not degraded leading to 
elevated levels of NFKBIZ mRNA in the cell.  
One of the future avenues of exploration involves a recently established 
collaboration with the Unrau and Audas labs, who specialize in RNA biology. We plan to 
investigate the Regnase-1 cleavage pattern of WT NFKBIZ 3′ UTR RNA as well as a 
selection of patient derived mutations. The goal is to directly determine whether 
individual mutations in the NFKBIZ 3′ UTR, especially those affecting the hotspot in SL2, 
lead to a decrease in cleavage of the RNA or a change the cleavage pattern. It would be 
interesting to eventually correlate the level of NFKBIZ expression in 3′ UTR mutants with 
the ability of Regnase-1 to either bind and/or cleave the RNA. We would expect that the 
degree to which the Regnase-1 recognition SL structure is disrupted would greatly 
impact the level of NFKBIZ expression seen for each mutation. 
Additionally, to further investigate the role of Regnase-1 in DLBCL cells, CRISPR 
experiments could be performed to knockout ZC3H12A in DLBCL cell lines. NFKBIZ 
expression would be expected to be elevated in ZC3H12A knockout cells. If the 
knockout of ZC3H12A leads to a similar phenotype as that of NFKBIZ 3′ UTR mutations, 
this would be additional evidence that Regnase-1 is the main target affected by NFKBIZ 
3′ UTR mutations.  
Lastly, if it becomes clear that Regnase-1 is not the main regulator affected by 
NFKBIZ 3′ UTR mutations, further experiments could be designed to investigate what 
other RBPs target the NFKBIZ 3′ UTR, especially in the SL2 region. In the case that 
there are other suspected RBPs, RNA immunoprecipitation (RIP) experiments could be 
performed with antibodies against the putative RBPs. Novel RBP targets of the NFKBIZ 
3′ UTR could them be investigated through similar approaches as described above for 
the Regnase-1 protein. 
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4.3.2. Novel Molecular Classification System 
As discussed above in section 4.2.1, there is potential utility in including NFKBIZ 
3′ UTR mutations in classification models as it appears to be a feature of the novel 
subtype of DLBCL that has been named BN2135,136, C1134 or NOTCH2137 by different 
groups. Although beyond the scope of this thesis, the Morin lab interested in further 
extending and refining the genetic model of DLBCL classification using a similar set of 
genetic features as the three groups mentioned above, while also including NFKBIZ 3′ 
UTR mutations and other driver mutations as features. I speculate that this should lead 
to a higher classification rate than that of LymphGen136 (~65%), revealing a larger 
proportion of tumours with clinically actionable characteristics. Though not immediately 
feasible, the eventual goal would be to develop a new DLBCL classifier that includes all 
relevant genetic drivers (both coding and non-coding) of DLBCL which leads to every 
patient being classified into a unique group that is predicted to respond to a pre-selected 
set of therapeutics tailored to the genetic attributes of that group. Given the expression 
of oncogenes such as NFKBIZ is not always associated with a driver mutation, such a 
classifier may also be required to leverage gene expression features.  
 
4.3.3. CRISPR-Mediated NFKBIZ Mutations in Primary Cells 
The results presented in Chapter 3 describing the overexpression of NFKBIZ in 
primary GC B-cells (Figure 3-6 and Figure 3-8) are of particular interest because they 
reveal that NFKBIZ can promote cancer cell growth even in the absence of other 
lymphoma driver mutations. The overexpression of many other cancer driver does not 
confer a selective growth advantage to primary cells273, therefore the result that the 
overexpression of NFKBIZ confers a growth advantage is noteworthy. This could 
suggest that NFKBIZ mutations are early acquired events and contribute to the process 
of lymphomagenesis. Although this hypothesis has not been validated, the further 
investigation of NFKBIZ mutations as early drivers of DLBCL is clearly warranted.  
In collaboration with Dr. Daniel Hodson and his group (Cambridge, UK) we have 
designed similar CRISPR experiments to that were done in DLBCL cell lines, in primary 
GC B-cells to investigate if the overexpression of NFKBIZ by 3′ UTR mutations is also 
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able to confer a growth advantage to these cells. If these experiments are successful, 
RNA-sequencing could then be performed on healthy primary cells and CRISPR-mutant 
cells. This may utilize flow-sorted cells, enriched for those with NFKBIZ mutations, or 
could alternatively rely on single cell RNA-seq. The results from gene expression 
analysis of NFKBIZ-mutant primary cells could provide an avenue to validate targets of 
IκB-ζ presented in this thesis. These results would not be biased by the genetic subtype 
of DLBCL cell line or other driver mutations in cancerous cells lines and would hopefully 
reveal the true targets of IκB-ζ in a genetically normal background. Moreover, NFKBIZ-
mutant primary cells could then be used to test targeted therapeutics. They could be 
beneficial for these experiments as they have genetically normal backgrounds and 
should not have differential responses to drugs like those of DLBCL cell lines.  
 
4.3.4. Novel IκB-ζ Targets 
Through analysis of RNA-seq data of NFKBIZ mutant and WT cell lines in 
Chapter 3 I reported on numerous novel candidate targets of IκB-ζ. I validated the 
elevated expression of HCK in mutant lines but did not explore the direct binding of the 
IκB-ζ protein to any of these candidate target genes. Although outside the scope of this 
thesis, it would be of interest to map out the binding sites of IκB-ζ and validate the 
candidate targets I have already identified. This could be assessed in CRISPR-mutant 
DLBCL cell lines or CRISPR-mutant primary cells mentioned in the above section. 
Specifically, chromatin immunoprecipitation (ChIP) could be performed to confirm the 
interaction of IκB-ζ with candidate targets or ChIP-Seq could be used to perform a global 
mapping of IκB-ζ binding sites within the genome. The result of such an analysis could 
be beneficial for determining if any other targets of IκB-ζ are valid options for therapeutic 
development.  
 
4.3.5. In vivo Models of Drug Resistance 
Another complementary approach that was outside the scope of this thesis is the 
use of in vivo patient-derived xenograft models to investigate therapeutic responses. The 
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data presented herein demonstrate that NFKBIZ-mutant DLBCL cell lines can be 
subcutaneously implanted into NSG mice to produce tumour xenograft models (Figure 
3-6 and Figure 3-7). Assuming patient-derived tissues could be established as 
xenografts, additional experiments could be designed to assess the effectiveness of the 
drugs evaluated in this work (ibrutinib, idelalisib, masitinib and bortezomib) as well as 
HCK inhibitors or PD-L1 antibodies for their effectiveness in WT and NFKBIZ-mutant 
DLBCLs. The preliminary in vitro results described in this thesis revealing that NFKBIZ-
mutant cell lines were more resistant to ibrutinib, idelalisib and masitinib are 
encouraging, however, to expand upon these results such that they might be translated 
into the clinic and improve patient outcomes in the future, in vivo studies confirming any 
such associations will be important next steps. 
 
4.3.6. Clinical Trial Data 
As discussed in Chapter 3, in a small cohort of patients treated with ibrutinib, the 
two (out of nine) that harboured NFKBIZ 3′ UTR mutations did not respond to treatment. 
Although this is a small sample size and not statistically significant, it is consistent with 
our hypothesis and if this preliminary observation can be confirmed in a larger cohort 
size, it could reveal that DLBCL patients with NFKBIZ 3′ UTR mutations will not respond 
to ibrutinib treatment and suggest they should be offered alternative treatment options. If 
we can obtain access to sequencing data from patients on clinical trials evaluating the 
effectiveness of ibrutinib, or any of the other drugs mentioned within this thesis, it would 
be justified to explore whether NFKBIZ mutation status is associated with a response to 
certain therapeutics. As it stands, this data is difficult to obtain but it could be important 
for determining the utility of NFKBIZ mutations as predictive biomarkers. 
 
4.4. Closing Perspective 
This thesis describes the investigation of the entire genomic landscape of 
DLBCL, with a specific emphasis on identifying novel non-coding recurrently mutated 
loci and the further characterization of one such loci, the 3′ UTR of the NFKBIZ gene. 
 127 
This work highlights the importance of interrogating the entire genome and the ability of 
WGS to facilitate the identification of novel drivers of cancer. We discovered and showed 
for the first time that 3′ UTR mutations could cause overexpression of an oncogene to 
drive cancer progression. Although the effects of non-coding mutations are not always 
as readily apparent as coding-mutations, they are not all passenger mutations and can 
also act as drivers. This thesis highlights the importance of conducting a full 
characterization of this type of mutation and I anticipate that many such drivers will be 
identified in cancers through similar comprehensive efforts. I have directly demonstrated 
that these 3′ UTR mutations act as bona fide drivers as they cause overexpression of an 
oncogene, resulting in competitive growth advantages as well as resistance to targeted 
therapeutics. These results together suggested that NFKBIZ mutations could potentially 
be a useful biomarker for predicting therapeutic responses for patients with NFKBIZ-
mutant DLBCL and I hope that these results will inform on the next generation of DLBCL 
classification methods.  
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Appendix A.  
 
NFKBIZ Mutations 
Table A-1 NFKBIZ Copy Number Variants 
Case ID Gene Status Copy 
number 
Chromosome Start End 
DLC_0010 NFKBIZ AMP 3 3 93543006 197833758 
DLC_0023 NFKBIZ AMP 3 3 93543006 197833758 
DLC_0046 NFKBIZ AMP 3 3 93543006 197833758 
DLC_0056 NFKBIZ AMP 3 3 93543006 197833758 
DLC_0067 NFKBIZ AMP 3 3 93543006 197833758 
DLC_0107 NFKBIZ AMP 3 3 93543006 105966369 
DLC_0109 NFKBIZ AMP 3 3 93543006 197833758 
DLC_0111 NFKBIZ AMP 3 3 93543006 102195661 
DLC_0118 NFKBIZ AMP 3 3 93543006 197833758 
DLC_0135 NFKBIZ AMP 3 3 93543006 197833758 
DLC_0165 NFKBIZ AMP 3 3 93543006 197833758 
DLC_0221 NFKBIZ AMP 3 3 93543006 197833758 
DLC_0228 NFKBIZ AMP 3 3 93543006 197833758 
DLC_0233 NFKBIZ AMP 3 3 93543006 197833758 
DLC_0243 NFKBIZ AMP 3 3 98877662 103837900 
DLC_0259 NFKBIZ AMP 3 3 99539664 101906861 
DLC_0260 NFKBIZ AMP 3 3 93543006 113842013 
DLC_0333 NFKBIZ AMP 3 3 93543006 197833758 
DLC_0388 NFKBIZ AMP 3 3 93543006 197833758 




Table A-2 NFKBIZ Structural Variations 
Cohort Sample Chromosome Start End Type Strand 
Discovery 06-23907 3 101560108 101560118 DUP + 
Discovery 06-23907 3 101568463 101568466 DUP + 
Discovery 09-33003 3 101578296 101578300 DEL + 
Discovery 09-33003 3 101578417 101578418 DEL + 
Discovery 15-18723 3 101578281 101578283 DEL + 
Discovery 15-18723 3 101578806 101578807 DEL + 
Discovery 16-11636 3 101545774 101545778 DUP + 
Discovery 81-52884 3 101548477 101548478 DUP + 
Discovery 81-52884 3 101554447 101554450 DUP + 
Discovery DO27811 3 101578318 101578323 DEL + 
Discovery DO27811 3 101578435 101578436 DEL + 
Validation DLC_0061 3 101578296 101578300 DEL + 
Validation DLC_0061 3 101578417 101578418 DEL + 
Validation DLC_0063 3 101568780 101568782 DEL + 
Validation DLC_0063 3 101568831 101568832 DEL + 
Validation DLC_0111 3 101578346 101578351 DEL + 
Validation DLC_0111 3 101578477 101578478 DEL + 
Validation DLC_0163 3 101578314 101578315 DEL + 
Validation DLC_0163 3 101578368 101578369 DEL + 
Validation DLC_0188 3 101578244 101578245 DEL + 
Validation DLC_0188 3 101578438 101578439 DEL + 
Validation DLC_0224 3 101578300 101578302 DEL + 
Validation DLC_0224 3 101578411 101578412 DEL + 
Validation DLC_0238 3 101568463 101568466 DUP + 
Validation DLC_0243 3 101578267 101578269 INV + 
Validation DLC_0248 3 101578267 101578269 INV + 
Validation DLC_0260 3 101578272 101578275 DEL + 
Validation DLC_0260 3 101578797 101578798 DEL + 
Validation DLC_0314 3 101578300 101578302 BND - 
Validation DLC_0314 3 101578294 101578295 BND + 
Validation DLC_0355 3 101578314 101578316 DEL + 
Validation DLC_0355 3 101578388 101578389 DEL + 
Validation DLC_0370 3 101578286 101578292 DEL + 
Validation DLC_0389 3 101570984 101570985 BND - 
Validation DLC_0389 3 101571037 101571039 INV + 
DUP, duplication; DEL, deletion; INV, inversion; BND, translocation 
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Table A-3  NFKBIZ SNVs and Indels (SSMs) 





Discovery NFKBIZ 3 101578257 101578257 3'UTR SNP T C 06-34043 
Discovery NFKBIZ 3 101578310 101578331 3'UTR DEL GTAAGTTGTTTCTATGAAACAA - 16-11636 
Discovery NFKBIZ 3 101578255 101578258 3'UTR DEL AGTT - 16-17861 
Discovery NFKBIZ 3 101578347 101578347 3'UTR SNP T A 13-30451 
Discovery NFKBIZ 3 101578261 101578261 3'UTR SNP G C 14-20962 
Discovery NFKBIZ 3 101578255 101578258 3'UTR DEL AGTT - 05-18426 
Discovery NFKBIZ 3 101578250 101578251 3'UTR DEL CT - 09-16981 
Discovery NFKBIZ 3 101578251 101578252 3'UTR DEL TG - DO27807 
Discovery NFKBIZ 3 101578255 101578258 3'UTR DEL AGTT - DO52675 
Validation NFKBIZ 3 101578361 101578361 3'UTR SNP T C DLC_0002 
Validation NFKBIZ 3 101578252 101578255 3'UTR DEL GTCA - DLC_0008 
Validation NFKBIZ 3 101578250 101578251 3'UTR INS - T DLC_0011 
Validation NFKBIZ 3 101578211 101578211 Missense_Mutation SNP A T DLC_0018 
Validation NFKBIZ 3 101578319 101578319 3'UTR SNP T C DLC_0018 
Validation NFKBIZ 3 101578322 101578322 3'UTR SNP T C DLC_0018 
Validation NFKBIZ 3 101578330 101578330 3'UTR SNP A T DLC_0018 
Validation NFKBIZ 3 101578338 101578338 3'UTR SNP T A DLC_0018 
Validation NFKBIZ 3 101578262 101578262 3'UTR SNP C T DLC_0028 
Validation NFKBIZ 3 101578210 101578210 Missense_Mutation SNP T C DLC_0029 
Validation NFKBIZ 3 101578243 101578256 3'UTR DEL ACACTCACTGTCAG - DLC_0029 
Validation NFKBIZ 3 101578289 101578289 3'UTR SNP A T DLC_0029 
Validation NFKBIZ 3 101578252 101578255 3'UTR DEL GTCA - DLC_0051 
Validation NFKBIZ 3 101578252 101578255 3'UTR DEL GTCA - DLC_0056 
Validation NFKBIZ 3 101578275 101578275 3'UTR SNP T G DLC_0060 
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Validation NFKBIZ 3 101578279 101578279 3'UTR SNP T C DLC_0060 
Validation NFKBIZ 3 101578322 101578328 3'UTR DEL TATGAAA - DLC_0064 
Validation NFKBIZ 3 101578296 101578311 3'UTR DEL TTATATTGGCAAATGT - DLC_0066 
Validation NFKBIZ 3 101578346 101578346 3'UTR SNP C G DLC_0099 
Validation NFKBIZ 3 101578250 101578251 3'UTR INS - TG DLC_0116 
Validation NFKBIZ 3 101578251 101578251 3'UTR SNP T C DLC_0125 
Validation NFKBIZ 3 101578296 101578310 3'UTR DEL TTATATTGGCAAATG - DLC_0127 
Validation NFKBIZ 3 101578315 101578321 3'UTR DEL TTGTTTC - DLC_0128 
Validation NFKBIZ 3 101578255 101578255 3'UTR SNP A C DLC_0141 
Validation NFKBIZ 3 101578284 101578284 3'UTR SNP A C DLC_0141 
Validation NFKBIZ 3 101578251 101578251 3'UTR SNP T G DLC_0198 
Validation NFKBIZ 3 101578255 101578258 3'UTR DEL AGTT - DLC_0203 
Validation NFKBIZ 3 101578411 101578411 3'UTR SNP C T DLC_0205 
Validation NFKBIZ 3 101578238 101578238 3'UTR SNP T A DLC_0207 
Validation NFKBIZ 3 101578318 101578318 3'UTR SNP T C DLC_0207 
Validation NFKBIZ 3 101578323 101578323 3'UTR SNP A C DLC_0207 
Validation NFKBIZ 3 101578351 101578351 3'UTR SNP A C DLC_0207 
Validation NFKBIZ 3 101578429 101578429 3'UTR SNP A T DLC_0207 
Validation NFKBIZ 3 101578255 101578258 3'UTR DEL AGTT - DLC_0221 
Validation NFKBIZ 3 101578309 101578315 3'UTR DEL TGTAAGT - DLC_0222 
Validation NFKBIZ 3 101578262 101578262 3'UTR SNP C G DLC_0226 
Validation NFKBIZ 3 101578319 101578319 3'UTR SNP T G DLC_0228 
Validation NFKBIZ 3 101578257 101578257 3'UTR SNP T C DLC_0230 
Validation NFKBIZ 3 101578255 101578258 3'UTR DEL AGTT - DLC_0231 
Validation NFKBIZ 3 101578251 101578251 3'UTR SNP T G DLC_0235 
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Validation NFKBIZ 3 101578260 101578260 3'UTR SNP G A DLC_0274 
Validation NFKBIZ 3 101578314 101578314 3'UTR SNP G C DLC_0276 
Validation NFKBIZ 3 101578252 101578255 3'UTR DEL GTCA - DLC_0284 
Validation NFKBIZ 3 101578252 101578255 3'UTR DEL GTCA - DLC_0339 
Validation NFKBIZ 3 101578179 101578179 Missense_Mutation SNP G T DLC_0340 
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Appendix B.  
 
Supplementary Data File  
Description:  
Supplementary Data 1. Metadata for each patient showing which cohort samples were 
a part of what type of sequencing was performed, cell-of-origin and relevant FCGR2B 
and NFKBIZ mutation status.  
Supplementary Data 2. Single Nucleotide Variants and Indels MAF. Annotated SSMs 
identified in 153 genomes (in MAF format).  
Supplementary Data 3. Structural Variants MAF. Full set of somatic SVs identified in 
153 genomes.  
Supplementary Data 4. Noncoding mutation peaks. Genomic loci identified as enriched 
for mutations using the Doppler/Rainstorm algorithms after removal of coding SSMs.  
Supplementary Data 5. Full Mutation Peaks. Genomic loci identified as enriched for 
mutations using the Doppler/Rainstorm algorithms using all somatic SSMs as input.  
Supplementary Data 6. Mutation peaks with differential mutation abundance in ABC 
and GCB DLBCLs. The result of comparing mutation abundance in these peaks 
between GCB and ABC genomes is shown. The raw and corrected P values from the 
Fisher’s exact test and 95% confidence intervals are included.  
Supplementary Data 7. Mutations with allelic imbalance by gene. All mutations 
identified as having allelic imbalance relative to the variant allele fraction of the tumour 
were identified. This table lists all genes that were subjected to targeted sequencing and 
tabulates the number, total and proportion of tumours in which a mutation with AI was 
identified in that gene.  
Supplementary Data 8. NFKBIZ in vitro RNA experiments. gBlock sequences of the 
wild-type and four mutant NFKBIZ 3′ UTR transcripts that were used in in vitro 
experiments. 
Supplementary Data 9. NFKBIZ in vitro RNA experiments Primers used to amplify 
gBlocks and the control UTR sequence and add XbaI sites for cloning. 
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